Published in final edited form as:

Chem Rev. 2015 May 13; 115(9): 3518–3563. doi:10.1021/cr500638n.

Amyloid β -protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies

Jessica Nasica-Labouze¹, Phuong H Nguyen¹, Fabio Sterpone¹, Olivia Berthoumieu², Nicolae-Viorel Buchete³, Sébastien Côté⁴, Alfonso De Simone⁵, Andrew J. Doig⁶, Peter Faller², Angel Garcia⁷, Alessandro Laio⁸, Suan Li Mai⁹, Simone Melchionna¹⁰, Normand Mousseau³, Yuguang Mu¹¹, Anant Paravastu¹², Samuela Pasquali¹, David J. Rosenman¹³, Birgit Strodel¹⁴, Bogdan Tarus¹, John H Viles¹⁵, Tong Zhang^{1,11}, Chunyu Wang¹², and Philippe Derreumaux^{1,16}

¹Laboratoire de Biochimie Théorique, UPR9080 CNRS, Université Paris Diderot, Sorbonne Paris Cité, IBPC, 13 rue Pierre et Marie Curie, 75005, Paris, France ²CNRS, LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, BP 44099, F-31077 Toulouse Cedex 4, and Université de Toulouse, UPS, INPT, F-31077 Toulouse Cedex 4, France ³School of Physics & Complex and Adaptive Systems Laboratory, University College Dublin, Belfield, Dublin 4, Ireland ⁴Département de Physique and Groupe de recherche sur les protéines membranaires (GEPROM), Université de Montréal, C.P. 6128, succursale Centre-ville, Montréal (Québec), Canada ⁵Department of Life Sciences, Imperial College, London, UK ⁶Manchester Institute of Biotechnology, 131 Princess St, University of Manchester, Manchester M1 7DN, UK ⁷Department of Physics Applied Physics and Astronomy, Rensselaer Polytechnic Institute, Troy, NY 12180, USA ⁸The International School for Advanced Studies (SISSA), Via Bonomea 265, 34136 Trieste, Italy ⁹Institute of Physics, Polish Academy of Sciences, Al. Lotnikow 32/46, 02-668 Warsaw, Poland, Institute for Computational Science and Technology, SBI Building, Quang Trung Software City, Tan Chanh Hiep Ward, District 12, Ho Chi Minh City, Vietnam ¹⁰Instituto Processi Chimico-Fisici, CNR-IPCF, Consiglio Nazionale delle Ricerche, Roma, Italy ¹¹School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, 637551, Singapore ¹²Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, 2525 Pottsdamer Street, Tallahassee, and National High Magnetic Field Laboratory, 1800 East Paul Dirac Drive, Tallahassee, Florida 32310, USA ¹³Department of Biology, Rensselaer Polytechnic Institute, Troy, NY 12180, USA ¹⁴Forschungszentrum Jülich GmbH, Institute of Complex Systems: Structural Biochemistry (ICS-6), 52425 Jülich, Germany ¹⁵School of Biological and Chemical Sciences, Queen Mary, University of London, UK

Graphical abstract

¹⁶Institut Universitaire de France, Paris, France, philippe.derreumaux@ibpc.fr, to whom correspondence should be addressed, Tel: 33 1 58 41 51 72.

1. Introduction

Alzheimer's disease (AD) challenges our society with an annual estimate cost of \$1.08 trillion in the USA alone by 2050.⁽¹⁾ AD is a progressive irreversible neurological disorder with marked atrophy of cerebral cortex and loss of cortical and subcortical neurons, which is characterized pathologically by accumulation of amyloid plaques, and numerous neurofibrillary tangles formed from filaments of microtubule associated highly phosphorylated tau proteins.⁽²⁾ The pathogenesis of AD includes other factors such as cholinergic malfunction and oxidative stress.⁽³⁾

The major constituents of the senile plaques are β -amyloid (A β) peptides of 39-43 amino acids. A β derives from cleavage of the transmembrane amyloid precursor protein (APP), located in chromosome 21, by β -secretase (BACE1) producing a 99 amino acid fragment (C99) that is further cleaved by the γ -secretase.⁽⁴⁾ The human A β ₁₋₄₂ wild type (WT) sequence is DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA. Five drugs are currently available for AD. These include four cholinesterase inhibitors: Donepezil, Reminyl, Razadyne and Rivastigmine, and the N-methyl-D-aspartate (NMDA) receptor antagonist, Memantine. However, they are only effective for 6 to 12 months, and for half of the patients with milder forms of Alzheimer's.⁽⁵⁾ Scientists are developing novel benzopolycyclic amines with increased NMDA receptor antagonist activity,⁽⁶⁾ and are targeting BACE1,⁽⁷⁾ Tau and A β proteins.^(8,9) Despite many *in vitro* and *in vivo* studies, drug after drug has failed to slow the progression of AD for several reasons.

First, while oligomers, such as dimers, trimers and 12-mers (A β *56), are the most critical players in the pathology of AD^(10,11a-b) and larger aggregates and fibril fragmentation are toxic as well^(12,13) there is currently little information on their rate and extent of formation. Experimental and theoretical studies showed that A β _{1-40/1-42} peptides self-assembly into amyloid fibrils by a nucleation-condensation polymerization mechanism. However, while

master equations allow interpreting the experimental sigmoidal kinetic profiles of amyloid formation by means of primary and/or secondary (fragmentation or lateral) nucleation processes,⁽¹⁴⁻¹⁶⁾ they do not provide any information on the 3D topology and size of the primary nucleus. Overall, probing the conformational changes of A β aggregation is challenging owing to the vast heterogeneity of the aggregates, the number of sub-states for each aggregate, and the sensitivity of the process to pH, agitation, temperature, concentration, ionic strength, surfactants, sample preparation and the sequence (A β 1-40 vs. A β 1-42).⁽¹⁷⁻¹⁹⁾

Second, standard tools of structural biology have failed to provide the 3D structures of the monomers and the oligomers of the A β 1-40/1-42 peptides in aqueous solution. A β monomer is described as random coil by solution nuclear magnetic resonance, NMR,⁽²⁰⁾ and circular dichroism, CD.⁽²¹⁾ Due to their heterogeneity and high propensity to aggregate, the low molecular weight A β oligomers are not amenable to NMR and X-ray crystallography. As a result, only low-resolution structural data from CD, ion-mobility mass spectrometry (IM-MS), electron microscopy (EM), transmission electron microscopy (TEM) and atomic force microscopy (AFM) measurements are available.^(11,20-26) At the end of the reaction, the fibrils are insoluble and we are left with complicated experiments using isotopic labeling to propose models. These experiments revealed that fibrils of synthetic A β 1-42 peptides have U-shaped conformations with β -strands at residues L17-F20 and I31-V40 with the 16 N-terminus residues disordered, while fibrils of synthetic A β 1-40 peptides have β -strands at Y10-D23 and A30-G38 with the 9 N-terminus residues disordered.^(27,28) Fibrils made of AD-brain derived A β 1-40 peptides show, however, deformed U-shaped conformations, with a twist in residues F19-D23, a kink at G33 and a bend at G37-G38, and a more ordered N-terminus.⁽²⁹⁾ Overall the final products are very sensitive to the nature of the sample (synthetic or brain-derived A β peptides). Fibril formation is also under kinetics rather than thermodynamics, adding further complexity to the determination of the physical factors governing A β 1-40/1-42 amyloid fibril formation.^(17,30)

Third, because of their presence in the brain, the metal ions (Cu²⁺, Zn²⁺ and Fe³⁺ and the cell membrane have to be considered. A full dynamic and thermodynamic picture of the interactions of A β 1-40/1-42 oligomers with metal ions or membrane is very difficult, but recent progress has been made.^(31,32)

Fourth, it is important to better understand the molecular interactions of A β oligomers with the proteins co-localised in the brain, and notably human serum albumin,⁽³³⁾ the most abundant protein in cerebral spinal fluid, and the prion protein, PrP, concentrated at the synaptic terminals with a high affinity for A β .^(34,35) Mapping all partners that bind to A β oligomers is a daunting task because disparate results can emerge from experiments depending on the initial state of the protein, its source, and its stoichiometry.⁽³⁶⁾ In addition, as functional genomics has taught us,⁽³⁷⁾ biomolecules are involved in a network of interactions, so toxicity is likely to be multifactorial and to result from interactions of A β with multiple partners. Three recent articles illustrate this feature.⁽³⁸⁻⁴⁰⁾ Murine paired immunoglobulin-like receptor B and its human ortholog leukocyte immunoglobulin-like receptor B2 were identified as receptors for A β oligomers, with nanomolar affinity.⁽³⁸⁾ A β oligomers also induce synaptic damage via tau-dependent microtubule severing by Tubulin-

Tyrosine-Ligase-Like-6 and spastin,⁽³⁹⁾ and A β oligomers-PrP generate metabotropic glutamate receptor 5-mediated increases of intracellular calcium.⁽⁴⁰⁾ Finally, among the apolipoprotein E (apoE) isoforms, apoE4 increases the risk of AD. While transporting cholesterol is its primary function, apoE regulates A β metabolism, aggregation, deposition, and competes with A β for cellular uptake through apoE receptors.⁽⁴¹⁾ Overall, our current structural knowledge of A β oligomers with receptors is still in its infancy.

Fifth, the summer 2012 was plagued by the release of bad news from clinical trials of two drugs targeting A β , bapineuzumab and solanezumab.⁽⁴²⁾ The general consensus for a couple of years has been that the drugs are given too late.⁽⁴³⁾ Scientists have failed to provide the structures of A β monomers or A β oligomers with known inhibitors of A β aggregation *in vitro* and toxicity, a prerequisite to develop more specific drugs with optimal affinities for A β oligomers.⁽⁴⁴⁾

In addition, working on the most abundantly produced species, A β 1-40, and the far less abundant but more aggregation prone and toxic form, A β 1-42, is a simplification as the γ -secretase generates peptides from A β 1-36 to A β 1-43.⁽⁴⁵⁾ Several truncated variants are also observed in the amyloid plaques with various populations. These include A β 4-42 and A β 5-42,⁽⁴⁶⁾ A β 1-26 and A β 1-30,⁽⁴⁰⁾ and post-translational modifications of A β peptides: isomerization at D1, phosphorylation at S26, dityrosine covalent bond at Y10 and proteolytic removal of D1 and A2 and the subsequent cyclizing of E3 and E11 to a pyroglutamate (designated A β 3(pE) and A β 11(pE)), among others.⁽⁴⁷⁻⁴⁹⁾ The A β (pE) species *in vivo* consist of A β 3(pE)-40/42 and A β 11(pE)-40/42, with A β 3(pE)-42 being most abundant. A β (pE) is more cytotoxic and aggregates more rapidly than conventional A β and a recent study raises the possibility that A β 3(pE)-42 formation acts at a primary step in AD pathogenesis.⁽⁵⁰⁾

Finally, while most Alzheimer's disease is sporadic, i.e. not the result of inheritance, (familial AD (FAD) represents 5% of the cases), we have learned a large amount about the genetic risk factors that predispose an individual to contract the disease. One of the major risk factors for AD is mutation in the APP gene, though many mutations in two presenilin genes have also been reported and are constantly discovered.⁽⁵¹⁾ Mutant APP may be more likely to be proteolytically cleaved into the A β form, which generates the amyloid plaques. Some familial mutations, including H6R (English), D7H (Taiwanese), D7N (Tottori), A21G (Flemish), E22Q (Dutch), E22G (Artic), E22 (Osaka) and D23N (Iowa), change aggregation and toxicity, and lead to different phenotypes.^(52,53) Two recent FAD mutations, however, turn that inheritance pattern on its head. The A673V mutation in APP or A2V in A β is associated with AD, but the inheritance pattern is recessive, i.e., a patient needs two mutant alleles in order to acquire the disease risk. In combination with the WT allele, A673V does not cause AD. Furthermore, the presence of the mutant peptide prevents the WT peptide from forming amyloid fibrils, even under very favorable *in vitro* conditions.⁽⁵⁴⁾ The second striking result comes from the coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders and the discovery that the mutation A673T in APP or A2T in A β protects against AD in both homozygous and heterozygous patients. Though A2T reduces the cleavage of APP by 40%, how the mixing of A β 1-40 A2T and A β 1-40 WT protects patients from AD remains to be determined.⁽⁵⁵⁾

Overall, a full understanding of AD within the amyloid cascade hypothesis requires the development and use of innovative biophysical techniques. Along with standard approaches, e.g. Fourier transform infrared spectroscopy (FTIR), CD, X-ray powder diffraction, TEM, AFM, solid-state nuclear magnetic resonance (ss-NMR), dynamic light scattering (DLS) and IM-MS, new techniques are being applied. These include, notably: pulsed hydrogen-deuterium exchange coupled with mass spectrometry analysis,⁽⁵⁶⁾ which unlike fluorescence methods, does not require labeling with a fluorophore, photonic crystal-based approaches,⁽⁵⁷⁾ single-molecule imaging techniques,⁽⁵⁸⁾ and specific isotope labelling with electron paramagnetic resonance (EPR), advanced hyperfine sub-level correlation (HYSCORE) and electron-nuclear double resonance (ENDOR) methods.^(59,60)

Experimental studies alone are not sufficient, however, since they generally give time- and space-averaged properties. Computer simulations by exploring different time and length scales can complement experiments. Simulations are very challenging due to the inherent flexibility and heterogeneous ensemble of the A β 1-40/1-42 monomers and oligomers, and the impact of a crowded environment. As a result, we need to develop and/or use various protein representations ranging from all-atom, coarse-grained (CG) to mesoscopic models and improve sampling techniques to converge rapidly to equilibrium and explore the dynamics over a wide range of time scales.^(44,61)

In summary, we provide an in-depth review on the contribution of biophysical and biochemical studies and computer simulations to characterize the molecular structures of A β 1-40/1-42 monomers, oligomers, protofibrils and amyloid fibrils in aqueous solution. We then focus on our current knowledge of the A β 1-40/1-42 nucleus and the structures and dynamics of A β 1-40/1-42 oligomers in or at proximity of the membrane. We summarize what is known about the interactions of A β monomer and oligomers with ion metals, cellular partners and potential inhibitors. We also report the main findings of the simulations on FAD mutations, and conclude by offering a perspective on the future of the field and the major questions that need to be addressed to discover drugs with much higher efficacy.

2. Molecular Structures of A β 1-40 and A β 1-42 Fibrils to Monomers from Experiments

Experimental characterization of amyloid fibril structures has been the topic of extensive research for decades, producing remarkable molecular-level insights.⁽⁶²⁻⁶⁵⁾ Non-fibrillar monomer and oligomer structures, in contrast, are not well understood. We summarize the major findings on A β 1-40/1-42 molecular structure from monomers to fibrils with emphasis on the most recent results. Structural understanding of A β fibrils and insights into the self-assembly process establish a basis for addressing the challenges associated with determining the structures of A β protofibrils and low molecular weight oligomers.

2.1 Fibrils

Due to the incompatibility of amyloid fibrils with X-ray crystallography and solution-state NMR, there is no single technique able to readily provide enough structural information to fully specify molecular structure within A β fibrils. Our structural knowledge of A β amyloid

fibrils, therefore, is derived from the integration of complementary information from different experimental techniques. Fibril dimensions (nm length scale) have been probed by EM and AFM.^(27,66-68) Fibril mass can be quantitatively measured by scanning TEM and, more recently, tilted beam TEM.⁽⁶⁹⁾ 2D structure (mostly β -strand) has been probed by FTIR.^(70,71) This technique, along with diffraction based measurements, hydrogen/deuterium exchange, mutagenesis, proteolysis, EPR, and ss-NMR, can provide information on molecular fold and inter-molecular packing (β -sheet formation and organization).^(25,27,71-79) Fibre diffraction studies established the “cross- β ” structure, in which A β molecules assemble into β -sheets with β -strands oriented perpendicular to the long axis of the fibril.^(72,80-82) The β -sheet structure was further confirmed by the binding of β -sheet-specific dyes such as Thioflavin-T and Congo red.⁽⁷⁰⁾ It should be noted that Sawaya *et al.* used X-ray diffraction to measure the detailed cross- β structures of microcrystals of several short peptides forming amyloid fibrils.⁽⁸³⁾ The data provide atomic details of “steric zippers” created by packing of interdigitated side chains between stacked β -sheets, described in terms of 8 possible symmetry classes. The free energies of different steric zipper configurations were also calculated using all-atom molecular dynamics (MD) simulations. Comparisons to experimental results suggest that the observed amyloid-like crystals are thermodynamically stable, although kinetic trapping can be driven by electrostatic side chain interactions.⁽⁸⁴⁾

Among the experimental techniques mentioned here, ss-NMR has provided the most atomic-level detail of A β amyloid fibrils. This technique is well suited for amyloid fibrils because it provides information on local structure without requiring long-range orientation order.⁽⁸⁵⁾ In 1998, Benzinger used ^{13}C - ^{13}C dipolar recoupling ss-NMR data on A β 10-35 fibrils to challenge the then common belief that A β amyloid fibrils are composed of antiparallel β -sheets.⁽⁸⁶⁾ This preference for antiparallel β -sheets originates from earlier interpretations of FTIR data, the intuition that like-charged side chains are unlikely to be in close proximity, and NMR studies of the A β 34-42 fibril.^(71,87-89) Controversy over the arrangement of β -strands within A β amyloid fibrils further motivated the development of improved measurements for nuclear magnetic dipolar interactions,⁽⁹⁰⁻⁹²⁾ and more analysis of A β fragments.^(85,93,94a) It was found that the A β 1-28 peptide forms in-register parallel β -sheets, in which β -strands are aligned for close proximity between like-residues.⁽⁹⁵⁾ The in-register parallel configuration which maximises overlap hydrophobic residues influenced the view that amyloid formation is driven by hydrophobic interactions.^(68,85) A recent review on FTIR examines the experimental complications leading to incorrect assignment of antiparallel β -sheets, and describes more reliable approaches to data interpretation.⁽⁶³⁾

In 2002, Petkova *et al.* reported a molecular model of an A β 1-40 fibril based on constraints obtained from ss-NMR and EM.⁽²⁷⁾ This model refined subsequently with additional NMR constraints⁽⁷⁹⁾ reported an unstructured peptide for the first 10 residues with 2 β -strands (residues 11-24 and 30-40), as shown in Fig.1A. The first 10 residues were assigned to unstructured because isotopic labelling (^{13}C and ^{15}N) yielded NMR signals that were either broad (static disorder) or not observed (dynamic disorder).⁽²⁷⁾ The β -strands form in-register parallel β -sheets to produce the protofilament (Fig.1B). Protofilaments associate in pairs to form the two-fold topology for the striated fibrils (Fig.1C). The turn region (residues 25-29) is stabilised by a salt bridge between the charged D23 and K28 side chains. Note

Nussinov *et al.* also proposed in 2002 the in-register parallel motif based on MD simulations using several topologies.^(94b)

The structural model of Petkova does not describe, however, every A β 1-40 fibril because fibrils are polymorphic. Polymorphism refers to the existence of multiple pathways for self-assembly, producing assemblies that differ in molecular structure. When observed by EM or AFM, distinct fibrils are observed with various width, twist, and cross-section dimensions.^(27,66-68) Multiple fibril polymorphs usually co-exist within the same samples, although many samples are characterised by a dominant fibril polymorph. Petkova showed that subtle environmental factors as solution agitation can produce samples with different predominant fibril morphologies (two-fold symmetry under agitation and threefold symmetry under quiescent conditions) and that distinct NMR peak positions and line shapes indicate distinct underlying molecular structures.^(27,29) Additional factors affecting fibril self-assembly are pH, the presence of metal ions, and interaction with interfaces.^(64,67,97) Furthermore, there is an inheritance of structure when fibrils of one morphology are used to seed the self-assembly of A β monomers into new fibrils.⁽²⁷⁾ A β fibril polymorphism was further characterized using cryo-EM by Meinhardt⁽⁶⁶⁾ and Paravastu⁽⁶⁷⁾ using ss-NMR. An important structural difference between different A β fibril polymorphs lies in the orientations of the residues within the β -strands and the presence or absence of the D23-K28 salt bridge (Fig.1D). By taking advantage of observed differences in seeding efficiencies between different fibril polymorphs and using quiescent conditions, Paravastu isolated a new A β 1-40 fibril with a 3-fold symmetric cross section (Fig.1E).⁽⁶⁷⁾ Bertini reported another A β 1-40 fibril model with a topology similar to that of Petkova (Fig. 1A-C), but with different atomic details.⁽⁹⁸⁾ An A β 1-42 fibril model with a similar configuration was also published by Luhers, based primarily on hydrogen/deuterium exchange and mutagenesis data, but with different residues in the β -strand and turn regions.⁽²⁸⁾ While this model differs from structures observed for A β 1-40, it is not clear how the ranges of possible A β 1-40 and A β 1-42 fibril structures could differ. The symmetries of all the experimentally constrained A β fibril structural models predict a single molecular conformation. Thus, detection of multiple NMR signals from each labelled site is normally assumed to imply polymorphism within the sample. Contrary to this interpretation, Lopez del Amo *et al.* recently published a NMR-derived fibril composed of A β molecules in two non-equivalent conformations.⁽⁹⁹⁾ An asymmetric fibril structure was also proposed by the theoretical work of Wu, but whether such A β fibril geometry is correct remains to be validated experimentally.⁽¹⁰⁰⁾

The growing consensus that A β 1-40 and A β 1-42 fibrils are composed of in-register parallel β -sheets has recently been disrupted by recent reports on fibrils formed by the Iowa Mutant (D23N) of A β 1-40 peptide.^(29,101) This peptide forms fibrils composed of anti-parallel β -sheets as depicted in Fig.1F. It was suggested that substitution of the positively charged D23 side chain with the uncharged N23 side chain affects the nucleation rate of the parallel β -sheet structure, which is stabilized by the D23-K28 salt bridge.⁽¹⁰¹⁾ Interestingly, the parallel β -sheet structure remains the thermodynamically preferred structure for the D23N mutant, but antiparallel β -sheet fibrils propagate more slowly in seeding experiments and dissolve at the expense of parallel β -sheet fibrils in mixtures.⁽²⁹⁾

Experimental observations of environment-dependent self-assembly led to questions about the biological relevance of structural information from *in vitro* generated A β samples. The use of repeated seeding steps to amplify early nucleating or fast growing fibrils within a sample, for example, could result in a kinetically favoured structure, which may differ from the most thermodynamically stable structure. The theoretical work of Pellarin based on a mesoscopic model with one internal degree of freedom per peptide supports this notion, suggesting that less thermodynamically favoured fibril structures could nucleate more rapidly.⁽¹⁰²⁾ In addition, the microenvironment *in vivo* is likely to differ significantly from environments accessible *in vitro*, and may be affected by conditions promoted by Alzheimer's disease. Paravastu showed that amyloid plaques in the brains of deceased Alzheimer's patients could be isolated at concentrations high enough to seed the self-assembly of synthetic A β 1-40 monomers, enabling the incorporation of isotopic labels into brain-derived fibril structures.⁽¹⁰³⁾ Lu analysed fibril samples from the brains of two deceased Alzheimer's patients with distinct clinical histories.⁽²⁹⁾ ss-NMR analysis of brain-seeded fibrils indicates that plaques from each brain are characterized by a single predominant fibril structure, though polymorphism was also observed.^(29,103) Dominant structures differed, however, between the two Alzheimer's brains. Lu established a constrained structural model for the brain-derived A β 1-40 fibril composed of in-register parallel β -sheets.⁽²⁹⁾ Fig.2 compares the all-atom pictures of the brain-derived A β 1-40 fibril model and the fibril models of the synthetic A β 1-40 peptides determined by Paravastu and Petkova. Lu observed NMR signals consistent with an ordered structure for every residue in A β 1-40, and particularly a structured N-terminal region in contrast to the synthetic A β 1-40 fibrils.⁽²⁹⁾ How this N-terminal structure will change with the binding of metal ions remains, however, to be determined.

2.2 Protofibrils and Oligomers

Complexity in A β self-assembly was observed with the discovery of multiple soluble metastable A β oligomers at early and intermediate aggregation times.⁽¹⁰⁴⁻¹⁰⁸⁾ While systematic classification of soluble A β species is difficult without more knowledge of structure and assembly pathways, soluble A β aggregates are generally referred to as protofibrils or oligomers. Protofibrils have elongated aspect ratios and a curvilinear appearance.⁽¹⁰⁶⁾ They are argued to be “on-pathway” intermediates to amyloid fibril formation and believed to convert to fibrillar structures without first dissociating to monomers.^(106,108,109) Protofibrils have been reported to seed the growth of fibrils, have molecular weights as near 250×10^3 kDa (~ 60 molecules), consist of β -sheets, and bind Thioflavin-T.⁽¹¹⁰⁾ Oligomers are smaller species, with molecular weights ranging from 9 kDa (A β dimers) to hundreds of kDa (~ 50 A β molecules). While oligomers exhibit β -strand secondary structure when probed by FTIR and CD, they do not necessarily bind Thioflavin-T or seed fibril formation.^(63,111) These observations motivate the interpretation that at least some oligomers are “off-pathway” to fibril formation. Since fibril formation is accelerated by seed- or nucleus-dependent self-assembly, conversion of oligomers into fibrils is prolonged when oligomers are separated from fibrils and protofibrils; this separation is normally accomplished by size exclusion chromatography (SEC).⁽¹⁰⁹⁾ Species isolation and dynamics also increase structural homogeneity, which prevents structure elucidation. Oligomers have been further stabilized by crosslinking or interactions with engineered

proteins.⁽¹¹²⁻¹¹⁴⁾ Several protocols for production and isolation of oligomers have been reported and the different oligomer products have been named amyloid-derived diffusible ligands, globulomers, amylospheroids, I β , and annular protofibrils.^(105,109,115-119)

Recent studies report structural characterization of protofibrils by ss-NMR. Scheidt stabilized A β 1-40 protofibrils through interaction with an antibody-derived fusion protein (B10AP) and found ¹³C NMR chemical shifts which differ from those observed for amyloid fibrils and also indicate shorter β -strand regions.^(120,121) The ¹³C NMR chemical shifts resemble reported values for I β oligomers, suggesting that protofibril structure more closely resembles oligomer structure than fibril structure.⁽¹²¹⁾ Although I β oligomers were reported to be composed of in-register parallel β -sheets, Scheidt *et al.* proposed an intramolecular antiparallel β -hairpin within A β oligomers.⁽¹¹²⁻¹¹⁴⁾ This β -hairpin model (Fig.3A) predicts hydrogen bonding between β -strands in the same molecule, which does not occur in the fibril structural models (Fig.1). Structural similarity between B10AP-stabilized A β 1-40 oligomers and protofibrils was supported by intramolecular proximity between E22 and I31 observed for both structures.⁽¹²⁰⁾ Although these results do not specify how neighboring A β molecules are arranged within protofibrils or oligomers, they suggest that structural rearrangement is required for protofibrils to convert to fibrils. Further evidence for structural reorganization from protofibrils to fibrils was found by Doi using lyophilization to stabilize A β 1-42 protofibrils and ss-NMR to show that protofibrils are not composed of in-register parallel β -sheets.⁽¹²²⁾

The diagrams in Fig.3A-3D depict alternative schemes for the inter-molecular organization based on experimental data of A β 1-42 oligomer samples. Hoyer observed that A β 1-40, which is normally an unstructured monomer in solution, adopts an antiparallel β -hairpin conformation (Fig.3A) upon binding to an antibody mimicking protein.⁽¹¹⁴⁾ This result inspired the construction of a double cysteine A β mutant (at positions 21 and 30) that was constrained to adopt the β -hairpin conformation. This mutant was shown to form oligomers and protofibrils but not fibrils.^(112,113) Yu performed solution NMR on preglobulomers produced through interactions between N-Met-A β 42 (additional M residue on the N-terminus) and sodium dodecyl sulfate (SDS) micelles (0.2% SDS by weight), resulting in the proposed model shown in Fig.3B.⁽¹²³⁾ This model also predicts intramolecular hydrogen bonds to produce an antiparallel β -hairpin between β -strands spanning residues 17-23 and residues 28-33. In addition, inter-molecular parallel β -sheet contacts are predicted for pairs of β -strands formed by residues 34-42. While the preglobulomer molecular weight was measured to be 16 kDa (~4 A β -molecules), it is not known how the dimer drawn in Fig. 3B would assemble into a larger structure. In another study, Ahmed prepared A β 1-42 pentamers by incubation of monomers at low temperature, and ss-NMR provided the basis for the model of Fig.3C.⁽¹²⁴⁾ This model does not include hydrogen bonds between any of the β -strands (no β -sheets). Another ss-NMR study conducted by Tay was based on 150 kDa (~33 A β molecules) oligomers produced using a procedure similar to that used for globulomers (removal of SDS from preglobulomer solutions by dialysis).⁽¹¹¹⁾ ss-NMR data were consistent with the molecular conformation found in fibrils (Fig.1A), but a significant distinction was reported in terms of intermolecular organization. Unlike fibrils, 150 kDa oligomers are not composed of in-register parallel β -sheets. Instead, Tay proposed the model shown on Fig.3D, with intermolecular antiparallel β -sheets.⁽¹¹¹⁾ Consistent with this

interpretation, Gu used site-directed spin labelling and EPR on A β globulomers to show that their structures are not consistent with in-register parallel β -sheets, but rather antiparallel β -sheet structures.⁽⁵⁹⁾ Finally, Nowick *et al.* designed a macro-cycle peptide derived from A β 17-36 in which residues 17-23 and 30-36 form the β -strands with two δ -linked ornithine β -turns connecting the side chains of D23 with A30, and the side chains of L17 with V36. X-ray structure shows that trimers consist of three highly twisted β -hairpins in a triangular arrangement (Fig.3E) and four trimers form a 12-mer A β *56 species with a central cavity, one important species to impair memory.⁽¹²⁵⁾

Despite significant advances, we emphasize that it is not yet clear how A β oligomer and protofibril structures may be distinguished. None of the diagrams in Fig.3 correspond to widely accepted models for A β protofibril or oligomer structures. In contrast, the fibril structures in Figs. 1 and 2 benefitted from much more sample preparation experience and better optimized structural measurements. While the solution NMR-derived model of Yu is based on many constraints,⁽¹²³⁾ the high concentration of SDS in the final sample is known to affect A β structure. The models in Figs. 3A and 3D are works in progress, in need of many more structural constraints, including complete residue-specific information about secondary structure and experimental constraints on inter-molecular packing. In fact, a recent proline mutagenesis study conducted by Haupt reported that oligomers might be distinguished from protofibrils by the structure of the N-terminus.⁽¹²⁶⁾ Using fluorescence correlation spectroscopy (FCS) and Foster Resonance Energy Transfer (FRET), Maiti showed that the two hydrophobic regions (residues 10-21 and 30-40) have attained the β -strand conformation in both oligomers and fibrils. However the conformations of the turn region (residues 22-29) and the N-terminal tail (residues 1-9) are markedly different.^(127a) The role of the turn region has also been emphasized by NMR and replica-exchange molecular dynamics (REMD) simulations which demonstrate that phosphorylation at S26, which interferes with formation of the D23-K28 salt bridge, impairs A β 1-40 fibrilization while stabilizing its monomer and non-fibrillar aggregates (Fig.3F).⁽⁴⁷⁾ Using pulse hydrogen-deuterium exchange MS, the middle region of A β 1-40 (residues 20-35) was found to be the first to aggregate, followed by the residues 36-42 and then the N-terminus (residues 1-19).⁽²⁴⁾

It is interesting that these A β NMR-derived models from 4 to 33 peptides predict anti-parallel β -sheets.^(111,120-121,123-124) In some cases, the oligomers take up a β -hairpin structure.⁽¹²³⁾ This conformation is, however, very different from that in the fibrils. The overall topology looks similar, but the orientation of the hydrogen bonding network and the side chain contacts are very different. This may be an important factor in the ability of the oligomers to insert into the membrane (because the only large family of membrane proteins with anti-parallel β -sheets consists of porins), and in the formation of the nuclei as described in Section 5. Further support for antiparallel β -sheet arrangement of A β oligomers (Figs. 3A, 3B and 3D) comes from FTIR⁽²²⁾ and X-ray crystallography data on an hexamer of a segment of α B crystallin (K11V).^(127b) These X-ray diffraction results suggest that it may be possible to study A β oligomer structure by crystallography without any chemical modification,⁽¹²⁵⁾ and A β oligomers could adopt a structure similar to the cylindrical antiparallel β -sheet structure (or cylindrin) of the K11V peptide.^(127b) Indeed these β -barrels were predicted prior to the determination of the KV11 peptide structure on several peptides

by computer simulations using coarse-grained and all-atom representations in explicit and implicit solvent.^(128-133a)

Atomistic characterization of the small and large A β 1-40/1-42 oligomers is very difficult as these oligomers are highly aggregation-prone, and degenerate by displaying multiple polymorphic structural variants analogous to strains in prion diseases. In a recent study, Glabe *et al.* designed 23 monoclonal antibodies against A β 1-42 and showed that no single antibody is able to recognize the different states of A β 1-42 *in vitro* and in AD brain.^(133b) What is clear from various experiments is that synthetic A β 1-40 and A β 1-42 polymerize through distinct pathways. Photo-induced cross-linking of unmodified protein (PICUP) with a Y10-Y10 side-chain – side-chain bridge followed by SDS-PAGE, DLS and SEC has been used to unveil the oligomer size distribution of A β oligomers.⁽¹³⁴⁻¹³⁶⁾ A first study showed that A β 1-40 exists as monomers, dimers, trimers and tetramers in rapid equilibrium, while A β 1-42 preferentially forms pentamer/hexamer units. This difference was linked to the specific roles of I41 and A42: I41 is essential to induce paranucleus formation while A42 enhances the self-association of these paranuclei.⁽¹³⁵⁾ Bowers *et al.* further used IM-MS to investigate the early oligomers of A β 1-40 and A β 1-42.⁽¹¹⁾ They confirmed that A β 1-40 dominantly populates monomers, dimers and tetramers, while A β 1-42 mostly forms dimers, tetramers, hexamers and dodecamers, and provided for each species a cross-collision section that can be used to validate the simulations. Moreover, they proposed an assembly mechanism in which the dimer plays a key role and they identified structural differences in the tetramer that rationalize the formation of higher order oligomers by A β 1-42, but not by A β 1-40.⁽¹¹⁾ However, using the same experiment with mutagenesis, Dadlez showed that A β 1-40 oligomers consist of at least two families of conformers: compact and extended. The compact form resembles the fibril-like structure while the extended form resembles the globular form determined by Lu *et al.* with the C-terminal ends forming intermolecular parallel β -sheets.^(137a-b) Note however that other globular structures could fit the cross collision section. Using fluorescence, Chen and Glabe found that the A β alloforms have different conformations and assembly states upon refolding from their unfolded conformations. A β 1-40 is predominantly an unstable collapsed monomer, while A β 1-42 samples a stable structured trimer or tetramer at concentrations > 12.5 μ M.^(137c)

Many experimental studies have revealed the importance of the central hydrophobic cluster (CHC, residues L17-A21) and the C-terminus. While these hydrophobic patches form intermolecular β sheets in fibrils, their role in aggregation is just beginning to become clear. Incubation of A β 40 fragments with the full-length peptide show enhanced fibrilization rates only for the fragments containing residues L17-F20 or A30-M35.⁽¹³⁸⁾ Proline mutations of residues in the 17-20 or 30-35 regions in A β 1-40 and A β 1-42 are more disruptive to fibrilization than mutations in other regions.⁽¹³⁹⁾ Finally, tethered A β 1-40 demonstrated decreased spin mobility at regions H14–V18, G29–A30, and G38–V40 when investigated with EPR spectroscopy.⁽¹⁴⁰⁾

Other experimental studies have helped clarify the role of the two additional C-terminal residues in A β 1-42-specific aggregation. The VPV substitution (G33V, V36P and G38V), promoting a β -hairpin at the C-terminus, increases A β aggregation rate and higher order oligomers, while the PP substitution (V36D-Pro, G37L-Pro), leading to a hairpin breaking

motif, disrupts the A β 1-42 aggregation kinetics and changes the oligomer size distribution to one more characteristic of A β 1-40.⁽¹⁴¹⁾ PICUP results suggest that a turn centered at residues V36 and G37 of A β 1-42 and its absence in A β 1-40 is responsible for the characteristic features of A β 1-42 early oligomers.⁽¹³⁶⁾ These findings suggest that the formation of an additional β topology sampled at the C-terminus, driven by hydrophobic side chain interactions, may be responsible for A β 1-42's unique assembly properties.

The central region, consisting of the hydrophilic residues E22-G29, has also been implicated for its unique properties and effects on A β assembly. This region was identified due to its inherent resistance to proteolysis, which is maintained when the A β 21-30 fragment is isolated. Solution NMR of this fragment reveals that V24-K28 samples two turn-like structures that may be critical in the folding of the monomer⁽¹⁴²⁾ and this was confirmed by computer simulations using various force fields.⁽¹⁴³⁻¹⁴⁵⁾ Further, substitution of contiguous pairs of residues in the V24-N27 region with a turn-nucleating D-ProGly motif largely accelerated fibril self-assembly of A β 1-40.⁽¹⁴⁶⁾ Lastly, charge-altering point mutants of residues E22 and D23 that are implicated in FAD and cerebral amyloid angiopathy also demonstrate increased oligomerization orders and fibrilization rates when introduced into A β 1-40. Further, the oligomerization propensities of each of these mutants in full length A β are directly correlated to both susceptibility of trypsin proteolysis and instability of the V24-K28 turn for the A β 21-30 fragment.^(147a) This suggests that these FAD mutants may destabilize turn like structures in the central region, possibly changing the ensemble and allowing the monomer to seed different types of aggregates. This change in turn confirmation has been confirmed by MD simulations on the A β 21-30 peptide with the Arctic, Dutch and Iowa mutations and two biological relevant salts (CaCl₂ and KCl).^(147b)

Recently, various experiments have shed light on the role of the N-terminus in self-assembly. The D7N (Tottori) mutation accelerates the kinetics of transition from random coil states to β -sheet-rich configurations and promotes the early formation of higher order oligomers with more α/β structures that are significantly more toxic than WT A β 1-40 and A β 1-42 peptides.^(148,149) The H6R mutation, the substitution of K16 by Ala and the substitution of D1 by Tyr also affect self-assembly and toxicity.^(150-151a) Single-molecule AFM experiment shows many dimer configurations stabilized by N-terminal interactions, although there is a difference in the interaction patterns of A β 1-42 and A β 1-40 monomers within dimers.⁽²⁶⁾ Finally, two single mutations at position A2 protect from AD.^(54,55)

In summary, *in vitro* and in AD brain experimental studies indicate polymorphism and inherent diversity of structures present in fibrils and aggregates. Many physical factors can contribute to the formation of strains, and in how the β -sheets pack or the strands hydrogen bond to each other: pH, temperature, concentration, supersaturation of the A β solution, ionic strength, sample, agitation conditions such as shear forces or sonication, interfaces, the presence of seeds.^(18,29,151b-d) Other data indicate that the structures and polymorphism of A β fibrils critically depend on the oligomeric states of the starting materials, the ratio of monomeric-to-aggregated forms of A β 1-42 (oligomers and protofibrils), and the probability of secondary nucleation.⁽¹⁶⁾ A recent study investigated how local physical forces interfere with the fibrillation kinetics, the general morphology, and the local structure and dynamics of the fibrils formed from the A β 1-40 peptide. The well described hydrophobic contact

between F19 and L34 was rationally modified and the F19G, F19E, F19K, F19W and F19Y mutants were studied in order to understand the impact of the change in electrostatic (E and K mutations), hydrophobic interactions (W and Y mutation) between side-chains and larger flexibility of the backbone (G mutation). Local interactions were observed to influence the fibrillation kinetics, dynamics and structure (the register of the hydrogen bond pattern) of A β 1-40, but leave the general fibril structure unchanged. These data also indicate the role of the non-local F19-L34 in the early oligomers.^(151e) Overall a solid fundamental understanding of the principles underlying polymorphism and strain behavior of fibrils remains to be determined.

2.3 Monomers

Although A β 1-40 and A β 1-42 monomers are described by disordered conformations, there is experimental evidence suggesting a bias toward β -strand character in the CHC core and the C-terminus and a propensity for turns at specific positions within the A β monomers. Solution NMR studies targeting the monomeric state best characterize A β with a collapsed coil ensemble and not by a unique structure.⁽¹⁵²⁾ Nevertheless, backbone H α , C α , and C β chemical shift indices suggest β -strand propensities in the CHC, I31-V36, and V39-I41, as well as turn character at D7-E11 and F20-S26 in A β 1-42.⁽²¹⁾ Residues V18-F20 (in A β 1-40, A β 1-42, and A β 1-42-M35ox, i.e. with oxidation of the M35 side chain) and V39-I41 (in A β 1-42 and A β 1-42-M35ox) also possess experimental $^3J_{\text{HNHA}} > 7.5$ Hz, indicative of a bias toward ϕ dihedrals characteristic of β -strands in these regions.^(153,154) Far UV CD spectra for A β 1-40 and A β 1-42 monomers are also dominated by random coil, but suggest β -strand content.^(149,135) Using different preparation methods, CD analysis reported a β -strand content between 12 % and 25% and an α -helix content between 3% to 9% at 295 K, pH 7.5 and day 0 (therefore for a mixture of aggregates), indicative of the dependence of the secondary structure on sample preparation.^(20,149) ^{15}N spin NMR relaxation data reveal that A β 1-42 monomer demonstrates more rigidity at the C-terminus than A β 1-40, both in terms of side chain and backbone dynamics,^(155,156) suggesting residual secondary structure formation. Although these biases may characterize the A β monomeric ensemble in aqueous conditions, other individual structures may be possible. For example, an NMR structure of A β 1-40 monomer forms a 3-10 helix from H13 to D23 at pH 7.3, even if exchange between the 3-10 helix and other conformations in this region cannot be ruled out.^(157a) In contrast to previous NMR studies, this study was conducted at 50 mM NaCl and it is well established that salt shifts the ensemble from unstructured to more helical conformations.^(157a) The structure of A β 1-40 monomer with a N-terminus cysteine attached to silver nanoparticles has also been interrogated by surface plasmon enhanced Raman spectroscopy (SERS). This shows no change between pH 10.5 and 5.5, the presence of partial α -helical content, indicating the existence of short and transient α -helical conformations for WT A β 1-40 monomer in physiological conditions.^(157b) Finally phase-modulated CLEAN chemical exchange experiment with a fast HSQC detection scheme⁽¹⁵⁸⁾ on A β 1-40 monomer shows that the residues 10-13, 17-22 and 30-36 are partially protected from exchange with solvent, while D23 and the region G25-G29 are susceptible to exchange,⁽¹⁵⁹⁾ consistent with the idea of a solvent exposed turn in the central region.

3. Simulations of A β 1-40 and A β 1-42 Monomers in Aqueous Solution

Characterizing the monomeric state of A β at atomic detail under physiological conditions can be key to understanding how A β assembles into disease-causing oligomers because they represent a base state common to all aggregation pathways.⁽²⁾ This knowledge could be crucial in developing therapeutics that prevent nontoxic monomers from progressing into toxic species, one of the fundamental strategies in the ongoing effort to treat AD. It is well established that self-assembly is profoundly influenced by very subtle chemical changes, ranging from the two-residue difference between A β 1-40 and A β 1-42,^(135,155) FAD mutations,^(21,53) to the single atom modification caused by M35-ox.⁽¹⁶⁰⁾ The polymorphism of monomeric A β under physiological conditions may underlie this relationship. In the absence of unambiguous stable native states, simple chemical modifications could have a profound effect on the type of ensemble sampled by that particular A β peptide. This intrinsic disordered property, in addition to the high aggregation propensity, has frustrated experimental efforts to characterize the A β 1-40/1-42 structures.

The challenges and limitations inherent to the current set of experimental techniques for studying these polymorphic, aggregation-prone A β monomers have encouraged many groups to use a wide variety of computational techniques to more thoroughly investigate the conformational properties of these peptides. Over the years, the ability to perform extensive MD simulations has improved. Today, simulations for A β extend over multiple microseconds using explicit and implicit solvent models. Additionally, REMD⁽¹⁶¹⁾, simulated tempering⁽¹⁶²⁾ and metadynamics⁽¹⁶³⁾ simulations are used to escape energy minima and enhance sampling. In general, the results obtained in simulations of intrinsically disordered proteins (IDP) like A β depend strongly on the set of parameters (such as the force field) used to describe the energy of the peptide and their interactions with the aqueous solvent. Widely used force fields for biomolecular simulations are OPLS-AA,⁽¹⁶⁴⁾ AMBER99sb and their variants,⁽¹⁶⁵⁾ and CHARMM22*,⁽¹⁶⁶⁾ while frequently used water models are the three-site models TIP3P⁽¹⁶⁷⁾ and SPC/E,⁽¹⁶⁸⁾ and the four-site models TIP4P⁽¹⁶⁷⁾ and TIP4P-Ew.⁽¹⁶⁹⁾ These force fields have been calibrated against model compounds and peptides, and in most instances the force fields reproduce folded conformations of small globular proteins with root-mean-square deviations (RMSDs) within Ångstroms of the experimentally determined structures.^(170a-d) However, experimental validation of the ensembles produced by these force fields, for either the unfolded states of globular proteins^(170e) or IDPs^(170f), remains essentially an unsolved problem. Here, we review some of the more recent simulation studies, which employ state-of-the-art strategies, ranging from all-atom REMD simulations to other approaches, to extensively characterize the equilibrium structures of A β 1-40 and 1-42 monomers.

All-atom REMD simulations on the μ s/replica timescale with OPLS-AA/TIP3P conducted by Rosenman *et al.*^(154b) revealed that A β 1-40 sampled β -hairpins between the L17-A21 and I31-V36 regions, while A β 1-42 sampled a second β -hairpin spanning V39-A42, forming transient β -meander structures. The hairpin model of A β 1-40 with the backbone of K16 hydrogen bonded to the backbone of G37 is found in both centroids 3 (4.2%) and 4 (3.9%) using a linkage clustering shown on Fig.4A (top). This conformation does not exist for A β 1-42, as the centroid 1 of A β 1-42 possesses a different CHC to C-terminal hairpin with a

backbone H-bond register shifted by two residues. The double hairpin for A β 1-42 is found in centroid 7 (Fig.4A, below). The predicted hairpin for A β 1-40 is consistent with the NMR structure of A β 1-40 in complex with a phage selected affibody⁽¹¹⁴⁾ as shown in Fig.4B, and the intrapeptide model of A β 1-40 fibrils as published by Bertini *et al.*⁽⁹⁸⁾ shown on Fig.4C. The predicted double hairpin for A β 1-42 is consistent with the intrapeptide model of A β 1-42 pentamers as published by Ahmed *et al.*⁽¹²⁴⁾ shown on Fig.4D. Taken together, these REMD-predicted hairpins, by demonstrating a structural similarity to models of higher order aggregates, suggest that they may act as the seeds for A β assembly.

Previous characterizations of A β through REMD simulations with OPLS-AA/TIP3P and AMBER99sb/TIP4P-Ew also predicted conformations where A β was mostly flexible but possessed some structured segments; in particular, β -hairpins populated the C-terminus in A β 1-42 but not A β 1-40.⁽¹⁷¹⁾ A different approach was taken by Ball *et al.*,⁽¹⁷²⁾ who had used 100 ns multiple reservoir replica exchange (MRRE) simulations with AMBER99sb/TIP4P-Ew to determine that A β 1-42 was mostly disordered, with significant α character in residues Y10-F19 and E22-N27 and little to no β content. The same group then reported their analysis of multiple trajectories acquired with the same simulation method, this time processing the resulting ensemble using the ENSEMBLE package⁽¹⁷³⁾ to select structures that best match experimental chemical shifts, residual dipolar couplings, ³J_{HNHA} couplings, and ¹H-¹⁵N NOEs.⁽¹⁷⁴⁾ After refinement with ENSEMBLE, the aforementioned α -content is de-emphasized, and antiparallel β -hairpins between the K16-A21 and G29-V36 regions are promoted in A β 1-42. A β 1-40 after ENSEMBLE refinement, in contrast, is characterized by reduced C-terminal β propensity and sampling of a hairpin between the CHC and residues G9-H13.⁽¹⁷⁴⁾ The data suggest that the extra two residues in A β 1-42 primarily promote hydrophobic clustering that direct the increase in β content in the CHC and G29-V36 region, rather than the direct formation of additional secondary structure, such as the second hairpin discussed above. Further, despite possessing similar overall biases, the ensembles generated by Ball⁽¹⁷⁴⁾ and Rosenman^(154b) also differ in β % per residue, with the largest residue propensities in the range 20-30% in the former and 50-60% in the latter. It is worth noting a 100 ns/replica REMD simulation with AMBER99sb/TIP3P also revealed that A β 1-42 forms contacts between L17-A21 and I31-V36 with a transient turn in the region D23-N26, consistent with a quasi-hairpin-like conformation.⁽¹⁷⁵⁾

Other approaches beyond atomistic REMD in explicit solvent have also been used to investigate the properties of A β . The two alloforms were explored using the Folding@home platform and thousands of MD trajectories with AMBER99sb/TIP3P, each of average length ~30 ns, for each species.^(176,177) Both WT A β s are described as mostly disordered ensembles, with some α -helical character from residue 10-20 and almost no β -content, in reasonable agreement with SERS experiment.^(157b) Of the β content that exists, β -sheet propensity near the C-terminus is notably less in A β 1-40 than in A β 1-42. Granata *et al.*^(178a) investigated the A β 1-40 ensemble with NMR guided metadynamics, which uses experimental data as collective variables to drive metadynamics calculations rather than using them purely for simulation validation or as hard structural restraints.^(178b) Simulations were carried out with CHARMM22*/TIP3P at 350 K and 8 replicas for 310 ns/replica. Each replica was biased by a history-dependent potential acting on a different collective variable, including two variables for the difference between predicted and experimental chemical

shifts. The resulting unbiased free energy surface (FES) has many extended and highly disordered states and large radii of gyration.^(178a) In terms of structured states, the FES displays structures with long α -helical content similar to the structure predicted by Vivekanadan,⁽¹⁵⁷⁾ and short α -helix content as predicted by Pande *et al.*,⁽¹⁷⁶⁾ and various β -hairpins spanning the L17-A21 and I31-V36 regions, similar to the structures predicted by Rosenman *et al.*⁽¹⁷⁸⁾ Further simulations showed the FES does not change at 300 K.

A β monomers have also been investigated by REMD⁽¹⁷⁹⁾ with the six-bead CG OPEPv3 model in implicit solvent^(180a) and Monte Carlo simulated annealing with the all atom PROFASI force field.^(181a) The OPEPv3 force field has been calibrated against non-amyloid peptides, and in most instances predicts folded conformations with 2-3 Å RMSD from the NMR structures,^(179,180a-e) although it cannot reproduce vibrational frequencies with high accuracy as all-atom models.^(180f-g) OPEP has also been coupled to a greedy algorithm for structure prediction of peptides with 9-52 amino acids.^(180h-i) The OPEP-REMD simulation revealed A β ensembles that were mostly turn/coil, but possessed substantial β -sheet propensity in the N-terminus.⁽¹⁸²⁾ It remains to be determined whether OPEPv5 with better electrostatic interactions leads to a different picture.⁽¹⁸³⁾ The PROFASI simulation characterized A β 1-42 as possessing strong β probability in many of the residues over the peptide.^(181b)

All-atom REMD simulation of both alloforms was performed for 110 ns per replica with AMBER99sb/Generalized Born (GB).^(184a) Each monomer behaves as a unique statistical coil at 298 K with five relatively independent folding units comprising residues 1-5, 10-13, 17-22, 28-37, and 39-42, connected by four turns. The two turns predicted at positions 6-9 and 23-27 are in agreement with NMR and the residues I41 and A42 increase contacts within the C-terminus and between the CHC and the C-terminus leading to a more structured C-terminus.^(184a) Finally, discrete MD (DMD) simulations, where all inter-particle interactions are expressed by square-well and step-like potentials, coupled to a four-bead CG model, find that A β 1-42 displays a turn centered at G37-G38 and a β -hairpin spanning V36-A42 that are absent in A β 1-40.^(184b) DMD simulations also capture two other differences between the alloforms: a highly populated β -strand at A2-F4 in A β 1-40 but not in A β 1-42, and a β -hairpin centered at S8-Y10 in A β 1-42 but not in A β 1-40.

While the most recent and exhaustive all-atom studies in explicit solvent have started to show some consistent depictions of the properties of the A β ensemble, most characterizations of the A β 1-40 and A β 1-42 peptides, in our opinion, remain highly divergent. These variations may arise from differences in simulation conditions, extent of sampling, or trajectory analysis. IDPs like A β , or even the unfolded ensembles of well-folded proteins, remain difficult test cases for our current range of computational techniques because they lack non-ambiguous energy minima. The types of conformations sampled through simulation may be much more sensitive to simulation conditions than that of globular proteins, where parameter differences could still lead to similar final results. For the globular villin headpiece, for example, independent MD simulations using different all-atom force fields were able to recapture the experimental folded structure and folding rate of the protein, but the unfolded states and folding mechanism were highly dependent on force field choice.⁽¹⁸⁵⁾ Meanwhile, in the case of two intrinsically disordered proteins (a 50 residue

peptide derived from a FG-nucleoporin and a 20 residue RS repeat peptide), μ s length REMD simulations with four different all-atom force fields were found to adopt substantially different hydrogen bonds, secondary structure tendencies, and radii of gyration.⁽¹⁸⁵⁾ With this in mind, the force fields that are capable of reversibly folding globular proteins such as AMBER99sb^(165a) with $\ast$ ^(165b) and/or ILDN^(165c) modifications and CHARMM22 $\ast$ ⁽¹⁶⁶⁾ in the studies described in Refs. 170b and 170d may not necessarily be the most suitable for characterizing the metastable states of disordered ensembles.

Given these circumstances, we suggest that multiple simulation studies consistent with experimental data are likely to be much more valuable than a single study with one force field. To sort out un-generalizable findings, more stringent and sensitive experimental validations are necessary, particularly using better reporters on the tertiary structural biases. Many of the values commonly used for experimental comparison, such as NMR chemical shifts and scalar J-couplings are good “sanity checks” on sampling, but primarily report on local structure and are highly prone to sequence-specific bias. Full characterization of the structures sampled by intrinsically disordered proteins remains a major challenge. The development of new experimental techniques to probe the A β monomer structures in solution is also needed.

4. Simulations of A β 1-40/1-42 Dimers and Higher Order Assemblies In Aqueous Solution From Random States

Soluble A β dimers are the smallest toxic species in AD⁽¹⁰⁾ and isolated from Alzheimer cortex they directly induce tau hyperphosphorylation and neuritic degeneration.⁽¹⁸⁶⁾ Trimers and larger aggregates are also toxic. Knowledge of their key structural and dynamical features is of significant interest to design drugs inhibiting their formation and toxicity. The conformational stability of preformed A β assemblies of various oligomer sizes, inspired from ss-NMR derived fibril structures (5-mers and 10-mers of A β 17-42),⁽¹⁸⁷⁾ fibril polymorphisms of other amyloid sequences (10-mers of A β 19-42),⁽¹⁸⁸⁾ globulomers (12-mers of A β 17-42)⁽¹⁸⁹⁾ and the design of triple-sheet motifs (24-mers and 60-mers of A β 17-42)⁽¹⁹⁰⁾ was assessed by atomistic MD of 50-100 ns, proving only that these states are stable within the simulation times. In what follows, we describe the most recent simulations aimed at understanding the aggregation of A β peptides from random states (Table 1). Along with A β 1-40 and A β 1-42, we also report the results of three non-pathogenic truncated variants, A β 9-40, A β 10-40 and A β 17-42. We recall the N-terminal, central and C-terminal regions cover residues 1-16, 22-29 and 30-40/42.

4.1. Dimer Simulations With Simplified Representations

Using the 6-bead CG OPEPv3 model with implicit solvent^(61,183,191-194) the structures of A β 1-40 and A β 1-42 dimers were determined by HT-REMD simulations starting from randomly chosen conformations.⁽¹⁹⁵⁾ HT-REMD⁽¹⁹⁶⁾ combines standard REMD⁽¹⁷⁹⁾ with a Hamiltonian exchange procedure, where several replicas with reduced non-bonded energies are used at the highest temperature. Both alloforms populate mostly turn/random coil conformations with a β -sheet propensity at the C-terminal region higher than in the monomers. Dimerization is characterized by inter-peptide hydrophobic contacts between

CHC/CHC, CHC/C-terminal region and C-terminal/C-terminal regions. However, the A β 1-42 dimer has a higher propensity than the A β 1-40 dimer to form β -strands at the CHC and in the C-terminal region. The free energy landscape of the A β 1-42 dimer is also broader and more complex than that of the A β 1-40 dimer.⁽¹⁹⁵⁾

United-atom REMD simulations with CHARMM19⁽¹⁹⁷⁾ and a solvent-accessible surface area (SASA) implicit solvent⁽¹⁹⁸⁾ were performed on A β 1-40 and A β 10-40 dimers.^(199,200) Truncation of the first 9 residues leads to minor changes in the structure of the dimer.⁽²⁰⁰⁾ The conformational ensemble of the A β 10-40 dimer can be described by three distinct basins differing with respect to the distribution of secondary structure and the amount of inter- and intrapeptide interactions. The interface is largely confined to the region 10–23, which forms the bulk of inter-peptide interactions and a few inter-peptide hydrogen bonds.⁽¹⁹⁹⁾ Random reshuffling of the amino acids, i.e. sequence permutation, does not impact the A β 10-40 dimer globule-like states, suggesting that the A β 10-40 peptides in the dimer behave as ideal chains in polymer melt, in which amino acids lose their identities.⁽²⁰¹⁾ These results run in contrast to MC simulations with the all-atom PROFASI model and implicit solvent^(181a) where the A β 1-42 dimer is mostly composed of a four-stranded anti-parallel β -sheet or two layers with mixed parallel/antiparallel arrangements and three major clearly identified turns at positions 13-16, 23-26 and 35-38.⁽²⁰²⁾

Finally, extensive DMD simulations coupled to a four-bead CG model found that the A β dimer conformations are collapsed and disordered with a small content of β -strands linked by loops and turns.⁽²⁰³⁾ The A β 1-42 dimer has a higher propensity of β -sheets at the CHC and C-terminal region than the A β 1-40 dimer. A β 1-40 dimer formation is mainly driven by intermolecular interactions between the CHC regions, while the C-terminal region plays a significant role for A β 1-42.⁽²⁰³⁾ 50-ns MD stability simulations with OPLS-AA/TIP3P or SPC/E starting from the dominant DMD-obtained CG structures confirm the main DMD results⁽²⁰³⁾ and enable a precise analysis of secondary structures, salt-bridges and free energy landscapes.⁽²⁰⁴⁾ Overall, the free-energy landscape of A β 1-42 is much more complex than that of A β 1-40.

4.2. All-Atom Dimers in Explicit Solvent

Solvation free energy analysis based on the integral-equation theory of liquids and MD trajectories of 100 ns suggests that dimerization occurs through a two-step nucleation-accommodation mechanism: decrease of the monomer solvation free-energy followed by structural reorganizations in the dimer leading to a decrease in the protein internal energy.⁽²⁰⁵⁾ 50-ns per-replica REMD with AMBER99sb/TIP4P-Ew, followed by ab-initio energy calculations on selected poses, concluded that the stability of the water molecules solvating around the dimer mainly determines the relative stability for the different conformations of the A β 1-42 dimer.^(206a)

Recently, REMD simulations using OPLS-AA/TIP3P with 250 ns per replica were performed on A β 1-42.⁽²⁰⁷⁾ The A β 1-42 dimer mostly populates coil/turn (80.4%), and then α -helix and β -strand with 11.1% and 8.4%. The latter values do not match exactly, but are consistent with the CD-derived values: a α -helix content varying from 3% to 10.5% and a β -strand content varying between 12% and 38%.^(20,149b) The most β -rich signal is at the C-

terminal region. Looking at the networks of inter-chain contacts, the interface of the 1-42 dimer is mainly composed of the C-terminal and CHC regions, as the regions of highest contact probability are C-terminal/C-terminal, CHC/CHC and CHC/C-terminal. The calculated collision cross sections of the three most populated dimer states nicely fit to IM-MS values.^(11a) Using a general method to characterize oligomer structures,^(206b) there is no evidence of well-formed intermolecular parallel and antiparallel β -sheet configurations. Rather the first 11 N-terminal residues are essentially disordered and the residues 12–17 have a non-negligible probability for α -helix.⁽²⁰⁷⁾

4.3 Towards Atomistic Structures For Dimers

As for the monomers, common trends start to emerge from the most recent dimer simulations: (1) the dimerization of A β is mainly driven by an hydrophobic collapse through intermolecular contacts involving CHC and the C-terminal region, agreeing with the importance of these regions during aggregation as observed experimentally,^(149,124) (2) A β 1-42 has a larger β -strand propensity than A β 1-40 at the CHC and C-terminal regions, (3) the free-energy landscape of A β 1-42 is more complex than that of A β 1-40, (4) all possible salt-bridges are highly accessible to the solvent,⁽²⁰⁷⁾ and (5) both alloforms have many structural differences already at the dimer level that can account for their very different oligomerization pathways and toxicity potencies as observed experimentally.^(135-136,11,53) For each alloform the results between the simulations still diverge and we can identify qualitative differences in the total and per-residue propensities of secondary structure (Table 2, Fig. 5) and the tertiary/quaternary structures.

4.4. Aggregation of High Order Assemblies

Simulations of higher order assemblies from random states are very challenging as the number of minima scales exponentially with the number of particles. CG and all-atom models coupled to implicit solvent schemes enable long timescales that are not reachable by all-atom explicit solvent MD.

The structural ensemble of the A β 17-42 trimer was investigated using REMD and the six-bead CG OPEPv3, with 1.2 μ s for each replica.⁽²⁰⁸⁾ This fragment was selected because it covers the β -strand–loop– β -strand in the A β 1-42 fibril. At equilibrium and 300 K, the trimer adopts globular conformations with 46% of turn, 35% of random coils, 8.7% of helix and 7% of β -strand. Using a RMSD cut-off of 3 Å, 35% of all sampled conformations can be described by two clusters. The first cluster with a population of 19% displays one chain with a β -hairpin spanning residues F17-L34, and the other two chains with a disordered β - α - β -turn- β motif. In this motif, the α -helix spans residues E22-K28, the turn spans G37-G38, and the β -strand signal is rather weak elsewhere. The second cluster (15.4%) is more disordered with an inter-peptide antiparallel β -sheet spanning the CHC region and residues I31-I34, a α -helix spanning A21-N26, and turns at positions G37-G38. The third (13.3%) and fifth (8.2%) clusters are random coil in character, but display inter-molecular antiparallel β -sheets between V36-G38 and V39-V41 (cluster 3) or between I31-G33 and G38-V40 (cluster 5). Overall, the preference for parallel β -sheet is not encoded in A β 17-42 trimer. This picture is fully different from the REMD results of A β 10-40 tetramer using

CHARMM19/SASA, showing rather amorphous states that are structurally similar to the dimers.⁽²⁰⁰⁾

A total of five all-atom MD simulations of 200 ns each with OPLS-AA⁽¹⁶⁴⁾ and GB/SA⁽²⁰⁹⁾ on a system of 20 A β 1-42 at a concentration of 0.8 mM starting from various structures and dispersed peptides⁽²¹⁰⁾ reveals that the early aggregation pathways at 300 K are very diverse and are dominated by unstructured oligomers characterized by 82% coil, 7.6% β -strand and 10% α -helix, consistent with atomistic REMD of A β 1-42 dimer in explicit solvent.⁽²⁰⁷⁾ The conformations are characterized by strong intermolecular interactions involving residues 31-42 and 17-21 and several differences between A β 1-42 and A β 1-40 aggregation are observed from the intermolecular contact maps. The oligomer mass distribution, though out of equilibrium within 200 ns, displays a higher population for dimers, tetramers, hexamers, octamers (globular shape), 12-mers and 18-mers (elongated shape), in agreement with experimental results.⁽¹³⁵⁾ A maximum flow transition network analysis unveils a complex aggregation process, although key preferential pathways are found: for instance the trimer serves as building block for the hexamer, while the dimer preferentially aggregates into tetramer and octamer.⁽²¹⁰⁾

Finally, CG DMD simulations have been used to study the aggregation of 32 peptides of both A β alloforms.^(184b,203) The simulations reproduce qualitatively the main features of the oligomer size distribution of A β 1-40 and A β 1-42 as measured experimentally. Overall, these oligomers, as for the dimer, form rather amorphous aggregates with a low propensity of β -sheet that are stabilized by intermolecular contacts between the CHC and C-terminal regions. The main differences between A β 1-42 and A β 1-40 oligomers are the larger β -strand propensity at the C-terminal region and turn propensity at G37-G38, and the larger flexibility and solvent-exposure of the N-terminal of A β 1-42. Interestingly, there is no substantial increase of β -strand content from dimers to hexamers and larger oligomers, with all β contents varying between 14% and 22%. We recall that the β -sheet content amounts to 50% in fibrils. DMD further indicates that A β 1-40 dimers and hexamers have indistinguishable intramolecular contact maps and tertiary structures, whereas the A β 1-42 transition from dimers to hexamers is accompanied by a partial loss of intramolecular contacts within the CHC.

In summary, higher-resolution experimental data going beyond cross-collision sections (IM-MS), secondary structure content averaged over different oligomer sizes (CD) and hydrodynamic radii (diffusion NMR) as well as standardized simulations will help converge on the most relevant dimer and oligomer structures. While the simulations agree on a few structural aspects, they wildly differ on the equilibrium ensemble due to the difficulties associated with correct sampling and force field accuracy. Comparisons between simulations with different force fields are required as well as multiscale approaches that couple cheap potential for fast sampling and more reliable force fields for refinement of selected poses.^(204,208) Another possibility is to run CG simulations for a short time and then switch to atomistic simulations for a few ps, and so on. It may be at this cost that we will obtain a convergent and reliable free energy landscape of dimers and high order oligomers.

5. A β Nucleus in Aqueous Solution

5.1. Nucleation and Protein Aggregation

The nucleation of amyloid fibrils is a process associated with the generation of nanoscale fibrils or protofilaments that have the property of irreversible growth.⁽¹¹⁴⁾ Unless the nanofibril size exceeds the size N_c of the so-called critical nucleus, the nanofibril is more likely to dissolve rather than grow. Only if the number of monomers becomes larger than N_c , the system can grow irreversibly into a macro-scale amyloid fibril. From a thermodynamic point of view, the size of critical nucleus may be defined as a turnover point of the free energy plotted as a function of the number of chains (Fig. 6A).⁽²¹¹⁾

Protein aggregation might occur through three possible pathways. In homogeneous nucleation,⁽²¹²⁾ new aggregates are generated at a rate that depends on the concentration of monomers alone and is independent of the concentration of existing fibrils. In the fragmentation process, the rate of generation of new aggregates depends only on the concentration of existing fibrils.⁽²¹³⁾ Finally, within the secondary nucleation process, the rate depends both on the concentration of the monomer and of existing fibrils.⁽²¹⁴⁾ The six-bead CG OPEPv3 simulations revealed that the fibril formation of short linear peptides occurs via the homogeneous nucleation mechanism.^(215a) OPEP has been optimized by discriminating native from non-native structures of proteins and successfully folding peptides to their NMR structures.^(179,180a) Using an off-lattice model coupled to enhanced sampling, the rate-limiting step has been suggested prior to nucleation to be associated with a change in the width of the fibrillar aggregate of 3.5.⁽²¹⁶⁾ A β 1-42 aggregation was shown to proceed through the secondary nucleation pathway rather than through a classical mechanism of homogeneous primary nucleation using a combination of kinetic studies, and selective radiolabeling experiments.⁽¹⁴⁾

In homogeneous nucleation, the lag phase (Fig.6B) is weak and at short times the fibril mass $M(t)$ scales with $C^{N_c+2} t^2$, where C is the monomer concentration. Thus, from the concentration dependence of the slope of $\log M - \log t^2$ one can extract the size of critical nucleus.⁽²¹⁷⁾ N_c can also be estimated from the dependence of the lag phase time on protein concentration, as approximately $C^{-N_c+1/2}$.⁽²¹⁸⁾

Using a simple two-state model and Langevin dynamics, the lag phase and the nucleus size N_c has been shown to vary from 4 to 35 linear peptides depending on the energy difference between the amyloid-competent and amyloid-protected minima and one can generate fibril topologies resembling those observed experimentally, e.g., twist and multifilament composition.⁽¹⁰²⁾ Using a lattice model and Monte Carlo (MC) simulations, it was evidenced that the balance between electrostatic and hydrophobic interactions not only modulates the populations of the amyloid-competent monomeric state and the lag phase, but also the topology of the fibrils.⁽²¹⁹⁾ Using a more complex onlattice model and dynamic MC, 10 linear peptides of seven amino acids with an alternative hydrophobic and hydrophilic pattern remain stable at low temperature. When the short fibrils are subsequently simulated in a grand canonical ensemble, further growth of the structure is observed, indicating that N_c is at least equal to 9.⁽²²⁰⁾ These N_c values are much higher than that derived by atomistic simulations followed by *ab initio* calculations where $N_c = 3$ was found to be sufficient to

trigger fibril growth of the GNNQQNY peptide.⁽²²¹⁾ This low N_c value is likely due to the neglect of conformational entropy. Indeed, based on multi-scale simulations, De Simone showed that a comprehensive description of the flexibility of the all states must also be considered for self-assembly.⁽²²²⁾

By using a mesoscopic model similar to that defined by Caflisch, one can establish a connection between the early nucleation events and the kinetic information available in the later stages of the aggregation process. Using an energy difference between amyloid-competent and non-amyloid-competent states from all-atom simulations and translational and rotational diffusion constants from experiment, the nucleus was estimated as $N_c=4$ for A β 1-42 using dynamic MC.⁽²²³⁾ This estimate does not agree with quasi-elastic light scattering (QLS) experiment at a A β concentration of 1.16 mM or 0.47 mM in 0.1 M HCl where the experimental kinetic data at low pH are reproduced correctly when the number of peptides involved in the critical nucleus of A β 1-40 is 10.⁽²²⁴⁾ The kinetic data vary, however, with the experimental conditions used, as described below. In contrast, calculating G as a function of the number of monomers with the help of a CG model, Fawzi *et al.* obtained $N_c=10$ for A β 1-40.⁽²²⁵⁾ Based on the experimental⁽²²⁶⁾ and theoretical⁽²²⁷⁻²²⁸⁾ observations that the binding of monomers to a preformed fibril obeys the dock-lock mechanism in which a monomer first docks and then undergoes the structural arrangement necessary to lock onto the template, Li *et al.* proposed that the time for adding a new monomer, τ_{add} , is expected to become independent of the template size when it exceeds N_c .^(219,229) By using a lattice model with 8 beads for A β 1-40 (Fig. 6C-D), N_c was found to be 11 (Fig. 6E). However the population of the amyloid-competent monomer is found to be on the order of 9% at the folding temperature, a value that is possibly overestimated. Nevertheless, one can show that this approach⁽²³⁰⁾ provides an estimate of N_c consistent with the dependence of the free energy variation on the number of monomers.⁽²¹¹⁾

By using classical nucleation theory to describe amyloid nucleation, Cabriolu *et al.* predict the nucleus size and the fibril nucleation rate as a function of the super-saturation of the protein solution. It was found that N_c is 15 for A β 1-40 at a protein concentration of 120 μ M, but variation in the supersaturation of the phase can cause N_c to increase to 50.^(231a) This is rather consistent with the experimental estimate of the size of the critical nucleus ($N_c > 29$) using fluorescence correlation spectroscopy at a supersaturation of 100 μ M A β 1-40 solution.^(231b) Note that Auer *et al.* argued that, in some cases, the dependence of the fibril nucleation rate on the concentration of monomer protein is stepwise and not power-law.⁽²³²⁾ If this were the case also for A β 1-40 and A β 1-42, a treatment of the nucleation process based only on CNT would be only approximately correct.

5.2. Nucleus of C-terminal A β Fragments by Atomistic Simulations

Recent advances in sampling techniques allowed studying by an all atom description the early stages of the aggregation process of the octa-valine-peptide (Val8) and the A β 35-40 peptide.^(233,234) Several studies reported the importance of the residues 35-40 in triggering the aggregation process of the whole A β peptide.⁽²³⁵⁻²³⁷⁾ The micro-crystalline structure of this peptide in a amyloid-like configuration reveals antiparallel (AP) β -strands within the sheets and parallel (P) β -sheets.^(83a) A β 35-40 was modeled with AMBER99sb/TIP3P at a

concentration of 120 mM and 350 K.⁽²³⁴⁾ At this concentration, the peptide spontaneously forms a compact disordered aggregate and the “rare event” is the formation of an ordered nucleus. The process was studied by bias-exchange metadynamics⁽²³⁸⁾ allowing reconstructing multidimensional free energy landscapes with large barriers and in which a reliable reaction coordinate is unknown.

The free energy landscape of 18 A β 35-40 peptides displays a funnel with two local minima at its bottom and a third local minimum at a free energy approximately 40 kcal/mol higher (Fig. 7).⁽²³⁴⁾ Basin 1 includes structures that are mainly disordered. Basin 2 contains a much larger fraction of anti-parallel β -sheets (up to 10-12 β -strands). In this basin the β -strands, although common, are not organized in a stable configuration and contacts between different layers form only transiently. Basins 1 and 2 are separated by a relatively low barrier that can be crossed on the time scale of a few tens of ns. Basin 3 includes structures with a high content of anti-parallel β -sheets, which are closely packed on top of each other in a steric zipper. This basin might represent a viable seed for the formation of an amyloid-like ordered aggregate. The structure is similar but not identical to those reported by Sawaya *et al.*^(83a) In particular the layer of β -sheets (top) is shifted by two residues with respect to the layer (below), as compared to the experimental structure. Consequently, inter-sheet contacts involve different side chains, providing a better screening from the solvent. The barrier associated with the disruption of the structure of basin 3 is 16 kcal/mol at 300 K, indicating that it is remarkably stable, at variance with basin 2, and at variance with the experimental structure, that, if used for constructing a model of an aggregate with less than 30 chains, is stable only for a few ns. These results led Baftizadeh *et al.* to hypothesize that the rate-limiting step for the nucleation of A β 35-40 is not associated with the formation of AP β -sheets, but with the formation of specific inter-digitation of the side chains observed in basin 3. Indeed, structures with a content of β -sheets comparable to the one observed in basin 3 will become disordered, while structures arranged in a correct steric zipper, are orders of magnitudes more stable. This scenario is qualitatively consistent with the dock-lock mechanism.⁽²³⁰⁾

An unbiased REMD simulation of 16 A β 37-42 peptides with CHARMM27/TIP3P was performed using 48 replicas, each for 500 ns.⁽²³⁹⁾ A β 37-42 with opposite charges at the termini is particularly intriguing because it forms amyloid fibrils with AP sheets and P β -strands. Despite frequent β -sheet formation/fragmentation events and 20% of free monomers, the population of 4-5 fully P β -strands, consistent with the fibril structure, is 1-2%, while the population of 4-5 fully AP β -strands is 3-8%. The global free energy minimum consists of structures with 2-3 β -sheets, each of 2-3 mixed AP/P β -strands and a variety of sheet-to-sheet pairing angles surrounded by random coil peptides.⁽²³⁹⁾ The aggregates of low-to-medium free energies consist of mixed P/AP β -strands in agreement with integrative temperature sampling simulations of the same peptide with 16 copies using AMBER99 and GB/SA,⁽²⁴⁰⁾ CG-REMD of 20 NNQQ and GNNQQNY peptides, and other amyloid-forming peptides.⁽²⁴¹⁻²⁴⁵⁾ This free energy picture is also consistent with atomistic metadynamics of 18 Val8 peptides in explicit solvent,⁽²³³⁾ where the maximum free energy involves a transition from P/AP to P orientations when a sufficient number of parallel sheets is formed so that the free energy starts to decrease with fully P β -sheets. The REMD

simulation for A β 37-42 indicates that N_c is > 8 , but whether N_c is around 12-16 as estimated for the Val8 peptide^(220,233) cannot be determined due to finite-size effects.

5.3. Structures of the Nuclei for A β 1-40 and A β 1-42 Peptides

Simulating the formation of the critical nucleus of full length A β starting from a disordered aggregate and by describing the system with an atomistic Hamiltonian in explicit water is still not possible with current computational resources. However, the results obtained from the nucleation process of smaller fragments, the MD structural ensemble of the A β 1-40/42 monomers, and experimental data on small oligomers, allow drawing some hypotheses on the structure of the nucleus of A β 1-40/42.

What is clear from various experimental studies is that small A β 1-40/1-42 oligomers are rich in antiparallel β -sheets.^(22,63,111,123,124) A solution NMR structure of A β 1-40 monomer with a dimer protein is also available,⁽¹¹⁴⁾ where the CHC and C-terminal forms a β -hairpin spanning residues 17-36, with the loop region resistant to proteolysis and the rest of A β residues disordered. This specific structure is also observed in three atomistic simulations of A β 1-40 monomer using three different force fields,^(154b,174,178) CG OPEP-REMD of the monomer of A β 17-36⁽¹⁴⁴⁾ and the trimer of A β 17-42,⁽²⁰⁸⁾ albeit with low probabilities. Based on these observations, one can speculate that during aggregation, soluble oligomers may form by stacking β -hairpin-like structures with a loop formed, and loose β -strands at positions 30-35 and 17-20. The next step towards the formation of the fibril, once a critical nucleus is formed, would be the crossing of a high energy barrier associated with a concerted conformational transition in which the β -sheets become parallel and pass from out-of-register to in-register arrangements via chains reptation.⁽²⁴⁶⁻²⁵⁰⁾

This scenario explains why the A β peptide with a lactam bridge between residues 23 and 28 does not display any lag phase,^(251,252) and the FAD mutations and Pro replacement at positions 21-23 change the time for aggregation.^(52,53,253) This scenario is also supported by IM-MS on A β 1-42 where the first region to aggregate spans residues 20-35, followed by residues 36-42 and then residues 1-19,⁽⁵⁶⁾ and the fact that a turn-nucleating D-ProGly motif in the V24-N27 region largely accelerates fibril formation of A β 1-40.⁽¹⁴⁶⁾ Finally, there is strong theoretical evidence on several amyloid peptides that β -hairpins formed in the monomer provide a perfect seed for further growth of the aggregates and reduce lag phases for fibril formation. This is supported by simulations on A β 25-35 peptides,⁽²⁵⁴⁾ prion fragment PrP106-122,⁽²⁵⁵⁾ β 2-microglobulin 20-41 and 83-99 peptides,^(256,257) and human islet amyloid polypeptide hIAPP1-37.^(258,259) For instance, simulations on A β 25-35 showed that, although the monomer preferentially forms a β -hairpin, a transition from compact β -hairpin conformations to extended β -strand structures occurs between dimer and trimer.⁽²⁵⁴⁾

An alternative A β nucleus is based on the atomistic metadynamics simulations of Val8,⁽²³³⁾ OPEP REMD simulations of GNNQQNY and A β 16-22,⁽⁶¹⁾ PROFASI MC simulations of A β 16-22 and A β 25-35,⁽²⁶⁰⁾ and enhanced sampling simulations of A β 37-42 peptides^(239,240) where a mixing of AP/P β -strands dominate in the early low-order oligomers. In this case, the maximum free energy involves a transition from mixed P/AP to fully P orientations, which occurs when a sufficient number of P β -strands is formed so that the free energy starts to decrease to a minimum. Clearly the transition time varies with the

frequency of fragmentation events dependent on the concentration. Aggregation could also start in the C-terminal region or at the CHC. Initiation in the C-terminal region is supported by the two IM-MS experiments,^(56,137b) and the propensity of A β 35-42 fibrils to display either P or AP β -strands within the sheets.^(261a) Initial aggregation at CHC is supported by mutagenesis where Pro replacement in any residue of the region 17-21 leads to the loss of A β fibril formation,⁽²⁵³⁾ and replacement of residues F19 and F20 by Leu or Ile does not prevent aggregation, but enhances amyloid formation.^(261b)

Lastly, it is possible that fully extended metastable states with a population of 7% as described in metadynamics of A β 1-40 monomer⁽¹⁷⁸⁾ and REMD of A β 1-28 monomer (see Section 10) in explicit solvent represent seeds for polymerization. Overall, several nuclei could co-exist with populations depending on the experimental conditions such as T, pH, agitation, etc.

6. Interactions of A β Peptides with Membranes

AD pathology is linked to interactions between various types of assemblies of A β peptides (e.g., oligomers, channels and fibrils) and neural cell membranes, the membrane integrity being directly affected. Several recent experimental and theoretical studies have been aimed at unveiling the details of the specific molecular interactions between A β peptides and lipid membranes, providing a wealth of information. Key findings and related hypotheses are:

1. Membranes become more permeable to ions in the presence of A β peptides. In contrast, monomers or fully developed fibrils have little or no effect on membrane permeability.^(262,263) Lipid vesicles may also become more permeable in the presence of attached growing (i.e., not mature) fibrils.⁽²⁶⁴⁾ Mature fibrils can also affect the structure of membranes to some extent,⁽²⁶⁵⁾ but the effect is thought to be much less dramatic. Moreover, if the A β peptides are modified such that amyloid fibril formation is accelerated and the formation of small soluble oligomers is decreased, both their toxicity and their propensity for binding to lipid membranes are attenuated.⁽²⁶⁶⁾
2. Several different mechanisms that could lead to membrane leakage^(267,268) have been proposed and discussed: (i) The simple mechanical “carpeting” by fibrillar peptide aggregates on one leaflet of the membrane surface, which destabilizes the membrane by creating an asymmetric pressure between the leaflets. (ii) The detergent effect - a result of the surfactant-like properties associated with the amphiphilic nature of A β , which causes the removal of lipids from the membrane, leading subsequently to thinning or even occurrence of holes in membranes. (iii) The formation of toroid-like A β pores and membrane channels. It is well accepted that neuronal death in AD is related to disturbances in Ca²⁺ homeostasis. The formation of Ca²⁺ channels in lipid bilayers was directly observed in experiments where A β 1-40 peptides were incorporated into planar phosphatidylserine bilayers. A linear current-voltage relationship in symmetrical solutions was recorded and, using AFM, an 8 to 12 nm doughnut-shaped structure with a 1 to 2 nm internal pore cavity that protrudes approximately 1 nm above the embedded bilayer surface was revealed.⁽²⁶³⁾ These channels are composed of 3,

4, 5 or 6 subunits with the most common structures being those with four or five subunits (Fig. 8).⁽²⁶⁹⁾

3. A β aggregation can be significantly accelerated by the presence of membranes.⁽²⁷⁰⁻²⁷²⁾ An important factor favouring membrane binding is the presence of electrostatic attractions between negatively charged lipid head-groups and peptides, which even persists in solutions with high ionic strength, where electrostatic interactions are almost fully screened.⁽²⁷⁰⁾ It has been suggested that electrostatics drives the initial binding of A β peptides while preventing a deeper insertion into the membrane.⁽²⁷³⁾ Using two novel mouse models expressing membrane-anchored or non-anchored versions of the human A β 1-42 peptide, membrane-anchored A β accelerates amyloid formation. This strongly suggests that A β -membrane interactions play a pivotal role in early-onset AD and exacerbate toxicity in mice.⁽²⁷⁴⁾
4. Another factor proposed to favour membrane binding is the propensity of A β to form weakly stable α -helical configurations that anchor the peptide to the membrane.^(275,276) Several effects have been discussed that might promote the aggregation of membrane-bound peptides.^(277,278) Peptides that bind to membranes are oriented and accumulated, and they have a reduced diffusion constant. Furthermore, membranes may induce conformational changes in the binding peptides themselves (i.e., may lower their unfolding activation barriers), and they may even serve as a template for fibril formation.⁽²⁷⁰⁾

Many techniques are used to demonstrate the membrane-mediated effect on A β aggregation, including imaging methods such as AFM and TEM,^(263,279) binding to amyloid-specific dyes, such as Thioflavin T, and techniques monitoring changes in protein size, i.e., gel electrophoresis, SEC, and DLS. AFM is the main technique to demonstrate amyloid pore formation in membranes.^(262,267) CD and attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy monitors secondary structure changes upon A β -membrane interactions. Electrophysiological techniques allow studying amyloid-enabled membrane leakage.^(263,270) Total internal reflection fluorescence microscopy (TIRFM) enables the visualization of individual A β species on membranes and the characterization of their oligomeric states, all at biologically relevant nanomolar concentrations.^(58b,280,281)

The numerous recent experimental studies examining A β -membrane interactions have led to key, central questions that remain open, such as: (i) What is the main pathway for the α -to- β molecular transition accompanying the aggregation of membrane-bound A β ? Though some studies have suggested an α helical conformation for the membrane-attached A β , there is also evidence that the oligomers that attach the membrane are β -sheet rich.⁽²⁸¹⁾ (ii) What is the primary molecular reason behind the toxicity of aggregated A β peptides, and (iii) Why are amyloid oligomers the most toxic species?^(149b,282) Molecular simulations may help answer these questions at greater detail as they allow the investigation of A β -membrane interactions at atomistic level.

The direct simulation of entire peptide aggregation processes using atomistic models remains a challenge by speed limitations of today's computers.⁽²¹⁰⁾ All-atom MD

simulations can give insight into the early stages of peptide adsorption and peptide-membrane interactions. Davis and Berkowitz have used REMD simulations and umbrella sampling to study the adsorption of A β 1-42 on bilayers^(283,284) and possible mechanisms of dimerization, focusing in particular on the role of electrostatic interactions.⁽²⁸⁵⁾ They found that lipid-protein interactions dominate the behaviour of A β on dipalmitoyl-phosphatidylcholine (DPPC) bilayers, whereas protein-protein interactions prevail on negatively charged 2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) bilayers. Independent simulation studies arrived at the conclusion that the adsorption of A β on membranes follows a two-step mechanism. First, electrostatic interactions between charged residues and phosphate lipid head-groups drive the initial binding of A β to the membrane surface. Once A β is anchored to the membrane, hydrophobic interactions involving residues 17-21 and the C-terminal region from residue 30 onwards gain in importance, stabilizing membrane-bound A β .^(272,283,284,286,287) Upon adsorption on the lipid bilayer, the A β peptides appear to preferentially adopt a structure involving two helices: a more flexible α -helix in the N-terminal half of A β , and a second one, with a higher conformational stability, involving residues 30-36 (Fig. 9A). In addition, binding to the membrane seems to induce the formation of the intrapeptide D23-K28 salt bridge in A β . This conformational propensity was determined from all-atom REMD with both implicit⁽²⁸⁸⁾ and explicit⁽²⁸⁶⁾ membranes, and is in agreement with NMR studies.^(275,276) The A β peptides are localized at the interface between membrane and water, with the C-terminal helix penetrating into the membrane core while the polar N-terminal region interacts mainly with the bilayer surface.

Tofoleanu and Buchete probed the molecular interactions between preformed fibrillar A β oligomers and lipid bilayers, in the presence of explicit water molecules, using atomistic MD.⁽²⁷³⁾ They studied the adsorption of models of A β 1-40 dimer fibrillar oligomers on phosphatidylethanolamine (POPE) lipid membranes (composing about a quarter of all phospholipids in living cells) under different relative orientations between membrane and fibrils. They investigated the relative contributions of different structural elements and interaction factors to the dynamics and stability of A β protofilament segments near membranes, and simulated the first steps in the mechanism of fibril-membrane interaction. The A β 1-40 fibril structures used here were constructed based on atomistic constraints from ss-NMR^(28,67,79) and refined by MD simulations.^(289,290) They identified the electrostatic interactions between A β charged side chains and lipid head-groups to be the main force driving conformational transitions, together with hydrogen bonds formed between specific residues in the A β protofilaments and the lipid head-groups. These interactions facilitate synergistically the insertion of the hydrophobic C-terminal segment of A β peptides through the lipid head-groups, leading both to a loss of the β -sheet-rich fibril structure, and to local membrane-thinning effects (Fig.9B).⁽²⁷³⁾ Additional computational studies showed that the chemical composition of the lipid head-groups can control in a specific manner both the type and magnitude of interactions between A β protofilaments and membranes.⁽²⁹¹⁾ These findings suggest a polymorphic structural character of amyloid ion channels embedded in lipid bilayers.⁽²⁹²⁾ Atomistic computational models suggest that putative amyloid channel structures could also be stabilized by inter-peptide hydrogen bonds (leading to the formation of long-range ordered β -strands) though A β channels may also present a significant helical content in peptide regions (e.g., the N- and C-peptide termini) that are subject to direct

interactions with lipids rather than with neighbouring A β peptides. Before experimental high-resolution structures of A β amyloid channels become available, various models of A β pore-like structures traversing lipid bilayers were constructed, including helical, β -sheet and combinations of these two secondary structures.⁽²⁹²⁾

Nussinov *et al.* developed a model for A β channel structures, which break into mobile β -sheet subunits and enable toxic ionic flux (Fig.9D).⁽²⁹³⁻²⁹⁵⁾ The subunits are preferentially tetramers or hexamers, which could serve as building blocks for the transmembrane pores reported from AFM studies (Fig. 8).⁽²⁹⁵⁾ Strodel *et al.* also proposed A β pore models composed of tetramer to hexamer β -sheet subunits, which emerged from a global optimization study of transmembrane A β (Fig.9C).⁽²⁹⁶⁾ Large-scale MD of these β -sheet subunits revealed that the tetramers themselves are sufficient to cause membrane damage while transmembrane A β monomers do not perturb the membrane sufficiently to make them permeable.⁽²⁹⁷⁾ The membrane damaging effect of the β -sheet tetramers is further enhanced by A β mutations (e.g., the “Arctic” E22G mutation), and may explain the higher toxicity of these mutants compared to wild-type A β peptides.^(297,298) Also, for helical A β peptides in their monomeric states, the membrane-inserted stability was tested for several pure and mixed model membranes.^(297,299-301) Different insertion depths were considered, with either K28, V24, D23 or K16 located at the membrane-water interface. The most stable transmembrane α -helix was observed for A β peptides positioned at residue D23 at the interface of a DPPC membrane⁽²⁹⁷⁾ while unsaturated lipids or smaller insertion depths cause a loss of α -helix, in some cases in favour of β -strands. The first stages of A β self-assembly inside mixed bilayers were recently tested by MD, revealing the formation of a β -sheet between two peptides in the presence of cholesterol⁽³⁰²⁾ or ganglioside GM1.^(303,304a-b) In the absence of GM1, no β -sheet formation is observed as GM1 mediates the initial interactions between A β peptides leading to oligomerization. These computational findings are in agreement with the observation that lipid rafts (i.e., cholesterol and sphingolipids enriched highly ordered membrane micro-domains) are potential modulators of A β production, aggregation and toxicity.⁽³⁰⁵⁾ Finally, one MD simulation with umbrella sampling has recently focused on the effect of attached A β 1-42 monomers on the free energy of membrane pores modelled with DPPC lipids. They found that the attached A β 1-42 monomers reduce the free energy of membranes pores by 2kcal/mol, increase the lifetime of pores and enlarge the pore density.⁽³⁰⁶⁾ Most of the simulations studying membrane interactions with A β are summarized in Table 3.

For studying the membrane-mediated aggregation of A β peptides on larger time scale, one must resort to coarse-grained simulations. A number of models have been proposed.⁽³⁰⁷⁻³¹¹⁾ One may distinguish between specific models, where amyloids are represented by a specific sequence,^(308a) and phenomenological models, which are designed to reproduce the aggregation process in general.⁽³⁰⁹⁾ One of the latter, the two-state mesoscopic model for proteins⁽³¹⁰⁾ has been combined with a simple solvent-free three-bead model for lipids by Friedman et al to study peptide adsorption and aggregation on small vesicles and peptide-induced membrane damage.⁽³¹¹⁾ In agreement with the experimental picture, this Langevin dynamics study found that vesicle leakage occurs primarily due to transient defects during filament growth; mature fibrils did not damage the vesicles. Studying the fibril degradation in the presence of vesicles, the simulation showed that it results in protofibrillar

intermediates whose structure differs from those formed upon aggregation or upon disaggregation without lipid vesicles.⁽³¹¹⁾

All these results suggest that, in spite of the high complexity of the systems including lipid membranes, computational studies are becoming increasingly more feasible due both to accelerated hardware and methodological developments and may guide new experiments that could test more efficiently the assembly and structural features of membrane-formed amyloid channels. Future simulations should be able to unravel how membranes can facilitate the aggregation of A β peptides and modulate the formation of oligomers, fibrils and channels, while novel experiments are still needed to provide high-resolution structures of membrane-bound A β aggregates.

7. Interactions of A β Peptides with Metal Ions

7.1. Relevance of the Interaction of Metal Ions (Cu, Zn and Fe) with A β

The accumulation of zinc, copper and iron ions in amyloid plaques, a hallmark of AD, is well documented.⁽³¹²⁾ Interestingly, human plaques showed higher metal content than plaques in AD model mice.⁽³¹³⁾ Raman studies further suggested that Zn(II) and Cu(II) are bound directly to A β , the main constituent of amyloid plaques. Amyloid plaques are also enriched in iron, mainly present as particles containing Fe(III) supposed to originate from ferritin. Whether ionic, mononuclear iron is bound to A β is not clear.⁽³¹⁴⁾

Although there is clear evidence for Zn and Cu interactions with A β in amyloid plaques, it is not known at which time point or which aggregation state these metal ions bind to A β *in vivo*. However, it seems that under normal physiological conditions Zn(II) and Cu(I/II) do not bind to monomeric A β , and the hypothesis is that only upon metal and/or A β deregulation the formation of metal-A β complexes can occur.⁽³¹⁵⁾ This is in agreement with the finding that amyloid plaques are formed around synapses in which high concentrations of Zn and Cu are released in the synaptic cleft. These released metal ions are a peculiar pool. Their ligands are not known, but these metals are readily accessible for chelation by ligands with moderate affinity. This is in contrast to classical metalloproteins, where metal ions are strongly bound and often buried in the proteins. This suggests that these synaptic metal pools are kinetically labile and thermodynamically moderate stable.⁽³¹⁶⁾

Numerous other studies, from *in vitro* to *in vivo*, report evidence of a connection between metal metabolism, A β metabolism and AD. This includes, for instance, reports on a Cu pool in the blood as AD marker, the mutual regulating effects of APP and metal ions, the association of a single nucleotide polymorphism of the Cu transporter ATPase (ATP7B) with sporadic AD and the decrease of amyloid plaque load in AD mice after disruption of the Zn transporter ZnT-3.⁽³¹⁷⁻³¹⁸⁾

Taken together, these data suggest that metal ions like Zn and Cu can bind to A β under AD conditions and could have two important impacts directly linked to AD: modulation of the aggregation behavior and, for Cu, catalysis of toxic reactive oxygen species (ROS) production.

7.2. Structure of the Cu, Zn and Fe-binding Sites of A β

The metal-binding sites of Cu(I/II), Zn(II) and Fe(II) within the A β sequence have been studied during the last two decades. Complexes of Fe(III) with A β at neutral pH are not stable enough to inhibit precipitation of Fe(III) as iron oxide.⁽³¹⁴⁾ This suggests that the interaction of Fe(III) with A β is only relevant in a ternary complex with another biomolecule or with particles containing Fe(III). There is a general agreement that the main binding sites for Cu(I/II), Zn(II) and Fe(II) are located in the first 16 amino acids of the peptide, at least for the monomeric form.⁽³¹⁴⁾ The truncated A β 1-16 peptide containing the metal-binding domain, which is more soluble and hence more appropriate for studies in solution and does not form amyloids, is often used instead of the full-length peptide. Indeed, several spectroscopic studies showed that the metal binding of A β 1-16 is very similar to the full-length A β 1-40/42. However, as small changes can have a large impact on aggregation, further experimental and theoretical studies well connected to experiments are needed to elucidate the detailed structures of truncated and full-length A β .

The current knowledge on the metal-binding sites of the most relevant metal ions is summarized in Fig.10.^(314,319-322) They have been identified for the soluble, monomeric complexes, but might be different in the aggregated A β . A general feature for all these metal-binding complexes is that they are very flexible and dynamic. Monomeric A β remains an intrinsically disordered peptide upon metal binding, as fast ligand exchange reactions and equilibrium between different binding sites exist leading to a polymorphism in the coordination environment.

There is consensus about the Cu(I)-binding site within A β at pH 6-8, that consist of a linear site with two His as ligands. The main site is with H13 and H14 as ligands (Fig.10 top), but this site is in fast exchange (< sec) with linear Cu(I) bound to H6 and H13/H14.⁽³¹⁴⁾ Cu(II)-A β around neutral pH exists with two different types of coordination spheres, called component I and II (Fig.10) which are in fast equilibrium (< sec). Moreover, in each of these two components, further exchange between the same type of ligand occurs (e.g. between H13 and H14). Recent MD simulations confirmed this polymorphism of Cu(II)-A β .⁽³²³⁾ There was a long debate about the coordination sphere of component I, but a consensus has been reached following the application of site specific isotope labelling and advanced EPR and other experimental and theoretical methods.^(314,319,322) Regarding component II there are still different models proposed, but most results support the structure shown in Fig.10. Drew described however an alternative structure.⁽³¹⁹⁾

Mutations of amino acids in A β (like A2V, H6R, D7N), even when they concern residues not directly involved in metal-binding, can have a large impact on the coordination site via second sphere interactions.⁽³²²⁾ This is exemplified by the comparison of Cu(II)-binding to human with murine A β , in which the mutation responsible for a dramatic change of the major coordination is R5G and leads to the following major coordination sphere: D1 (via NH₂, O=C) and H6 (N imidazole and N amide). The impact of mutants outside the metal-binding domain remains to be established.⁽³²⁵⁾

Less is known about the binding sites in aggregated A β (oligomers, amyloids etc). Most studies suggest the same type of residues coordinating Cu(II) for the soluble A β , but these

might come from two different A β molecules. A very recent study based on advanced EPR methods of fibrillar Cu(II)-A β 1-40, confirmed the same equatorial coordination sphere of component I as in monomeric Cu(II)-A β 1-16.⁽³²⁶⁾ The results propose that the Cu(II) sites along the fibrils alternate between the two sub-components Ia (D1, H6, H13) and Ib (D1, H6, H14). This would be in contrast to the soluble form, in which a fast (< sec) equilibrium between subcomponents Ia and Ib exists. Cu(II)-binding to amyloid A β 1-40 fibrils was also studied by ss-NMR coupled to MD.⁽³²⁷⁾ In general, the results agreed with the EPR measurements, because H13 and H14 resonances were broadened upon addition of Cu(II) (H6 and D1 were not addressed). Other residues were also affected in particular the C-terminal COO⁻ and Glu side chains. This might be explained by axial binding to Cu(II), as it was also suggested for COO⁻ groups in monomeric Cu(II)-A β 1-16.⁽³²⁸⁾

In contrast to Cu, the coordination spheres of Zn(II) and Fe(II) have been less investigated. Current favoured models are given in Fig.10. The models show the main ligands involved, but due to their flexibility a polymorphism in the coordination can be expected.⁽³²⁹⁾ Indeed, recent MD simulations on Zn(II)-A β reported that the COO⁻ from either D1 or E7 can bind, but in two different conformations and with a higher population for E7. The binding of either D1 or E7 had an impact on the preferred partner (i.e. D22 or E23) of the salt-bridge with K28.⁽³³⁰⁾ Due to the insolubility of Fe(III) even in the presence of A β no well-defined species for structural studies was so far obtained.^(320,331)

The apparent binding constants of metal ions to A β have been determined by several methods (Fig. 10 and Refs. 331,332). After some discussions in the literature, an apparent dissociation constant K_d^{app} (pH 7.4 in the absence of buffer) of Cu(II) from monomeric A β on the order of 10^{-10} M is now relatively consensual.⁽³³²⁾ Interestingly, the affinity for aggregated A β is about 2 orders of magnitude higher.⁽³³³⁾ A consensual value for K_d^{app} for Zn around 1-10 μ M is reported, with an up to 10 fold higher affinity for aggregated A β .⁽³²¹⁾ No values are reported for Fe(II/III). The binding affinity of Cu(I) to A β is still under debate, with values for K_d^{app} from 10^{-7} to 10^{-10} M.^(334,335) In general, the affinities obtained for Cu(I/II)- and Zn(II)-A β are several magnitudes below the affinities of Cu- and Zn-proteins with a defined 3D structure. This is in line with the entropic penalty of metal binding to a disordered peptide. Moreover, this suggests that metals might only be able to bind A β at the Zn- and Cu-rich synapses and under Alzheimer conditions where metal deregulation occurs.

7.3. Role of Metal Ions in the Aggregation of A β

The effects of metal ions on A β aggregation, i.e. in terms of kinetics, thermodynamics, structures formed and their populations, are not clear and are condition-dependent.^(320,326,336a) There are two effects on which there is a wide agreement in the literature: i) metal ions (mainly Cu(II) and Zn(II) are studied) modulate the aggregation and ii) the effects are metal-specific, e.g. Cu(II) affects A β differently from Zn(II). We did recently a survey of the literature about the effects of Cu(II) and Zn(II) on the aggregation of A β .^(320,325) Several tendencies could be identified: i) Zn(II) and Cu(II) at high μ M concentrations and/or in large superstoichiometric ratios compared to A β promote amorphous type aggregates (precipitation) over the ordered formation of fibrillar amyloids.

ii) Metal ions affect the kinetics of A β aggregation, with the most significant impact on the nucleation phase; and iii) Cu(II) and Zn(II) affect the population and/or the type of aggregation intermediates formed.

At least two parameters might be important in the influence of Zn(II) and Cu(II) binding on A β aggregation: changes in the 3D structure(s) and in the overall charge of the A β complexes. At neutral pH A β has an overall charge of about -3: divalent metal ion-binding hence yields a more neutral charge (about -2 with Cu(I/II)-A β and -1 to -2 with Zn(II)-A β at pH 7.4: note that one has not only to consider the charge of the metal ion, but also the replacement of protons by metal-binding) and a faster aggregation is expected. The fact, that the aggregation behavior is metal-dependent, shows clearly that the structural changes upon metal-binding (which are also metal specific, see Fig.10) play an important role as well.

In a more general way, metal ions can promote amorphous aggregates and amyloid-type aggregates in a condition dependent way. It seems that the system proneness to aggregation is crucial to determine which type of aggregates are formed (amorphous vs. amyloid). If conditions are such that aggregation of A β is already fast (as with high concentrations of A β , A β 1-42, pH close to pI, etc), Cu(II) or Zn(II)-binding (in particular at high concentrations or ratios) accelerates aggregation and favors amorphous aggregates. Aggregation is too fast, however, to properly align the A β peptides into an ordered β -sheet structure like in amyloids. For a system with a low propensity to aggregate (as with higher pH, low concentrations of A β , A β 1-40, etc.), metal ions (in particular at lower concentrations or ratios) favor formation of amyloid-type aggregates. Using MD simulations, Miller *et al.* showed that Zn ions promote A β aggregation via a population shift of polymorphic states.^(336b)

It is not well known how much the structure of amyloid fibrils differs from metal-free A β peptides to metal-A β peptides for Cu(II, I) and Fe(II, III). For Cu(II), addition of this metal to preformed amyloid fibrils of A β does not change the peptide structure, as monitored by ss-NMR.⁽³²⁷⁾ The conformation of the Zn(II)-attached fibrils has also been investigated by ss-NMR.^{336c} The data show the absence of the D23-K28 salt-bridge, but the presence of the F19-L34 contact. Also, Zn(II) tends to accelerate the precipitation of the oligomers without changing the overall solubility of the peptide, which may help explain why Zn(II) at low concentrations lowers A β toxicity.^{336d}

7.4. Cu-A β as a Catalyst for the Production of Reactive Oxygen Species

A large body of evidence suggests that oxidative stress is implicated in AD, but it is not clear if it is a primary cause or a consequence.⁽³³⁷⁾ The production of reactive oxygen species (ROS) is a major contributor to oxidative stress, and indeed AD affected tissue shows signs of enhanced ROS production, in particular around the amyloid plaques. Cu is well known to be able to catalyze the production of ROS and hence it is possible that the complex Cu-A β is implicated in the production of ROS in AD.⁽³³¹⁾

Indeed, *in vitro* experiments reported that Cu-A β is able to catalyze the production of H₂O₂ and HO $^{\circ}$ in the presence of a biologically relevant reducing agent (like ascorbate) and dioxygen (Fig.11 top). There is an ongoing discussion if A β is an antioxidant or prooxidant.

A β is considered as an antioxidant based on the fact that Cu in buffer catalyses ROS production more efficiently than Cu-A β . However, “free” Cu concentrations are extremely low in biology as Cu metabolism is tightly controlled. Hence, an antioxidant activity of A β compared to “free” copper might be only relevant under particular conditions where “free” Cu reaches higher concentrations. It seems not evident that this ever occurs, when taking into account the presence of high concentrations of potential ligands (like glutathione, histidine, cysteine etc.).

So in the framework of an imbalance of Cu, it seems more relevant to compare the efficiency of Cu-A β with the Cu-pool from which A β obtains Cu in AD instead of “free” Cu. However the identity of this Cu-pool is not known. In order to address this, the ROS efficiency of Cu-A β was compared with several biological relevant Cu-peptide or Cu-protein complexes. Generally, Cu-A β was quite active, and hence one can conclude that Cu-A β has the potential to contribute to oxidative stress in AD. This is supported by the finding that oligomeric Cu-A β aggregates have a higher ROS production activity than monomeric Cu-A β , in line with the higher toxicity of oligomeric A β .⁽³³¹⁾

Electrochemistry of Cu-A β suggested that the reduction and oxidation does not occur directly between the two ground states (most populated), shown in Fig.10.⁽³¹⁴⁾ The reorganization energy is too important as can be seen from the very different structures of Cu(I) and Cu(II)-A β . Instead a low populated (0.1%), intermediate state exists in equilibrium with the ground states, but only this intermediate state undergoes a rapid redox reaction. Thus this state can be considered as a kind of transient entatic state. This suggests that this low populated, intermediate state is responsible for all the redox activity and hence such a type of state might also be responsible for the reactivity with dioxygen and a biological reducing agent to produce ROS. Recent advances were made in the understanding of this intermediate, “hot” state.⁽³³⁸⁾ First, the ligands of this intermediate state were assessed and H13, H14 and D1 were identified. Interestingly H6 is not involved. This shows that the intermediate redox competent state is different from the two ground states.

Further computational studies using MD (Car-Parrinello) and DFT suggested that the highly reactive Cu(I)-A β state consists of N-Cu(I)-N coordination with an angle far from 180°, and high water crowding at the open side (Fig.11 bottom).⁽³³⁹⁾ This allows side on entrance of H₂O₂ and its cleavage to form a hydroxyl radical. Interestingly, a reactive Cu(I)-A β state was more easily originated when starting with a dimer model (Cu(II)-A β ₂) compared to a monomer (Cu(II)-A β), likely due to structural constraints of the peptide. This in line with the higher ROS production reactivity of Cu(II)-A β oligomers.

7.5. Metal-based therapeutics

As above discussed, AD involves a mismetabolism of Cu and Zn. This mismetabolism is rather an imbalance than a general overload or lack. The imbalance tends toward an extracellular increase and an intracellular decrease of Zn and Cu. Moreover, the extracellular Cu(II) is prone to catalyze ROS.⁽³⁴⁰⁾ Based on that, therapeutical strategies have been developed in order to use compounds that bind the misplaced Zn and/or Cu pool and diminish the Cu prooxidant activity (i.e. redox silence it that it does not catalyze ROS production).^(312,341) This can be achieved by moderate affinity ligands. Such drugs should

have the following properties i) not be toxic: ii) cross the blood brain barrier iii) have the right affinity, higher than A β but lower than essential metalloproteins, and iv) the complex of Cu-ligand should not itself produce ROS.⁽³⁴²⁾

Moreover, it seems also more advantageous not only to bind the misplaced pool and redox silence it, but to transport it back into the cell.⁽³⁴³⁾ Thus a fifth property can be added: v) relocation of the metals, from extracellular to intracellular. The free ligand as well as its metal complex should be able to cross the membrane. A driving force is needed to release the metal intracellularly. In the case of Cu with two chemical ligands gtsm (glyoxal-bis(N(4)-methyl thiosemicarbazone) and PBT2 (hydroxyquinoline), the driving force is the reduction of Cu(II) to Cu(I) and subsequent decomplexation.⁽³⁴³⁾ These properties are referred to as ionophores or chaperones. Several compounds have been synthesized along these lines and tested *in vitro* or in AD models as inhibitors of A β aggregation or toxicity (for some examples see Fig.12). The compound PBT2 went to a phase IIa clinical trial and showed improvements in two executive function component tests in a battery of neuropsychological tests.^(312,315) These effects have been attributed the ability of PBT2 to facilitate intracellular copper uptake (point v).

8. A β interactions with Protein Receptors

Understanding the interactions that A β establishes with various cellular components is a key challenge to unveil the molecular mechanisms at the onset of AD. Aberrant interactions with membrane associated proteins and receptors can mediate the neurotoxic effects of A β 1-42 oligomers, such as in the case of the highly specific binding to the cellular prion protein (PrP^C).^(34,35,345) This controversial interplay has been associated with impaired activity of N-methyl-D-aspartate (NMDA) receptors,^(345,346) which mediate critical functions in the central nervous system, in conjunction with copper binding from both A β oligomers and prion protein. Other proposed receptors for toxic A β assemblies include mGluR5⁽³⁴⁷⁾, EphB2⁽³⁴⁸⁾ and GM1⁽³⁴⁹⁾, for which the first simulations of GM1 complexes with A β 1-42 in lipid membranes have been reported.^(304,305)

In contrast, other proteins are functionally employed as a primary biological defence against the effects of A β aggregation. In this context, both intracellular and extracellular chaperones are able to bind and stabilize misfolded oligomer species in such a way to prevent further fibrilization or dissociation. In particular clusterin, highlighted in genome wide association studies, is thought to play role as an extracellular chaperone.^(350,351) Furthermore serum albumin, the most abundant protein in blood plasma and cerebrospinal fluid (CSF), inhibits A β fiber formation.⁽³⁵²⁾

In addition to PrP, A β can bind to other amyloid peptides, in particular serum amyloid P (SAP),⁽³⁵³⁾ islet amyloid polypeptide (IAPP. Ref. 354) and transthyretin.⁽³⁵⁵⁾ Both SAP and PrP have been found within plaques of AD patients.^(356,357) Finally we should not forget that A β 1-42 interactions with other forms of A β , for example A β 1-40, that may be crucial to the misassembly process.^(358,359)

8.1 A β – Prion Protein

The membrane anchored cellular prion protein (PrP^C) has been identified as a cell surface receptor of A β . Specifically a screen of more than 200,000 proteins, using an unbiased cDNA expression library, has identified PrP^C as a principle candidate to bind to A β .⁽³⁴⁾ This study also showed that interaction between PrP^C and A β 1-42 oligomers leads to the inhibition of long-term potentiation (LTP) in the hippocampal slices from normal mice expressing PrP^C. Crucially it was shown using a mouse model of AD with a knockout PrP that AD pathology was dependent on the expression of PrP^C,⁽³⁴⁾ while PrP knockout mice can develop A β plaques but do not exhibit neurotoxicity.⁽³⁶⁰⁾

A nanomolar affinity between A β oligomers and PrP^C has consistently been reported.^(34,361-364) This interaction is generally accepted, what remains contested is the influence of PrP^C on A β toxicity *in vivo*.⁽³⁶³⁻³⁶⁶⁾ The conflicting observations might be explained by the multifactorial nature of AD, some of its pathology could be independent on PrP^C while other aspects of A β toxicity could be PrP^C dependent. The conflicting observations might simply reflect differences in the AD mouse model used, or in some instances the A β preparations used. There are however a growing number of reports in animal models and hippocampal primary culture, showing PrP^C dependent A β toxic effects, which impair synaptic plasticity and cause spatial memory defects and axon degeneration.^(34,345,360,367-372) Furthermore *ex vivo* AD brain extracts indicate the co-localisation of A β and PrP in amyloid plaques.^(357,373,374)

Numerous lines of enquiry have consistently highlighted the natively unstructured N-terminal domain of PrP^C as the recognition site for A β . For example, the α -helical folded domain of PrP^C spanning residues 113-231 has no influence on A β fiber growth while the N-terminal half of PrP^C spanning residues 23-126 inhibits amyloid fiber formation in favour of non-ThT binding A β oligomers.⁽³⁵⁾ These PrP^C trapped A β oligomers bind the oligomer specific A11 antibody and SEC indicates they are 12 and 24 A β monomers in size. More recently larger protofibrils structures of A β have also been identified in the presence of PrP^C.⁽³⁷²⁾ Solution NMR indicates that the interaction between A β and PrP^C is conformation-dependent. A β monomer has little affinity for PrP^C and it is not until A β forms oligomers that it interacts with PrP^C. It is also clear PrP profoundly inhibits fiber formation by trapping A β in an oligomer form and is capable of disassembling mature fibrils.⁽³⁵⁾ The ability to trap and concentrate A β into toxic oligomers suggests a mechanism by which PrP^C might confer A β neurotoxicity in AD.

The structural bases of this interaction are currently unknown. A major limiting factor in this context is the inability of current techniques of structural investigation to characterise A β oligomers, which is largely due to the transient and heterogeneous nature of these aggregates. Several models of A β oligomers have been proposed based on direct and indirect experimental evidence. These range from highly structured assemblies (mainly composed of β -sheets scaffold) to poorly ordered oligomers. Yet, a consensus is still elusive on the size of the most toxic assemblies, showing a dynamic distribution of assemblies ranging from 2 to 14 monomers. An additional barrier in the study of the interaction between A β oligomers and PrP^C is associated with the unstructured nature of the N-terminal domain of PrP^C (residues 23-126), which poses significant challenges of studying intrinsically disordered

proteins.^(375,376) It was proposed that the N-terminus of PrP^C is the locus of the interaction with poorly structured, highly toxic A β oligomers.⁽³⁶²⁾ This interaction was recently studied using computational approaches based on extensive MD simulations of dodecameric A β assemblies featuring short antiparallel β -hairpins at the C-terminus of the protein monomers.⁽³⁷⁷⁾ The resulting oligomer models were used to infer on the interaction with the unstructured N-terminal tail of residues 23-127 by using PrP^C models from an experimental NMR ensemble (PDB code 1QLX) and by performing mutant deletions according to Ref. 362. While this study could only rely to a massive use of modelling and simulations, it evidenced a conceptual model for the interaction between PrP^C and toxic A β oligomers that can be useful for seeding new experiments.

While the function and misfunction roles of the disordered N-terminal domain of PrP^C remain largely elusive, a large number of studies have dissected the misfolding pathways of the C-terminal PrP^C domain in the mechanisms leading to PrP^{Sc}, the scrapie fibrillar form of the protein that is associated with the prion disorders. The large number of NMR structures of the C-terminus domain provides an important starting point to sample misfolding pathways using computational⁽³⁷⁸⁻³⁸⁰⁾ or experimental⁽³⁸¹⁻³⁸²⁾ approaches. One of the most accredited scenarios, which accounts for the role of a number pathological mutations, is the misfolding of the native interface between two subdomains of PrP^C, the first spanning strands S1 and S2 and helix H1 and the second spanning helices H2 and H3.⁽³⁸³⁻³⁸⁵⁾ This pathway, corroborated by a series of experimental evidences, possibly can interplay also in the mechanisms of interaction with A β oligomers by the exposure of hydrophobic surfaces that are natively hidden in the interior of the folded part of the protein.

It has been proposed that A β has an effect on CNS function mediated by NMDA receptors activity including strong inhibition of long-term potentiation and enhancement of long-term depression.⁽³⁴⁶⁾ Interestingly, it has been shown that PrP^C limits excessive NMDA receptors activity that might otherwise promote neuronal damage.⁽³⁸⁶⁾ Significantly, PrP^C only affects the NMDA receptor in a copper-loaded state.⁽³⁴⁵⁾ A mechanism for the PrP^C dependent A β toxicity has been proposed which indicates A β disrupts copper homeostasis at the synapse which is required for normal PrP^C dependent inhibition of excessive NMDA receptors activity.⁽³⁴⁵⁾ A β released at the synapse, with a picomolar affinity for Cu²⁺,⁽³⁸⁷⁾ may disrupt Cu²⁺ binding to PrP^C and so, in part, mediate neuronal and synaptic injury.⁽³⁴⁵⁾ The mechanism by which PrP mediates A β toxicity and NMDA activity⁽³⁴⁶⁾ may also involve the Fyn receptor.⁽³⁶⁹⁾ Several evidences have been reported on the direct binding between A β and NMDA receptors both *in vitro* and *in vivo*⁽³⁸⁸⁻³⁹¹⁾ as well as on the activation of NMDA receptors by A β oligomers.⁽³⁹²⁾ Furthermore A β promotes endocytosis of NMDA receptors and so reduces the surface of NMDA receptors.⁽³⁴⁶⁾

The structural details of the A β -PrP interaction are clearly of interest and yet to be fully elucidated, indeed if the PrP-A β interaction is responsible, at least in part, for A β toxicity then identifying a molecule that blocks this interaction represents a novel pharmaceutical target.⁽³⁶⁷⁾

8.2 A β - Clusterin

Genome wide association studies have highlighted link between the development of AD and an ATP-independent chaperone, clusterin.⁽³⁹³⁾ Clusterin belongs to a family of extracellular protein-folding chaperones, including α 2-macroglobulin, haptoglobin, and α S1- and β -casein, which have been shown *in vitro* to stabilize proteins and prevent their aggregation under condition that normally lead to the formation of amyloids.^(350,351,394-396) Clusterin is able to intervene in amorphous aggregation of a broad range of proteins in such a way to redirect the aggregation process in the assembly process of soluble high-molecular-weight aggregates.^(395,397) It has been shown by single-molecule fluorescence that clusterin interacts with small A β oligomers ranging from dimers to 50-mers in such a way to form long-lived, stable complexes.⁽³⁵¹⁾ In this way clusterin can interplay with both aggregation and disaggregation processes of A β sequestering small oligomers, which have been shown to be the most toxic forms of A β , thereby mitigating the toxic effects of A β aggregation. This Alzheimer's disease mechanism is corroborated by the recent discovery of co-localization of clusterin with extracellular amyloid deposits containing A β .⁽³⁵⁰⁾ It has indeed been suggested that clusterin may interplay in a novel extracellular proteostasis system, in which a series of extracellular chaperones bind to misfolded proteins *in vivo* to keep them soluble and to inhibit the formation of toxic aggregates in order to facilitate their bulk uptake and degradation via receptor-mediated endocytosis.⁽³⁹⁸⁾ The A β -clusterin interactions remain to be studied by computer means.

8.3 A β - Albumin

An extra-cellular binding partner identified for A β is human serum albumin (HSA). This interaction was first described when A β was isolated from blood plasma, with 90-95% of A β within blood plasma directly bound to albumin.^(399, 400) It is suggested that this interaction might explain why, unlike systemic amyloid related diseases, although A β is found at a similar concentration in blood plasma and CSF (0.1–0.5 nM),^(401,402) A β plaque deposits are typically only observed in the brain and not peripheral tissue.

Albumin is the most abundant protein found in blood plasma with a concentration of *ca.* 640 μ M. Concentrations of albumin in the CSF are much lower (3 μ M)⁽⁴⁰³⁾. Although markedly less concentrated than in blood, this still constitutes the most abundant protein in the CSF. The affinity of monomeric A β for HSA has been determined and a dissociation constant (K_d) of 5-10 μ M, for both A β 1-40 and A β 1-42 has been consistently reported.^(400,404,405) Despite the relatively weak micro-molar affinity (K_d = 5-10 μ M) of A β for albumin, a concentration in the CSF of 3 μ M suggests the capacity of albumin to bind approximately half of A β in the brain CSF. Furthermore this will be quite sensitive to changes in HSA concentrations. It is generally presumed that A β will bind to the hydrophobic pockets within albumin, which are often occupied by fatty acids, although this is not confirmed. There are reports to indicate HSA binds monomeric^(400,404) or oligomeric^(406,407) A β .

Recently it has been shown *in vitro* that physiological micro-molar levels of albumin found in the CSF does indeed inhibit A β amyloid fiber formation, significantly increasing the time before fiber nucleation occurs and decreasing the total amount of fibrils produced,⁽³⁵²⁾ as shown in Fig.13. Furthermore, it was shown that the amount of amyloid fibers generated

directly correlates to the proportion of A β not competitively bound to HSA.⁽³⁵²⁾ Indeed it is likely nearly half of A β in the CSF will be bound to HSA and inhibited from forming fibers. This suggests a role for HSA in regulating A β fibril growth in the brain interstitium and computer simulations should be able soon to provide insights into the A β -HAS energy landscape as reported for HAS interacting with other molecules.⁽⁴⁰⁸⁾ Thus levels of albumin in CSF should represent a risk factor and therapeutic target in AD. It is therefore perhaps surprising that the correlation between albumin levels in CSF and risk of developing AD pathology is yet to be conclusively identified. It might suggest that typically A β has already formed fibers within intra-cellular vesicles before release into the synapse. Alternatively Alzheimer's is a multi-factorial disease and albumin might just be one of many risk factors associated with the disease. Small variations in albumin levels in middle age may not be easily recognised, masked by a multitude of other factors that protect against or exacerbated AD pathology.

In summary we have characterised A β -protein interactions into three broad themes: cell surface interactions, for which we have focused on the prion protein (PrP^C), and its connection with NMDA receptors activity. In addition, we have looked at protective defences against the effects of protein misfolding and aggregation *in vivo*, in particular by the extracellular chaperone clusterin and also human serum albumin. Finally, the interaction with other amyloidogenic proteins suggests possible interconnections between different protein misfolding diseases. For A β -Tau interactions, the reader can find recent data in Refs. 186 and 408b. Overall, A β may exert its toxicity on neurons via more than one mechanism. Furthermore, different forms of A β , monomeric, oligomeric and fibrillar, can present different recognition sites to different binding partners. There is still much to be understood about the molecular interactions of A β , both intra- and extra-cellular and at the synaptic cleft, as it is these interactions that may constitute new pharmaceutical targets.

9. Interactions of A β with Inhibitors

The failures of recent phase III clinical trials on two A β -targeting monoclonal antibodies, bapineuzumab and solanezumab, in the summer of 2012 indicate that the timing of the intervention of AD needs to be reconsidered.^(42,409) In the light of these reports, are we back to 2008 when news in Nature reported that the major conundrum in the field is: are we just treating people too late? The good news is that three studies are to be launched in 2014 on asymptomatic individuals identified as being at increased risk of developing AD on the basis of genetic predisposition or amyloid levels.⁽⁴²⁾

First of all, several protein-like drugs are briefly discussed. A homodimeric protein of 58-residues, Z_{A β 3}, was found to bind to A β 1-40 monomer and inhibit the fibrilization process. The structure of the Z_{A β 3}:A β 1-40 complex by solution NMR revealed that the A β 1-40 is locked into a β -hairpin conformation spanning residues 17-36 with the rest of the amino acids disordered, and the edges of A β 1-40 β -sheets were capped by the 2 β -strands of Z_{A β 3}, thus blocking the β -sheet extension of A β 1-40.⁽¹¹⁴⁾ Similarly, Reelin, an extracellular matrix protein, was reported to stabilize the A β 1-42 oligomers, leading to reduced toxicity and delayed fibrillization.⁽⁴¹⁰⁾

A series of N-methylated peptides or D-amino acid peptides were also found capable of inhibiting A β amyloid formation, targeting either A β residues 32-37⁽⁴¹¹⁾ or 16-21 (SEN304, Ref. 412). For instance, SEN304 was found to bind to A β 1-42 monomer and oligomers and to promote the formation of non-toxic aggregates. With a concentration as low as 100 nM, SEN304 was able to almost completely remove the inhibition of long-term potentiation (LTP) by 1 μ M of A β 1-42 in a hippocampal slice.⁽⁴¹²⁾ Recently, two inhibitors with alternating D- and L-amino acids of lengths 21 and 23 designed by MD simulations to form α -sheet, α -sheet having all its peptide groups orientated in the same direction, were found to reduce A β 1-42 aggregation and toxicity at molar ratio of at least 10:1.⁽⁴¹³⁾

Small molecules as potential drug candidates against AD have been investigated intensively in recent years. Though differing in size, geometry and chemical properties, the compounds in general exhibit inhibitory effects by three modes. First, the compounds can bind to fibrils and reduce toxicity by limiting fibril fragmentation. In a recent study, several compounds, including BAF31 shown in Fig.14, were found to reduce A β 1-42 cytotoxicity against mammalian cells by up to 90%.^(9b) The compounds were identified through virtual screening of 18,000 purchasable molecules and ranked according to their calculated binding energies to fibrillar A β 16-21 segments. What is interesting in this study is that the compound binding increases the fiber stability to limit fragmentation, rather than reducing fiber formation, and the compounds do not bind to oligomers.

Second, the compounds can accelerate the formation of fibrils and reduce the lifetime of toxic oligomers. An example is an orcein-related polyphenol, O4 (Fig.14). The molecule was found to bind directly to oligomers and promote the conversion into larger amyloid fibrils, with O4 interacting with hydrophobic residues of A β 1-42.⁽¹⁴⁾

In the third mode, the small molecules interact with oligomers and prevent fibrillization. The resulting complexes are believed to be off-pathway and nontoxic. Several polyphenols were reported to rescue AD in this way. *e*-Viniferin glucoside (EVG for short, Fig.14) is one of the polyphenols that inhibits fibril formation in A β 25-35, A β 1-40 and A β 1-42 and protects against PC12 cell death induced by these peptides.⁽⁴¹⁵⁾ Electrospray ionization mass spectrometry showed a non-covalent complex between one A β 1-40 peptide and two EVG molecules.⁽⁴¹⁵⁾ Solution NMR and molecular modelling were used to characterize the interaction between the compounds, using 1mM A β 40 and 2mM EVG in DMSO.⁽⁴¹⁶⁾ EVG induces the formation of turns in the 10-12 and 28-30 regions of A β . Chemical shift perturbations and short-range intra-molecular NOEs confirmed that EVG predominantly interacts with clefts formed by Y10, V12, Q15 and F19 or by K28, G29, A30 and I31, although no intermolecular NOE's were observed.⁽⁴¹⁶⁾

The epigallocatechin gallate (EGCG, Fig.14) is another polyphenol showing similar effects as EVG. EGCG is currently undergoing a phase 2-3 clinical test against early stages of Alzheimer's disease (NCT00951834), which is expected to complete in June 2015. EGCG was shown to redirect the A β aggregation pathway, and generate off-pathway non-toxic oligomers which are incapable of amyloid fibrillogenesis.⁽⁴¹⁷⁾ EGCG can also remodel mature A β fibrils into non-toxic oligomers,⁽⁴¹⁸⁾ suggesting its therapeutic potential for treatment of AD patients. Thermodynamic analysis using isothermal titration calorimetry for

EGCG and A β fragments/full length peptides by Wang et al. reported that EGCG mainly interacts with A β residues 1-16 through hydrogen bonding and residues 17-42 through hydrophobic interactions.^(419,420) Higher resolution structures of A β /EGCG complex are also available. Solution-state NMR measurements performed by Lopez del Amo *et al.* showed that the EGCG-induced A β 1-40 oligomers adopt a well-defined structure, rather than disordered, in which residues 22-39 maintained a β -sheet conformation, and residues 1-20 were unstructured.⁽⁴²¹⁾ Atomistic REMD simulations for A β 1-42 dimer with 10 EGCG found that the equilibrium structures of A β 42 dimer in the presence of EGCG were characterized by the existence of 5% free A β 42 monomers. Upon EGCG binding, the intermolecular contacts between the CHC and residues 29-42 were also greatly impacted.⁽²⁰⁷⁾ The simulations also revealed EGCG was most likely to interact with F4, R5, H6, Y10, L17-F20, I31-I32, L34-V36, V39 and I41 (Fig.15A).

Apart from the polyphenols discussed above, non-polyphenol molecules were also found to inhibit A β fibrilization through binding to oligomers. Carnosine (β -alanyl-L-histidine, Fig. 14), a naturally occurring dipeptide, was found to bind A β and inhibit fibril formation. With MD simulations and NMR experiments, again without any detection of intermolecular NOE's, carnosine was found to form transient salt bridges with charged residues in A β (R5, K16 and K28) and hydrophobic contacts with the CHC and flanking regions.⁽⁴²²⁾ Arai *et al.* also designed a non-peptidic inhibitor targeting CHC under the assumption that intermolecular side chain and main chain interactions must be optimal and minimal, respectively.⁽⁴²³⁾

Recently, the auto-oxidation of polyphenols, (+)-taxifolin⁽⁴²⁴⁾ and EGCG⁽⁴²⁵⁾ into quinone-derivatives was reported to be essential. The experiments revealed the potential of quinone-derivatives as A β aggregation inhibitors. Indeed, the quinones and quinone derivatives were found to inhibit amyloid aggregation several years ago.⁽⁴²⁶⁻⁴²⁸⁾ In 2010, Scherzer-Attali *et al.* observed that a quinone derivative, NQTrp (1,4-naphthoquinon-2-yl-L-tryptophan, Fig. 14), was able to inhibit fibril formation by A β 1-42 and completely recover the phenotype in a transgenic AD drosophila model.⁽⁴²⁹⁾ An extensive REMD simulation using the coarse-grained OPEP force field, followed by all-atom docking calculations, picked the NQTrp molecule as the best ligand of A β 17-42 trimeric structures among five small-molecule drugs, including 3 polyphenols.⁽²⁰⁸⁾ The NMR study with the presence of a 0.25 molar ratio of NQTrp to A β 12-28 monomer found that the structures of NQTrp-bound A β 12-28 were characterized by 2 turns formed by residues 18-20, and 22-26, although no intermolecular NOEs were observed.⁽⁴²⁹⁾ While several simulations focusing on the binding of NQTrp to A β fragments were performed,^(430,431) an all-atom REMD simulation of A β 1-42 dimer with the presence of 2 NQTrp molecules in explicit solvent provided a different binding picture.⁽⁴³²⁾ The structure representing the first most populated cluster shown in Fig.16A is characterized by two helices spanning the CHC or part of CT (residues 30-35) region in each chain. The second cluster in Fig.16B is essentially random coil with two short helices spanning residues 3-6 in one chain and residues 24-28 in the other chain. A structure with 3 β -strands is found in Cluster 8 (Fig.16C) where a β -hairpin formed by residues 32-34 and 37-40 of one chain packed against a third strand formed by residues 39-41 of the other chain. Overall, 555 clusters were identified and the residues with high probabilities to

interact with NQTrp are F4-D7, Y10, H13-H14, K16-L17, F19-F20, S26, K28, I31-I32, L34-M35 and V39 (Fig.15B).⁽⁴³²⁾

Complexes of EGCG or NQTrp to A β both involve several hydrophobic residues including Y10, L17, F19-F20, I31-I32, L34 and V39, though overall, the sites with the highest interaction probability are clearly different (Fig. 15A and 15B). R5, K16, K28 and the CHC region are found in the binding sites of both NQTrp and Carnosine. The proclivity of A β 1-42 monomer to form pockets able to bind small molecules was investigated by Zhu *et al.* with a 100ns REMD simulation with AMBER99sb/TIP3P.⁽¹⁷⁵⁾ The 35 most populated A β 1-42 monomer centroids were subjected to fragment-based calculations, and the most populated binding pockets identified using FTMap⁽⁴³³⁾ and FRED.⁽⁴³⁵⁾ The CHC residues were found to have the highest propensity to bind small molecular fragments, but F4, Y10, and M35 were also involved in many of the hotspots (Fig.15C).⁽¹⁷⁵⁾ In contrast, the central region (particularly 22-26) had a much lower tendency to form binding hot spots. This reduced probability agrees with the reduced experimental ¹H-¹⁵N HSQC chemical shift perturbation of central region residues when certain small compounds are titrated into A β monomer sample.^(435,436)

Obtaining high-resolution structures of A β monomer/inhibitor complexes from NMR with intermolecular NOEs remains a challenge. The strategy adopted in REMD simulations of A β /EGCG and A β /NQTrp complexes suggests a general first-order approach to screen A β /inhibitor interactions, but this remains a very difficult task because current inhibitors interacting with A β monomer, dimer and trimer show many binding sites with small occupancies and contact surfaces.^(207,432,437) Apart from simulations, the cost-effective virtual screening favors the discovery of novel inhibitors with high-quality receptor structures. Recently, a ligand-based drug design provided a different approach from virtual screening to the discovery of novel inhibitors.⁽⁴³⁸⁾ The method used a known inhibitor, a substituted A β 1-42 peptide termed [Nle³⁵, D-Pro³⁷] A β 1-42. The structure of residues 35-40 from the inhibitor was stripped of side-chain atoms except D-Pro, and used as query to screen for small molecules with similar spatial geometry and recapitulated hydrogen-bonding interactions. A compound was found to inhibit A β 1-42 aggregation with an IC₅₀ of 13 μ M. The approach is of great interest as it provides a good demonstration for both theoretical and experimental work of how to cooperate and the great benefits.

10. Truncated Variants of A β and Pathogenic and Protective A β Mutations

Familial forms of Alzheimer's Disease (FAD) represent only a small fraction of all AD cases and show an autosomal dominant pattern of inheritance, which often results in early onset symptoms (in general between 40 and 65 years old). FAD mutations occur on the presenilin PSEN1 and PSEN2 genes as well as on the APP gene from which A β is processed.⁽⁴³⁹⁾ We will therefore focus on APP mutations and particularly within A β spanning residues 672-714 for the 42 amino acid sequence.

10.1 Experimental Findings

Over 30 mutations in the APP gene are known today, 25 of which are pathogenic and autosomal dominant with an early-onset disease phenotype and two of which are reported to

be protective mutations against AD.⁽⁴⁴⁰⁾ In order to better understand the pathogenic and/or protective effects of AD mutations, it is important to genetically screen significantly large groups of AD and non-AD patients to obtain very good statistics SNPs.

Four types of FAD genetic aberrations have been observed to happen within the APP gene: complete gene duplications, single-point missense substitutions and deletion or insertion of a nucleotide. Gene duplications cause an overexpression of APP, which inevitably implies an overproduction of A β ⁽⁴⁴¹⁾ and all the consequential toxicity known to accompany it. Some mutations occur near the APP-to- A β β - and γ -cleavage sites, which generally results in an overproduction of A β ^(442,443) or shifts the relative amounts of A β 1-40 and A β 1-42 towards a higher production of the more toxic A β 1-42.

Many pathogenic FAD mutations increase A β propensity to aggregate *in vitro*.^(442,443) In particular, the mutations located in and near the CHC, the Flemish (A21G), Dutch (E22Q), Italian (E22K), Arctic (E22G) and Iowa (D23N) mutations, are also known to increase the toxicity mediated by A β . Because of their close proximity to the α -cleavage site (K16-L17), some of these mutations have been reported to also decrease the production of non-amyloid products and increase A β levels while making the mutant A β resistant to the A β -degrading enzyme neprilysin.⁽⁴⁴⁴⁾ Teplov *et al.* characterized the role of various residues and reported that A β 1-40 is mostly sensitive to mutations at positions 22 and 23 such as E22G and D23N, while A β 1-42 is most affected by A21G.⁽¹⁵⁰⁾ It has been shown that A21G decreases fibril elongation and promotes protofibril and toxic oligomer formation, while E22G is observed to increase the rate of protofibril formation. The effects of the FAD A21G and E22G mutations have also been studied using IM-MS showing that the early oligomer distributions differ for each mutant and the A β alloform.⁽⁵³⁾ Another pathogenic FAD mutation is the Osaka E22 mutation, which consists of a deletion of residue 22. E22 is known to induce a cholesterol-mediated toxicity as the mutation modulates levels of intracellular and extracellular A β , the secretion of which normally regulates cholesterol efflux.⁽⁴⁴⁵⁾ The *de novo* D23Y mutant and proline substitutions in the CHC have also been shown to affect self-assembly and toxicity.^(139,446)

Experiments have also highlighted the importance of the N-terminal residues 1 to 16,^(50,53-55,444,447) whose role has been underestimated in the past owing to its highly disordered structure in synthetic A β fibrils. These include the pathogenic FAD H6R (English), D7H (Taiwanese) and D7N (Tottori) mutations. In particular, D7N accelerates the kinetics of transition to β -sheet-rich configurations and promotes the early formation of higher order oligomers with more α/β structures that are significantly more toxic compared to WT A β 1-40 and A β 1-42.^(149a) An IM-MS study also showed that the FAD D7N mutation leads to early oligomer distributions that differ from A β 1-40 to A β 1-42.⁽⁵³⁾ The double substitution D1E/A2V also affects A β 1-40 fibrillogenesis and predominantly forms neurotoxic aggregates.⁽⁴⁴⁸⁾ Finally, a novel FAD mutation, K16N, found in one family was shown to increase A β production as it is a poorer substrate for α -secretase. The mutant K16N A β is itself not harmful, but becomes toxic when mixed upon equimolar ratio of WT A β , inhibiting WT A β 1-42 fibril formation and producing more A β oligomers.⁽⁴⁴⁴⁾ In many cases, key side chain interactions are reported to be at the origin of A β toxicity. Based on the A β 1-42 fibril model,⁽²⁹⁾ the K16N mutation is reported to add a hydrogen bond between the

side chains of K16 and N16 in hetero-tetramers, increasing therefore the stability of the aggregates.⁽⁴⁴⁴⁾ The importance of the lysine residues in A β has been further highlighted by Sinha *et al.* who rationally designed K16A and K28A mutants.^(151a) K16 is known to be important for driving fibrillogenesis while K28 is thought to stabilize a loop driving A β folding. What they found is that each mutation by alanine has profound effects on A β assembly and dramatically reduces A β toxicity, suggesting the design of inhibitors targeting K16 and K28. Another example is provided by the FAD D23N mutation, which by preventing the formation of a salt bridge with K28, also modifies toxicity. Finally, the English mutation by adding one charged residue and the Taiwanese and Tottori mutations, by deleting one charged residue, are also likely to change the network and populations of all salt bridges.

Surprisingly, there are no toxic FAD mutation reported in the C-terminal region (residues 30-42), though a high percentage of A β with a Met-sulfoxide at position 35 is present in the AD brain.⁽⁴⁴⁹⁾ Yet the *de novo* A β G33A and G133 variants have been shown to promote the aggregation process *in vitro* by increasing the population of large oligomers (16- to 20-mers) at the expense of small oligomers (2- to 4-mers); however, how they affect the structures of the early formed A β 1-42 oligomers is an open question.⁽⁴⁵⁰⁾ On the basis of *in vitro* and *in vivo* experiments, A β 1-42 oligomers with substitution of G33 by alanine and isoleucine are much less toxic than the WT A β 1-42, suggesting that G33 may represent the critical residue linking toxicity and oligomerization, adding therefore complexity to the origin of toxicity.⁽⁴⁵⁰⁾ Enhanced aggregation propensity of A β 1-40 was also confirmed in the double *de novo* mutants G33V/V40A and I31L/M35L⁽⁴⁵¹⁾ and, in a more extensive study Hecht *et al.* demonstrated that particular nonpolar side chains in the C-terminal half of A β 1-42 are not required for aggregation and amyloidogenesis.⁽⁴⁵²⁾

Besides the A β 1-40 and A β 1-42, the truncated A β 4-42 and A β 5-42,⁽⁴⁶⁾ A β 1-26 and A β 1-30 and A β 1-39 peptides are found in amyloid plaques.⁽⁴⁰⁾ The A β 1-43 peptide, extended by a single threonine at the C-terminus relative to A β 1-42, has a stronger neural toxicity and higher aggregation capacity than A β 1-42,⁽⁴⁵³⁾ and increases the rate of extent of protofibril aggregation and confers slow C-terminal motions in the monomeric and protofibril-bound forms of A β 1-43.⁽⁴⁵⁴⁾ In addition, many post-translational modifications of A β peptides are also observed in amyloid plaques. Among the modifications, proteolytic removal of D1 and A2 and the subsequent cyclizing of E3 and E11 to a pyroglutamate (A β 3(pE) and A β 11(pE)) are particularly interesting.⁽⁴⁷⁻⁴⁹⁾ A β (pE) is more cytotoxic and aggregates more rapidly than conventional A β . Only 5% of A β 3(pE)-42 mixed with 95% of WT A β 1-42 is enough to significantly enhance the cytotoxicity *in vivo* through the formation of hybrid A β 3(pE)-42/A β 1-42 oligomers. In light of these observations, it was postulated that A β 3(pE) might trigger AD by propagating through a template-folding prion-like mechanism with A β 1-42. This truncated variant is also known to be acting in a tau-dependent manner and to be particularly resistant to degradation.⁽⁵⁰⁾

The most intriguing and interesting mutations are undoubtedly the AD-protective ones, but they have not been extensively studied experimentally and theoretically. Two protective mutations at the position 2 of A β (position 673 in APP) have been reported. A rare genetic mutation observed in a single Italian kindred, A2V, causes an early-onset of AD when it is

only inherited from both parents, while heterozygous carriers of A2V are unaffected. A2V enhances A β 1-40 aggregation kinetics by a factor of four, but the mixture of the A β 1-40 WT and A2V peptides protects against AD.⁽⁵⁴⁾ Using multiple low-resolutions methods, an equimolar solution of A β 1-42 WT and A2V produces smaller aggregates with much slower kinetics than A β 1-42 WT, suggesting instability of the mixed aggregates.⁽⁴⁵⁵⁾

The A2T mutation, on the other hand, is always a protective mutation, independently of its homozygous or heterozygous form. It was reported in 79% of a non-AD control group with better cognitive test results compared to an AD group by using a large-scale DNA screening of Icelanders.⁽⁵⁵⁾ Thus far, this mutation has not been observed in non-Nordic populations.^(456,457) This mutation reduces A β production by 40%, at variance with A2V in its homozygous state which enhances A β production⁽⁵⁴⁾. Importantly, ThT fluorescence essays reveal that the mutations, while having little effect on A β 1-42 peptide aggregation, drastically modify the properties of the A β 1-40 pool with A2V accelerating and A2T delaying aggregation of the peptides. In agreement with the results of Ref.455 on the mixed A2V/WT aggregates, A2T forms smaller aggregates than the WT peptides.⁽⁴⁵⁸⁾ This finding on the kinetics and oligomer sizes should be however confirmed by Nile red binding and static light scattering experiments, respectively. Whether more unstable oligomers render them more available for degradation is sufficient to explain *in vitro* experiments showing that A2T attenuates the APP-mediated intracellular cell-death⁽⁴⁵⁹⁾ remains to be determined. Taken together, the physical properties of the A β 1-40/42 A2V/A2T and A β 3(pE)-42 peptides raise many questions and opens new drug-design perspectives.

10.2 What we have learned from Mutational Computational Studies

Most of the simulations studying the effects of mutations are summarized in Table 4. For each mutant, we give its polymeric state, the method used and the main findings. Many simulations of the Arctic E22G mutation have been performed and highlight its destabilizing effect on the region 20-30^(184b,202) and its increased β -strand effect on the N-terminal.^(184b) The other mutations at the position 22 also have significant effects on the CHC structure and flexibility and either induce more^(176,177,460) or less⁽¹⁷⁶⁾ α -helix structure, although all mutants remain essentially disordered. Lin *et al.*, on the basis of thousands of MD trajectories simulated with AMBER99sb/TIP3P have therefore postulated that there might exist a link between α -helix propensity and aggregation kinetics.⁽¹⁷⁷⁾ As a result, an increased helix-helix interaction between dimers may result in altered kinetics of oligomerization.

Other mutations in the region 20-23 have been shown experimentally to modulate the rate of aggregation.^(442,443) This effect is observed in several computational studies showing an increased aggregation propensity for E22Q,⁽⁴⁶¹⁾ and a reduced aggregation propensity for F20E dimers.⁽²⁰²⁾ In some cases, the CHC residues may also become solvent exposed and then serve as docking sites for A β deposition onto fibril (E22Q).⁽⁴⁶¹⁾ MD simulations on A21G report a decrease in β -strand propensity for the A β 1-40 and A β 1-42 dimers upon substitution,⁽⁴⁶²⁾ and this was confirmed by IM-MS experiment.⁽⁵³⁾ The simulations also reveal that the per-residue β probability varies from A β 1-40 and A β 1-42 dimers upon A21G. The D3N mutant in both alloforms was also studied by all-atom MC simulations and OPEP

CG REMD simulations both in implicit solvent and showed that, by perturbing the side-chain H-bond network, the peptide remains compact⁽²⁰²⁾ or displays a rather independent N-terminus.⁽¹⁹⁵⁾ In particular, the latter simulation showed that the D23N mutation causes non-local perturbations of the WT conformational ensemble by increasing the β -sheet propensity at the C-terminal region. This result is in agreement with the ss-NMR structure of a highly synaptic A β 1-40 toxic oligomer with a stable N-terminal β -strand.⁽¹²⁶⁾ Finally, the dimers of A β 15-40 WT and D23N were studied using a selected numbers of parallel and antiparallel molecular mechanics-generated conformations that were refined by *ab-initio* FMO (fragment molecular orbital) calculations. It is found that in water, the parallel conformation is more stable than the antiparallel one, due to the larger hydration energy for the parallel conformation for both the WT and the D23N- A β 15-40 dimers.⁽⁴⁶³⁾

Simulations of the FAD D7N and H6R variants also proposed different mechanisms for the increased A β aggregation.⁽⁴⁶⁴⁻⁴⁶⁶⁾ For instance, all-atom MD simulations showed that D7N enhances the aggregation rate by decreasing the turn propensity at residues 8-9, by perturbing salt-bridges half-lives and by reducing the bending free energy of the loop region.⁽⁴⁶⁴⁾ Simulations on H6R, in contrast, the rate of fibril formation of A β 1-42 increases due to increased β -structure at the C-terminal in both monomer and dimer and enhanced stability of salt bridge Asp23-Lys28 in monomer, while the enhancement of turn at residues 25-29 and reduction of coil in regions 10-13, 26-19, and 30-34 would play the key role for A β 1-40.⁽⁴⁶⁵⁾ The results of the FAD D7H simulations⁽⁴⁶⁶⁾ are discussed in Table 4.

De novo mutations were also investigated such as the mutation D23Y, whose effect on the hexamer of A β 1-40 was reported to favour the locking of A β monomer onto fibrils, thus promoting fibril growth. Simulations found that the interactions with the aromatic ring of Y23 are more fibril-compatible than with the negatively charged D23.⁽⁴⁶⁷⁾ The *de novo* G33A and G33I mutations were also explored on the monomer and dimer of A β 29-42, and the REMD simulations showed a significant reduction of the β -hairpin population upon both mutations and a destabilization of the dimer due to an increase in hydrophobicity.⁽⁴⁶⁸⁾

Atomistic MD simulations of monomeric A β 1-40 Met-ox found that M35 oxidation decreases the β -strand content of the C-terminal (residues 29-40), with a specific effect on the secondary structure of residues 33-35, thus potentially impeding aggregation. Further, there is an important interplay between oxidation state and solution conditions, with pH and salt concentration augmenting the effects of oxidation.⁽⁴⁶⁹⁾ REMD simulations of A β 1-43 dimers followed by *ab initio* calculations revealed a ring-shaped conformation, in which T43 is hydrogen bonded to R5, that is absent in A β 1-42 dimers.⁽⁴⁷⁰⁾ Simulations of A β 1-39 monomer and dimer with CHARMM/SASA revealed a very high percentage of α -helices, which is likely due to the very high bias for α -helix of this force field.^(471,472)

Finally, the A2V variant and the A β 3(pE)-42 peptides have started to be studied by computer simulations. First of all, Nguyen *et al.* have found via all-atom REMD simulations that the A2V mutant of A β 1-28 is much less intrinsically disordered than the WT peptide, increases the propensity to form β -hairpins and enhances the α -helix in the region 17-24. Both peptides display a non-negligible population (7%) of extended metastable conformations differing however in their atomic details that represent ideal seeds for

polymerization. More importantly, the two conformational ensembles are totally different, suggesting unstable dimers.⁽⁴⁷³⁾ This result is in agreement with the increase in β -propensity of pure A2V aggregates by light scattering and provides a first answer for the reduced aggregation kinetics of the mixture of WT and A2V peptides.⁽⁵⁴⁾ Atomistic REMD simulations of WT-WT, WT-A2V and WT-A2T A β 1-40 dimers are in progress.

A DMD-CG simulation in aqueous solution of 32 A β pE3 and A β pE11 peptides lacking pyroglutamate at position 3 and 11 reported than truncation of the N-terminal residues in A β 3-40, A β 3-42, A β 11-40 and A β 11-42 shifts the oligomer size distribution towards larger oligomers as observed experimentally.⁽⁴⁷⁴⁾ Moreover, the fact that the N-terminal of the A β pE3-40/42 and A β 11-42 variants is more flexible than the A β 1-40/42 WT peptides could be related to their increased toxicities relative to the WT peptides. The activity of A β 3(pE)-42 pores has been studied using a planar bilayer recording and their architectures provided by all-atom MD simulations showing that the N-termini β -strands tend to reside in the hydrophobic lipid core, in contrast to WT A β 1-42 peptides.⁽⁴⁷⁵⁾ Using multiple experimental essays and MD simulations, Lee *et al.* compared the adsorbed and membrane-inserted oligomeric species of A β pE3-42 and A β 1-42 peptides. They found lower concentrations and larger dimensions for both species of membrane-associated A β pE3-42 oligomers. The larger dimensions are attributed to the faster self-assembly kinetics of A β pE3-42. Membrane-inserted A β pE3-42 oligomers were also found to modify the mechanical properties of the membrane.⁽⁴⁷⁶⁾

11. Conclusions

We have reviewed what experiments and computer simulations can tell us about the amyloid- β protein and its link to Alzheimer's disease. Our knowledge of the structures of synthetic A β 1-40/1-42 fibrils, protofibrils, and large oligomers has markedly increased in the recent years and it is clear that polymorphism is present from the monomer to fibrils. We know that fibrils with different molecular structures can result from environment-dependent self-assembly and kinetic rather than thermodynamic control. We also know that metastable states can be alleviated by using appropriate seeds or under shear flow and the structural models of the A β 1-40 fibrils that build up take on different structures in the brain of diseased Alzheimer's patients with different AD symptoms. This high degree of polymorphism, which arises from many physical factors and persists *in vitro* and in brain tissues, is correlated to different phenotypes and is rather a bad news for drug design because one drug may be efficient for one patient but not for another.

Structural and dynamical characterization of the smallest oligomers, the most toxic species, and the monomers has been moving at a lower pace due to their transient character and intrinsic disorders, but with the help of new experimental methods and efficient sampling methods using multiple force fields and representations, our knowledge of these species in aqueous solution, in proximity or in the membranes, with and without ion metals should significantly increased, although polymorphism of the aggregates and high sensitivity of external conditions will not facilitate the reproducibility of the experimental readouts and the convergence of the simulations. One particular advantage of computer simulations, however,

is that calculations can be repeated using different pH conditions and model membranes and the effects of site-specific mutations can be investigated.

Characterization of the primary nucleus/nuclei and the population of amyloid-competent monomeric state⁽⁴⁷⁷⁾ prior to the lag phase remain difficult both experimentally and theoretically due to the sensitivity of the experimental conditions and the amino acid sequence. One amino acid substitution is sufficient to change the free energy landscape as evidenced from the kinetics and the oligomer sizes distribution of FAD A β variants and the recent isotope-edited and ss-NMR findings that A β 16-22 with E22Q displays by unexpected antiparallel β -strand orientation intermediates that later transition completely into parallel β -strands, suggesting a new nucleation mechanism in a progressive assembly pathway.⁽⁴⁷⁸⁾

Understanding the interactions that the A β 1-40/42, A β 1-40/42 A2V and A2T variants and the A β 3(pE)-42 peptides in both monomeric and oligomeric forms, establishes with metal ions and various cellular components is a top challenge to unveil the molecular mechanisms at the onset of AD. Again both biochemical and biophysical experiments along with simulations have just started to give a more precise picture, but important efforts towards this direction should be pursued.

How the structures of A β may relate to the mechanism of toxicity is still unknown since toxicity comes from all oligomers to the fibrils. One source of toxicity comes from membrane channel formation, and the cylindrin conformation has been suggested to be toxic. But other antiparallel beta-sheet conformations are also considered toxic. In addition a single amino acid change is able either to reduce (A2T, A2V) or increase (FAD, K16A) toxicity. Another source of toxicity comes from metal-ions and the interactions with the cellular partners, but our understanding is still limited. To this end, we are currently investigating the polymerization and depolymerization process of A β WT, A2V and A2T assembly in the absence and presence of PrP as well as the toxicity of the assemblies.

Despite extensive studies, drug after drug aimed at targeting A β has failed to slow the progression of AD in clinical trials. If it is true that we are treating people too late, there are however two other hurdles for drug improvement. While many groups are working on developing drugs that bind to A β fibrils (reducing therefore the fragmentation process) or bind to A β oligomers to slow down or accelerate fibrillation, and in all cases reduce A β cytotoxicity, how any interact with A β 1-42 and A β 3(pE)-42 oligomers is unknown at an atomic resolution. Yet, obtaining high-resolution structures of the A β oligomers/drug complexes is a prerequisite to optimize the kinetic and thermodynamic binding properties of promising compounds (and thus their specificity), prior to cell viability essays, animal models for AD and clinical trials. The second hurdle is that repeated identification of the same types of molecules as promising hits against different proteins is polluting the chemical literature. For instance, quinones are redox cyler, metal complexer and covalent modifier.⁽⁴⁷⁹⁾ It has also been found that curcumin from turmeric, EGCG from green tea, and resveratrol from grapes, which reduce A β aggregation *in vitro*, also alter lipid bilayer properties and the function of diverse membrane proteins.⁽⁴⁸⁰⁾ So the effect of one drug might not be what we expect, and in this context we recently showed using expressed and then produced A β 1-28, A β 1-40 and A β 1-42 peptides with multiple essays and different

readouts that the NQTrp inhibitor exerts its inhibitory effect via other mechanisms than direct interactions with A β peptides (O. Berthoumieu et al., unpublished).

Along with the next steps already described at the end of each section, some challenges should be considered. The first challenge is that the population of dimers, trimers and dodecamers (A β *56) in brain tissues vary with aging, indicating that the species to be targeted at early or late-onset AD are not the same. By using 75 cognitively intact individuals, ranging from young children to the elderly, and 58 impaired subjects with mild cognitive impairment or probable Alzheimer's disease, It was found that A β *56 may play a pathogenic role very early in the pathogenesis of AD.⁽⁴⁸¹⁾

The second challenge is that experiments have reported drastic acceleration of fibril formation for the A β 1-40 peptide in shear flow.⁽⁴⁸²⁻⁴⁸⁴⁾ The origin of such a kinetic speed up is still debated. In addition, while atomistic simulations in explicit solvent of the full aggregation of the A β 1-40/42 peptides and causing- or protecting-variants are still out of reach, coarse-grained simulations in implicit solvent require the treatment of hydrodynamics effects.^(61,485) In Fig.17 we report preliminary results of the early steps of the aggregation of 18 A β 16-22 blocked by acetyl and amine under shear flow as obtained from simulations using the CG model OPEP with hydrodynamic interactions (S. Melchionna, P. Derreumaux and F. Sterpone, unpublished). For sake of exemplarity the simulations were performed at rather high concentration (109 mM) and in the absence of shear rates or in the presence of high shear rates (10^8 , 10^9 and 10^{10} s⁻¹). With hydrodynamics effects, the early steps of aggregation are already very different from Langevin dynamics as seen from the size of the oligomers. With high shear rates, we observe formation of a unique elongated aggregate within 10 ns. For this highly concentrated system the presence of the laminar shear flow seems not affecting the overall kinetics of the collapse, but however does influence the way the aggregation proceeds. Namely increasing the rate an oscillatory behaviour in the aggregation process emerges (see left panel reporting the time evolution of the system's gyration radius). The highest shear rate also breaks down the hydrogen bonds and side-chain contacts in the aggregates, thus a non-monotonic behaviour as a function of the hydrodynamic perturbation is expected for similar aggregation processes of proteins. We are currently investigating the dynamics over a much longer time scale.

A third challenge is to have a direct observation of A β protein self-assembly in live cells as a result of crowding effects. Using noninvasive fluorescence lifetime recordings and super-resolution fluorescence, the formation of A β 1-40 and A β 1-42 aggregates in live cells was dissected. Both peptides are retained in lysosomes, where their accumulation leads to aggregation, but the kinetics of A β 1-42 aggregation are considerably faster than those of A β 1-40 and, unlike A β 1-40, show no detectable lag phase. Compact amyloid aggregates were observed for both alloforms.⁽⁴⁸⁶⁾ While, these experiments represent one step ahead towards understanding aggregation in the cells, higher spatial resolution methods and how the cellular environment affects the dynamics of A β 1-40/42 and their variants are major concerns. To this end, in cell-NMR of A β protein is an ideal tool for gaining information at the atomic level, but several obstacles remain.⁽⁴⁸⁷⁻⁴⁸⁸⁾

It is also a challenge to determine the impact of PrP and HAS on A β oligomerization. We are addressing both aspects experimentally by polymerization and de-polymerization kinetic experiments and theoretically by performing exascale simulations. In this respect, we have recently shown that it is possible to get the dynamics of 18 000 HAS proteins comprising 80 millions of particles with hydrodynamics interactions consistent with the experimental translational and rotational diffusion constants as a function of the density of the system.⁽⁶¹⁾

Finally, pathogenic events involve an imbalance between the production and the clearance of the A β peptide. It is important to understand at atomic detail how the A β is cleaved by γ -secretase and how this process is affected by A2V and A2T mutations. Clearly, the recent release of the 3D structure of the human γ -secretase complex at 4.5 Å⁽⁴⁸⁹⁾ combined with simulations going beyond the A β 1-55 dimer⁽⁴⁹⁰⁾ should help clarify this issue.

While many inhibitors have been designed to target a specific region of A β , it would be interesting to study in cells the cumulative effect of inhibitors designed to recognize different regions of A β . It will be also of great interest to combine different drugs targeting A β processing and rendering A β aggregates very unstable and more prone to degradation. Today, we are just seeing the top of the iceberg in understanding phenotype-related toxicity and aggregation propensity of WT A β and their familial-disease and protective variants. But continuous and synergetic efforts between *in vitro* and *in vivo* studies (including basic verifications such as purity and reproducibility of the results using various readouts or transgenic animals with different sex and times of AD incubation) and theoretical studies (using multiple approaches) should get us closer to finding a cure for AD.

Acknowledgments

Jessica Nasica-Labouze thanks funding from the European Social Fund (ESF), Op. Programme 2007-2013, Ob. 2, Axis 5, TALENTS FVG Programme - Activity 2 - Outgoing Scheme - FP code: 1418521006, managed by AREA Science Park. Phuong Nguyen, Bogdan Tarus and Philippe Derreumaux thank DARI (grant x2014077198) for computer resources. Fabio Sterpone and Simone Melchionna acknowledge funding from ERC under the European Community's seventh framework program (FP7/2007-2013) grant agreement no. 258748. Simulations with shear forces used HPC resources from GENCI (CINES and TGCC, grants 2012 c2012086818 and 2013 x201376818. Olivia Berthoumieu and Peter Faller would like to thank their collaborators and in particular Drs. Christelle Hureau, Emmanuel Gras, Fabrice Collin, Giovanni La Penna, for helpful discussions. Viorel Buchette and Birgit Strodel would like to thank Ratnesh Lal and Ruth Nussinov for providing the AFM images shown in Fig.8, and John E. Straub and Ruth Nussinov for providing the structure files of the membrane-bound A β models illustrated in Fig.9. Li Mai thanks Narodowe Centrum Nauki in Poland (Grant 2011/01/B/NZ1/01622). Yuguang Mu acknowledges Tier 1 grant RG 23/11 from Nanyang Technological University, Singapore.

Finally Philippe Derreumaux thanks support of University of Paris Diderot, ANR SIMI7 GRAL 12-BS07-0017, ANR LABEX Grant "DYNAMO" (ANR-11-LABX-0011), 6th European PRCD (Immunopron, FP6-Food023144), IUF, French/Singapore Merlion PhD program (Grant 5.08.10), Pierre de Gilles de Gennes Foundation and its international PhD grant program, Fudan University in China, CNRS – Polish Academy of Sciences (Grant 168836) and the CNRS Institute of Chemistry (INC).

References

1. Alzheimer US Association. <http://www.alz.org/>
2. Hardy J, Selkoe DJ. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on The Road To Therapeutics. Science. 2002; 297:353–356. [PubMed: 12130773]
3. Hernández-Rodríguez M, Correa-Basurto J, Martínez-Ramos F, Padilla-Martínez II, Benítez-Cardoza CG, Mera-Jiménez E, Rosales-Hernández MC. Design of Multi-target Compounds as

- AChE, BACE1, and amyloid- β (1-42) Oligomerization Inhibitors: in silico and in vitro Studies. *J Alzheimers Dis.* 2014; 41:1073–1085. [PubMed: 24762947]
4. Selkoe DJ. Alzheimer's Disease: Genes, Proteins, and Therapy. *Physiol Rev.* 2001; 81:741–766. [PubMed: 11274343]
 5. Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-analysis. *J Alzheimers Dis.* 2014; 41:615–631. [PubMed: 24662102]
 6. Valverde E, Sureda FX, Vázquez S. Novel Benzopolycyclic Amines with NMDA Receptor Antagonist Activity. *Bioorg Med Chem.* 2014; 22:2678–2683. [PubMed: 24698811]
 7. Yan R, Vasser R. Targeting the β secretase BACE1 for Alzheimer's Disease Therapy. *Lancet Neurol.* 2014; 13:319–329. [PubMed: 24556009]
 8. Wischik CM, Harrington CR, Storey JM. Tau-aggregation Inhibitor Therapy for Alzheimer's Disease. *Biochem Pharmacol.* 2014; 88:529–539. [PubMed: 24361915]
 9. (a) Doig AJ, Derreumaux P. Inhibition of Protein Aggregation and Amyloid Formation by Small Molecules. *Curr Opin Struct Biol.* 2015; 30C:50–56. (b) Jiang L, Liu C, Leibly D, Landau M, Zhao M, Hughes MP, Eisenberg DS. Structure-based Discovery of Fiber-binding Compounds that Reduce the Cytotoxicity of Amyloid beta. *Elife.* 2013; 2:e00857. [PubMed: 23878726]
 10. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta Protein Dimers Isolated Directly from Alzheimer's Brains Impair Synaptic Plasticity and Memory. *Nat Med.* 2008; 14:837–842. [PubMed: 18568035]
 11. (a) Bernstein SL, Dupuis NF, Lazo ND, Wytenbach T, Condrón NN, Bitan G, Teplow DB, Shea JE, Ruotolo BT, Robinson CV, Bowers MT. Amyloid- β Protein Oligomerization and the Importance of Tetramers and Dodecamers in the Aetiology of Alzheimer's Disease. *Nat Chem.* 2009; 1:326–331. [PubMed: 20703363] (b) Sherman MA, Lesné SE. Detecting A β *56 Oligomers in Brain Tissues. *Methods Mol Biol.* 2011; 670:45–56. [PubMed: 20967582]
 12. Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, Muhs A, Lashuel HA. Abeta42 Neurotoxicity is Mediated by Ongoing Nucleated Polymerization Process Rather Than by Discrete Abeta42 Species. *J Biol Chem.* 2011; 286:8585–8596. [PubMed: 21156804]
 13. Knowles TP, Waudby CA, Devlin GL, Cohen SI, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME, Dobson CM. An Analytical Solution to the Kinetics of Breakable Filament Assembly. *Science.* 2009; 326:1533–1537. [PubMed: 20007899]
 14. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP. Proliferation of Amyloid- β 42 Aggregates Occurs Through a Secondary Nucleation Mechanism. *Proc Natl Acad Sci USA.* 2013; 110:9758–9763. [PubMed: 23703910]
 15. Schmit JD, Gosh K, Dill K. What Drives Amyloid Molecules to Assemble into Oligomers and Fibrils? *Biophys J.* 2011; 100:450–458. [PubMed: 21244841]
 16. Jeong JS, Ansaloni A, Mezzenga R, Lashuel HA, Dietler G. Novel Mechanistic Insight into the Molecular Basis of Amyloid Polymorphism and Secondary Nucleation During Amyloid Formation. *J Mol Biol.* 2013; 425:1765–1781. [PubMed: 23415897]
 17. Qiang W, Kelley K, Tycko R. Polymorph-specific Kinetics and Thermodynamics of β -amyloid Fibril Growth. *J Am Chem Soc.* 2013; 135:6860–6871. [PubMed: 23627695]
 18. Tycko R, Wickner RB. Molecular Structures of Amyloid and Prion Fibrils: Consensus versus Controversy. *Acc Chem Res.* 2013; 46:1487–1496. [PubMed: 23294335]
 19. Meisl G, Yang X, Hellstrand E, Frohm B, Kirkegaard JB, Cohen SI, Dobson CM, Linse S, Knowles TP. Differences in Nucleation Behavior Underlie the Contrasting Aggregation Kinetics of the A β 40 and A β 42 peptides. *Proc Natl Acad Sci USA.* 2014; 111:9384–9389. [PubMed: 24938782] (b) Assarsson A, Hellstrand E, Cabaleiro-Lago C, Linse S. Charge Dependent Retardation of Amyloid β Aggregation by Hydrophilic Proteins. *ACS Chem Neurosci.* 2014; 4:266–274.
 20. Kirkitadze MD, Condrón MM, Teplow DB. Identification and Characterization of Key Kinetic Intermediates in Amyloid beta-protein Fibrillogenesis. *J Mol Biol.* 2001; 312:1103–1119. [PubMed: 11580253]

21. Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, Brewer JM, Byeon IJL, Ray DG, Vitek MP, Iwashita T, Makula RA, Przybyla AB, Zagorski MG. Solution NMR studies of the Abeta(1-40) and Abeta(1-42) Peptides Establish that the Met35 Oxidation State Affects the Mechanism of Amyloid Formation. *J Am Chem Soc.* 2004; 126:1992–2005. [PubMed: 14971932]
22. Sarroukh R, Cerf E, Derclaye S, Dufrêne YF, Goormaghtigh E, Ruyschaert JM, Raussens V. Transformation of Amyloid beta(1-40) Oligomers into Fibrils is Characterized by a Major Change in Secondary Structure. *Cell Mol Life Sci.* 2011; 68:1429–1438. [PubMed: 20853129]
23. Bertini I, Gallo G, Korsak M, Luchinat C, Mao J, Ravera E. Formation Kinetics and Structural Features of beta-amyloid Aggregates by Sedimented solute NMR. *Chembiochem.* 2013; 14:1891–1897. [PubMed: 23821412]
24. Kim BH, Lyubchenko YL. Nanoprobng of Misfolding and Interactions of Amyloid β 42 Protein. *Nanomedicine.* 2014; 4:871–878.
25. García S, Cuscó C, Brissos RF, Torrents E, Caubet A, Gamez P. Dual Role of Cu^{2+} Ions on the Aggregation and Degradation of soluble $\text{A}\beta$ Oligomers and Protofibrils Investigated by Fluorescence Spectroscopy and AFM. *J Inorg Biochem.* 2012; 116:26–36. [PubMed: 23010326]
26. Lv Z, Roychaudhuri R, Condrón MM, Teplow DB, Lyubchenko YL. Mechanism of Amyloid β -protein dimerization determined using single-molecule AFM force spectroscopy. *Sci Rep.* 2013; 3:2880–2888. [PubMed: 24096987]
27. Petkova AT, Leapman RD, Guo ZH, Yau WM, Mattson MP, Tycko R. Self-Propagating, Molecular-Level Polymorphism in Alzheimer's beta-Amyloid Fibrils. *Science.* 2005; 307:262–265. [PubMed: 15653506]
28. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. A Structural Model for Alzheimer's β -amyloid Fibrils based on Experimental Constraints from Solid State NMR. *Proc Natl Acad Sci USA.* 2002; 99:16742–16747. [PubMed: 12481027]
29. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Doeli H, Schubert D, Riek R. 3D Structure of Alzheimer's Amyloid- β (1–42) Fibrils. *Proc Natl Acad Sci USA.* 2005; 102:17342–17347. [PubMed: 16293696]
30. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. Molecular Structure of β -amyloid Fibrils in Alzheimer's Disease Brain tissue. *Cell.* 2013; 154:1257–1268. [PubMed: 24034249]
31. Gunderson W, Hernández-Guzmán J, Karr J, Sun L, Szalai V, Warncke K. Local Structure and Global Patterning of Cu^{2+} Binding in Fibrillar Amyloid- β [$\text{A}\beta$ (1–40)] Protein. *J Am Chem Soc.* 2012; 134:18330–18337. [PubMed: 23043377]
32. Eury H, Bijani C, Faller P, Hureau C. Copper(II) Coordination to Amyloid β : Murine versus Human Peptide. *Angew Chem Int Ed.* 2011; 50:901–905.
33. Stanyon HF, Viles JH. Human Serum Albumin Can Regulate Amyloid- β Peptide Fiber Growth in the Brain Interstitium. *J Biol Chem.* 2012; 287:28163–28168. [PubMed: 22718756]
34. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-beta Oligomers. *Nature.* 2009; 457:1128–1132. [PubMed: 19242475]
35. Younan ND, Sarell CJ, Davies P, Brown DR, Viles JH. The Cellular Prion Protein Traps Alzheimer's $\text{A}\beta$ in an Oligomeric Form and Disassembles Amyloid Fibers. *FASEB J.* 2013; 27:1847–1858. [PubMed: 23335053]
36. (a) Zou K, Gong JS, Yanagisawa K, Michikawa M. A Novel Function of Monomeric Amyloid beta-protein Serving as an Antioxidant Molecule against Metal-induced Oxidative Damage. *J Neurosci.* 2002; 22:4833–4841. [PubMed: 12077180] (b) State of aggregation. *Nat Neurosci | Editorial Nat Neurosci.* 2011; 14:399.doi: 10.1038/nn0411-399 [PubMed: 21445061]
37. Götz J, Matamalas M, Götz NN, Ittner LM, Eckert A. Alzheimer's Disease Models and Functional Genomics—How Many Needles are there in the Haystack? *Front Physiol.* 2012; 3:320.doi: 10.3389/fphys.2012.00320 [PubMed: 22934069]
38. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, Hyman BT, Shatz CJ. Human LILRB2 Is a β -Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. *Science.* 2013; 341:1399–1404. [PubMed: 24052308]

39. Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, Mandelkow EM. Amyloid- β Oligomers Induce Synaptic Damage via Tau-dependent Microtubule Severing by TTL6 and Spastin. *EMBO J.* 2013; 32:2920–2937. [PubMed: 24065130]
40. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM. Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer A β Oligomer Bound to Cellular Prion Protein. *Neuron.* 2013; 79:887–902. [PubMed: 24012003]
41. Kanekiyo T, Xu B, Bu G. ApoE and A β in Alzheimer's Disease: Accidental Encounters or Partners? *Neuron.* 2014; 81:740–754. [PubMed: 24559670]
42. Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. *Nat Rev Drug Discov.* 2013; 4:324.doi: 10.1038/nrd3842-c1
43. Abbott A. The plaque plan. *Nature.* 2008; 458:161–164.
44. Nguyen P, Derreumaux P. Understanding Amyloid Fibril Nucleation and A β Oligomer/Drug Interactions from Computer Simulations. *Acc Chem Res.* 2014; 47:603–611. [PubMed: 24368046]
45. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE. Overlapping Profiles of A β Peptides in the Alzheimer's Disease and Pathological Aging Brains. *Alzheimers Res Ther.* 2012; 4:18.doi: 10.1186/alzrt121 [PubMed: 22621179]
46. Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoek C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL. AIBL research group. Changes in Plasma Amyloid beta in a Longitudinal Study of Aging and Alzheimer's Disease. *Alzheimers Dement.* 2014; 10:53–61. [PubMed: 23491263]
47. Rezaei-Ghaleh N, Amininasab M, Giller K, Kumar S, Stündl A, Schneider A, Becker S, Walter J, Zweckstetter M. Turn Plasticity Distinguishes Different Modes of Amyloid- β Aggregation. *J Am Chem Soc.* 2014; 136:4913–4919. [PubMed: 24617810]
48. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI. Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-beta. *Biochemistry.* 2004; 43:560–568. [PubMed: 14717612]
49. Masters CL, Selkoe DJ. Biochemistry of Amyloid β -Protein and Amyloid Deposits in Alzheimer Disease. *Cold Spring Harb Perspect Med.* 2012; 2:a006262. [PubMed: 22675658]
50. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Röncke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS. Prion-like Behaviour and Tau-dependent Cytotoxicity of Pyroglutamylated Amyloid- β . *Nature.* 2012; 485:651–655. [PubMed: 22660329]
51. Deng B, Lian Y, Wang X, Zeng F, Jiao B, Wang YR, Liang CR, Liu YH, Bu XL, Yao XQ, Zhu C, Shen L, Zhou HD, Zhang T, Wang YJ. Identification of a Novel Mutation in the Presenilin 1 Gene in a Chinese Alzheimer's Disease Family. *Neurotox Res.* 2014; 26:211–215. [PubMed: 24737487]
52. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H. A New Amyloid beta Variant Favoring Oligomerization in Alzheimer's-type Dementia. *Ann Neurol.* 2008; 63:377–387. [PubMed: 18300294]
53. Gessel MM, Bernstein S, Kemper M, Teplow DB, Bowers MT. Familial Alzheimer's Disease Mutations Differentially Alter Amyloid β -Protein Oligomerization. *ACS Chem Neurosci.* 2012; 3:909–918. [PubMed: 23173071]
54. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A, Falcone C, Gobbi M, Colombo L, Bastone A, Beeg M, Manzoni C, Francescucci B, Spagnoli A, Cantù L, Del Favero E, Levy E, Salmona M, Tagliavini FA. Recessive Mutation in the APP Gene with Dominant-negative Effect on Amyloidogenesis. *Science.* 2009; 323:1473–1477. [PubMed: 19286555]
55. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Björnsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Björnsdóttir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdóttir U, Watts RJ, Stefansson K. A Mutation in APP Protects against

- Alzheimer's Disease and Age-related Cognitive Decline. *Nature*. 2012; 488:96–99. [PubMed: 22801501]
56. Zhang Y, Rempel DL, Zhang J, Sharma AK, Mirica LM, Gross ML. Pulsed Hydrogen–deuterium Exchange Mass Spectrometry Probes Conformational Changes in Amyloid beta (A β) Peptide Aggregation. *Proc Natl Acad Sci USA*. 2013; 110:14604–14609. [PubMed: 23959898]
57. Santi S, Musi V, Descrovi E, Paeder V, Di Francesco J, Hvozda L, van der Wal P, Lashuel HA, Pastore A, Neier R, Herzig HP. Real-time Amyloid Aggregation Monitoring with a Photonic Crystal-based Approach. *Chemphyschem*. 2013; 14:3476–3482. [PubMed: 24105966]
58. Johnson RD, Schauerte JA, Chang CC, Wisser KC, Althaus JC, Carruthers CJ, Sutton MA, Steel DG, Gafni A. Single-molecule Imaging Reveals a β 42:a β 40 Ratio-dependent Oligomer Growth on Neuronal Processes. *Biophys J*. 2013; 104:894–903. [PubMed: 23442968] (b) Narayan P, Ganzinger KA, McColl J, Weimann L, Meehan S, Qamar S, Carver JA, Wilson MR, St George-Hyslop P, Dobson CM, Klenerman D. Single Molecule Characterization of the Interactions between Amyloid- β Peptides and the Membranes of Hippocampal Cells. *J Am Chem Soc*. 2013; 135:1491–1498. [PubMed: 23339742]
59. Gu L, Liu C, Guo Z. Structural Insights into A β 42 Oligomers using Site-directed Spin Labeling. *J Biol Chem*. 2013; 288:18673–18683. [PubMed: 23687299]
60. Drew SC, Noble CJ, Masters CL, Hanson GR, Barnham KJ. Pleomorphic Copper Coordination by Alzheimer's Disease Amyloid- β Peptide. *J Am Chem Soc*. 2009; 131:1195–1207. [PubMed: 19119811]
61. Sterpone F, Melchionna S, Tuffery P, Pasquali S, Mousseau N, Cragnolini T, Chebaro Y, St-Pierre J, Kalimeri M, Barducci A, Laurin Y, Tek A, Baaden M, Nguyen PH, Derreumaux P. The OPEP Protein Model: From Single Molecules, Amyloid Formation, Crowding and Hydrodynamics to DNA/RNA Systems. *Chem Soc Rev*. 2014; 43:4871–4893. [PubMed: 24759934]
62. Tycko R. Solid-State NMR Studies of Amyloid Fibril Structure. *Annu Rev Phys Chem*. 2011; 62:279–299. [PubMed: 21219138]
63. Sarroukh R, Goormaghtigh E, Ruyschaert J, Raussens V. ATR-FTIR: A “Rejuvenated” Tool to Investigate Amyloid Proteins. *Biochim Biophys Acta*. 2013; 1828:2328–2338. [PubMed: 23746423]
64. Miller Y, Ma B, Nussinov R. Polymorphism in Alzheimer A β Amyloid Organization Reflects Conformational Selection in a Rugged Energy Landscape. *Chem Rev*. 2010; 110:4820–4838. [PubMed: 20402519]
65. Faendrich M, Schmidt M, Grigorieff N. Recent Progress in Understanding Alzheimer's β -Amyloid Structures. *Trends Biochem Sci*. 2011; 36:338–345. [PubMed: 21411326]
66. Meinhardt J, Sachse C, Hortschansky P, Grigorieff N, Faendrich M. A β (1-40) Fibril Polymorphism Implies Diverse Interaction Patterns in Amyloid Fibrils. *J Mol Biol*. 2009; 386:869–877. [PubMed: 19038266]
67. Paravastu AK, Petkova AT, Tycko R. Polymorphic Fibril Formation by Residues 10-40 of the Alzheimer's β -Amyloid Peptide. *Biophys J*. 2006; 90:4618–4629. [PubMed: 16565054]
68. Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular Structural Basis for Polymorphism in Alzheimer's β -Amyloid Fibrils. *Proc Natl Acad Sci USA*. 2008; 105:18349–18354. [PubMed: 19015532]
69. Chen B, Thurber KR, Shewmaker F, Wickner RB, Tycko R. Measurement of Amyloid Fibril Mass-Per-Length by Tilted-Beam Transmission Electron Microscopy. *Proc Natl Acad Sci USA*. 2009; 106:14339–14344. [PubMed: 19706519]
70. Nilsson MR. Techniques to Study Amyloid Fibril Formation In Vitro. *Methods*. 2004; 34:151–160. [PubMed: 15283924]
71. Fraser P, Nguyen J, Surewicz W, Kirschner D. pH-Dependent Structural Transitions of Alzheimer Amyloid Peptides. *Biophys J*. 1991; 60:1190–1201. [PubMed: 1760507]
72. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CCF. Common Core Structure of Amyloid Fibrils by Synchrotron X-ray Diffraction. *J Mol Biol*. 1997; 273:729–739. [PubMed: 9356260]
73. Eanes ED, Glenner GG. X-ray Diffraction Studies on Amyloid Filaments. *J Histochem Cytochem*. 1968; 16:673–677. [PubMed: 5723775]

74. Serpell LC, Fraser PE, Sunde M. X-ray Fiber Diffraction of Amyloid Fibrils. *Methods Enzymol.* 1999; 309:526–536. [PubMed: 10507046]
75. Morris KL, Serpell LC. X-Ray Fibre Diffraction Studies of Amyloid Fibrils Amyloid Proteins: Methods and Protocols (Second). 2012; 849:121–135.
76. Kisilevsky R. Review: Amyloidogenesis - Unquestioned Answers and Unanswered Questions. *J Struct Biol.* 2000; 130:99–108. [PubMed: 10940218]
77. Kheterpal I, Williams A, Murphy C, Bledsoe B, Wetzel R. Structural Features of the A β Amyloid Fibril Elucidated by Limited Proteolysis. *Biochemistry.* 2001; 40:11757–11767. [PubMed: 11570876]
78. Torok M, Milton S, Kaye R, Wu P, McIntire T, Glabe CG, Langen R. Structural and Dynamic Features of Alzheimer's A β Peptide in Amyloid Fibrils Studied by Site-Directed Spin Labeling. *J Biol Chem.* 2002; 277:40810–40815. [PubMed: 12181315]
79. Petkova AT, Yau WM, Tycko R. Experimental Constraints on Quaternary Structure in Alzheimer's β -Amyloid Fibrils. *Biochemistry.* 2006; 45:498–512. [PubMed: 16401079]
80. Makin OS, Sikorski P, Serpell LC. Diffraction to Study Protein and Peptide Assemblies. *Curr Opin Chem Biol.* 2006; 10:417–422. [PubMed: 16931111]
81. Jahn TR, Makin OS, Morris KL, Marshall KE, Tian P, Sikorski P, Serpell LC. The Common Architecture of Cross- β Amyloid. *J Mol Biol.* 2010; 395:717–727. [PubMed: 19781557]
82. Sipe JD, Cohen AS. Review: History of the Amyloid Fibril. *J Struct Biol.* 2000; 130:88–98. [PubMed: 10940217]
83. (a) Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJW, McFarlane HT, Madsen AO, Riekel C, Eisenberg D. Atomic Structures of Amyloid Cross- β Spines Reveal Varied Steric Zippers. *Nature.* 2007; 447:453–457. [PubMed: 17468747] (b) Eisenberg D, Jucker M. The Amyloid State of Proteins in Human Diseases. *Cell.* 2012; 148:1188–1203. [PubMed: 22424229]
84. Park J, Kahng B, Hwang W. Thermodynamic Selection of Steric Zipper Patterns in the Amyloid Cross- β Spine. *PLoS Comput Biol.* 2009; 5:e1000492. [PubMed: 19730673]
85. Tycko R. Biomolecular Solid State NMR: Advances in Structural Methodology and Applications to Peptide and Protein Fibrils. *Annu Rev Phys Chem.* 2001; 52:575–606. [PubMed: 11326075]
86. Benzinger TLS, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC. Propagating Structure of Alzheimer's β -amyloid(10-35) is Parallel β -sheet with Residues in Exact Register. *Proc Natl Acad Sci U S A.* 1998; 95:13407–13412. [PubMed: 9811813]
87. Lansbury PT, Costa PR, Griffiths JM, Simon EJ, Auger M, Halverson KJ, Kocisko DA, Hendsch ZS, Ashburn TT, Spencer RGS, Tidor B, Griffin RG. Structural Model for the β -Amyloid Fibril Based on Interstrand Alignment of an Antiparallel-Sheet Comprising a C-Terminal Peptide. *Nat Struct Biol.* 1995; 2:990–998. [PubMed: 7583673]
88. Lazo ND, Downing DT. Amyloid Fibrils May be Assembled from β -Helical Protofibrils. *Biochemistry.* 1998; 37:1731–1735. [PubMed: 9492738]
89. Fabian H, Nauman D, Otvos L, Schultz C, Backmann J. Impact of Point Mutations and Amino Acid Modifications on the Structure and Stability of Peptides and Proteins Probed by FTIR Spectroscopy. *J Mol Struct.* 1995; 348:5–8.
90. Halverson K, Fraser PE, Kirschner DA, Lansbury PT Jr. Molecular Determinants of Amyloid Deposition in Alzheimer's Disease: Conformational Studies of Synthetic β -Protein Fragments. *Biochemistry.* 1990; 29:2639–2644. [PubMed: 2346740]
91. Ishii Y. C-13-C-13 Dipolar Recoupling Under Very Fast Magic Angle Spinning in Solid-State Nuclear Magnetic Resonance: Applications to Distance Measurements, Spectral Assignments, and High-Throughput Secondary-Structure Determination. *J Chem Phys.* 2001; 114:8473–8483.
92. Ishii Y, Balbach JJ, Tycko R. Measurement of Dipole-Coupled Lineshapes in a Many-Spin System by Constant-Time Two-Dimensional Solid State NMR with High-Speed Magic-Angle Spinning. *Chem Phys.* 2001; 266:231–236.
93. Tycko R. Symmetry-Based Constant-Time Homonuclear Dipolar Recoupling in Solid State NMR. *J Chem Phys.* 2007; 126:064506–064506. [PubMed: 17313228]
94. (a) Balbach JJ, Ishii Y, Antzutkin ON, Leapman RD, Rizzo NW, Dyda F, Reed J, Tycko R. Amyloid Fibril Formation by A β (16-22), a Seven-Residue Fragment of the Alzheimer's β -

- Amyloid Peptide, and Structural Characterization by Solid State NMR. *Biochemistry*. 2000; 39:13748–13759. [PubMed: 11076514] (b) Ma B, Nussinov R. Stabilities and Conformations of Alzheimer's β -Amyloid Peptide Oligomers ($A\beta(16-22)$, $A\beta(16-35)$, and $A\beta(10-35)$): Sequence Effects. *Proc Natl Acad Sci USA*. 2002; 99:14126–14131. [PubMed: 12391326]
95. Mikros E, Benaki D, Humpfer E, Spraul M, Loukas S, Stassinopoulou C, Pelecanou M. High-resolution NMR Spectroscopy of the beta-amyloid(1-28) Fibril Typical for Alzheimer's Disease. *Angew Chem Int Edit*. 2001; 40:3603–3065.
 96. Antzutkin ON, Balbach JJ, Leapman RD, Rizzo NW, Reed J, Tycko R. Multiple Quantum Solid-State NMR Indicates a Parallel, not Antiparallel, Organization of β -Sheets in Alzheimer's β -Amyloid Fibrils. *Proc Natl Acad Sci U S A*. 2000; 97:13045–13050. [PubMed: 11069287]
 97. Chi EY, Frey SL, Winans A, Lam KL, Kjaer K, Majewski J, Lee KY. Amyloid- β Fibrillogenesis Seeded by Interface-Induced Peptide Misfolding and Self-Assembly. *Biophys J*. 2010; 98:2299–2308. [PubMed: 20483339]
 98. Bertini I, Gonnelli L, Luchinat C, Mao JF, Nesi A. A New Structural Model of $A\beta(40)$ Fibrils. *J Am Chem Soc*. 2011; 133:16013–16022. [PubMed: 21882806]
 99. Lopez del Amo JM, Schmidt M, Fink U, Dasari M, Fandrich M, Reif B. An Asymmetric Dimer as the Basic Subunit in Alzheimer's Disease Amyloid β Fibrils. *Angew Chem Int Ed Engl*. 2012; 51:6136–6139. [PubMed: 22565601]
 100. Wu C, Bowers MT, Shea JE. Molecular Structures of Quiescently Grown and Brain-Derived Polymorphic Fibrils of the Alzheimer Amyloid $A\beta(9-40)$ Peptide: A Comparison to Agitated Fibrils. *PLoS Comput Biol*. 2010; 6:e1000693. [PubMed: 20221247]
 101. Qiang W, Yau W, Luo Y, Mattson MP, Tycko R. Antiparallel β -sheet Architecture in Iowa-Mutant β -amyloid Fibrils. *Proc Natl Acad Sci USA*. 2012; 109:4443–4448. [PubMed: 22403062]
 102. Pellarin R, Schuetz P, Guarnera E, Cafilisch A. Amyloid Fibril Polymorphism is Under Kinetic Control. *J Am Chem Soc*. 2010; 132:14960–14970. [PubMed: 20923147]
 103. Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R. Seeded Growth of β -Amyloid Fibrils from Alzheimer's Brain-Derived Fibrils Produces a Distinct Fibril Structure. *Proc Natl Acad Sci USA*. 2009; 106:7443–7448. [PubMed: 19376973]
 104. Snyder SW, Lador US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. Amyloid- β Aggregation: Selective Inhibition of Aggregation in Mixtures of Amyloid with Different Chain Lengths. *Biophys J*. 1994; 67:1216–1228. [PubMed: 7811936]
 105. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Drafft GA, Klein WL. Diffusible, Nonfibrillar Ligands Derived from $A\beta(1-42)$ are Potent Central Nervous System Neurotoxins. *Proc Natl Acad Sci USA*. 1998; 95:6448–6453. [PubMed: 9600986]
 106. Kodali R, Wetzel R. Polymorphism in the Intermediates and Products of Amyloid Assembly. *Curr Opin Struct Biol*. 2007; 17:48–57. [PubMed: 17251001]
 107. Walsh DM, Selkoe DJ. $A\beta$ Oligomers - A Decade of Discovery. *J Neurochem*. 2007; 101:1172–1184. [PubMed: 17286590]
 108. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid β -Protein Assembly and Alzheimer disease. *J Biol Chem*. 2009; 284:4749–4753. [PubMed: 18845536]
 109. Rangachari V, Moore BD, Reed DK, Sonoda LK, Bridges AW, Conboy E, Hartigan D, Rosenberry TL. Amyloid- $\beta(1-42)$ Rapidly Forms Protofibrils and Oligomers by Distinct Pathways in Low Concentrations of Sodium Dodecylsulfate. *Biochemistry*. 2007; 46:12451–12462. [PubMed: 17910477]
 110. Nichols MR, Moss MA, Reed DK, Lin W, Mukhopadhyay R, Hoh JH, Rosenberry TL. Growth of β -Amyloid(1-40) Protofibrils by Monomer Elongation and Lateral Association. Characterization of Distinct Products by Light Scattering and Atomic Force Microscopy. *Biochemistry*. 2002; 41:6115–6127. [PubMed: 11994007]
 111. Tay WM, Huang D, Rosenberry TL, Paravastu AK. The Alzheimer's Amyloid- $\beta(1-42)$ Peptide Forms Off-Pathway Oligomers and Fibrils that are Distinguished Structurally by Intermolecular Organization. *J Mol Biol*. 2013; 425:2494–2508. [PubMed: 23583777]
 112. Sandberg A, Luheshi LM, Sollvander S, Pereira de Barros T, Macao B, Knowles TP, Biverstal H, Lendel C, Ekholm-Pettersson F, Dubnovitsky A, Lannfelt L, Dobson CM, Hard T. Stabilization of

Neurotoxic Alzheimer Amyloid- β Oligomers by Protein Engineering. *Proc Natl Acad Sci U S A*. 2010; 107:15595–15600. [PubMed: 20713699]

113. Hard T. Protein Engineering to Stabilize Soluble Amyloid β -Protein Aggregates for Structural and Functional Studies. *FEBS J*. 2011; 278:3884–3892. [PubMed: 21824290]
114. Hoyer W, Gronwall C, Jonsson A, Stahl S, Hard T. Stabilization of a β -hairpin in Monomeric Alzheimer's Amyloid- β Peptide Inhibits Amyloid Formation. *Proc Natl Acad Sci USA*. 2008; 105:5099, 5104. [PubMed: 18375754]
115. Klein WL. A β Toxicity in Alzheimer's Disease: Globular Oligomers(ADDLs) as New Vaccine and Drug Targets. *Neurochem Int*. 2002; 41:345–352. [PubMed: 12176077]
116. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H. Globular Amyloid β -Peptide(1-42) Oligomer - A Homogenous and Stable Neuropathological Protein in Alzheimer's Disease. *J Neurochem*. 2005; 95:834–847. [PubMed: 16135089]
117. Moore BD, Rangachari V, Tay WM, Milkovic NM, Rosenberry TL. Biophysical Analyses of Synthetic Amyloid- β (1-42) Aggregates Before and After Covalent Cross-Linking. Implications for Deducing the Structure of Endogenous Amyloid- β Oligomers. *Biochemistry*. 2009; 48:11796–11806. [PubMed: 19916493]
118. Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, Ishii Y. Evidence of Fibril-Like β -sheet Structures in a Neurotoxic Amyloid Intermediate of Alzheimer's β -Amyloid. *Nat Struct Mol Biol*. 2007; 14:1157–1164. [PubMed: 18059284]
119. Matsumura S, Shinoda K, Yamada M, Yokojima S, Inoue M, Ohnishi T, Shimada T, Kikuchi K, Masui D, Hashimoto S, Sato M, Ito A, Akioka M, Takagi S, Nakamura Y, Nemoto K, Hasegawa Y, Takamoto H, Inoue H, Nakamura S, Nabeshima Y, Teplow DB, Kinjo M, Hoshi M. Two Distinct Amyloid β -protein (A β) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses. *J Biol Chem*. 2011; 286:11555–11562. [PubMed: 21292768]
120. Scheidt HA, Morgado I, Huster D. Solid-state NMR Reveals a Close Structural Relationship between Amyloid- β Protofibrils and Oligomers. *J Biol Chem*. 2012; 287:22822–22826. [PubMed: 22589542]
121. Scheidt HA, Morgado I, Rothmund S, Huster D, Fandrich M. Solid-State NMR Spectroscopic Investigation of A β Protofibrils: Implication of a β -Sheet Remodeling Upon Maturation into Terminal Amyloid Fibrils. *Angew Chem Int Ed Engl*. 2011; 50:2837–2840. [PubMed: 21387500]
122. Doi T, Masuda Y, Irie K, Akagi K, Monobe Y, Imazawa T, Takegoshi K. Solid-State NMR Analysis of the β -Strand Orientation of the Protofibrils of Amyloid β -Protein. *Biochem Biophys Res Commun*. 2012; 428:458–462. [PubMed: 23131555]
123. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, Barghorn S, Ebert U, Richardson PL, Miesbauer L, Solomon L, Bartley D, Walter K, Johnson RW, Hajduk PJ, Olejniczak ET. Structural Characterization of a Soluble Amyloid β -peptide Oligomer. *Biochemistry*. 2009; 48:1870–1877. [PubMed: 19216516]
124. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Nostrand WEV, Smith SO. Structural Conversion of Neurotoxic Amyloid- β 1-42 Oligomers to Fibrils. *Nat Struct Mol Biol*. 2010; 17:561–568.
125. Spencer RK, Li H, Nowick JS. X-ray Crystallographic Structures of Trimers and Higher-Order Oligomeric Assemblies of a Peptide Derived from A β . *J Am Chem Soc*. 2014; 136:5595–5598. [PubMed: 24669800]
126. Haupt C, Leppert J, Ronicke R, Meinhardt J, Yadav JK, Ramachandran R, Ohlenschlager O, Reymann KG, Gorlach M, Fandrich M. Structural Basis of β -Amyloid-Dependent Synaptic Dysfunctions. *Angew Chem Int Ed Engl*. 2012; 51:1576–1579. [PubMed: 22234970]
127. (a) Sarkar B, Mithu VS, Chandra B, Mandal A, Chandrakesan M, Bhowmik D, Madhu PK, Maiti S. Significant Structural Differences Between Transient Amyloid- β Oligomers and Less-Toxic Fibrils in Regions Known To Harbor Familial Alzheimer's Mutations. *Angew Chem Int Ed*. 2014; 53:6888–6892. (b) Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, Zhao M, Pensalfini A, Soriaga AB, Landau M, Teng PK, Cascio D, Glabe C, Eisenberg D. Atomic View of a Toxic Amyloid Small Oligomer. *Science*. 2012; 335:1228–31. [PubMed: 22403391]

128. (a) Wei G, Mousseau N, Derreumaux P. Sampling the Self-Assembly Pathways of KFFE Hexamers. *Biophys J*. 2004; 87:3648–3656. [PubMed: 15377527] (b) Mousseau N, Derreumaux P. Exploring the Early Steps of Amyloid Peptide Aggregation by Computers. *Acc Chem Res*. 2005; 38:885–891. [PubMed: 16285711]
129. Melquiond A, Mousseau N, Derreumaux P. Structures of Soluble Amyloid Oligomers from Computer Simulations. *Proteins*. 2006; 65:180–191. [PubMed: 16894607]
130. Song W, Wei G, Mousseau N, Derreumaux P. Self-Assembly of the β 2-microglobulin NHVTLSQ Peptide Using a Coarse-Grained Protein Model Reveals a β -barrel Species. *J Phys Chem B*. 2008; 112:4410–4418. [PubMed: 18341325]
131. Irback A, Mitternacht S. Spontaneous β -barrel Formation: an All-atom Monte Carlo Study of A β 16–22 Oligomerization. *Proteins*. 2008; 71:207–214. [PubMed: 17932914]
132. Bellesia G, Shea JE. Effect of β -sheet Propensity on Peptide Aggregation. *J Chem Phys*. 2009; 130:145103. [PubMed: 19368476]
133. (a) De Simone A, Derreumaux P. Low Molecular Weight Oligomers of Amyloid Peptides Display β -barrel Conformations: a Replica Exchange Molecular Dynamics Study in Explicit Solvent. *J Chem Phys*. 2010; 132:165103. [PubMed: 20441311] (b) Hatami A, Albay R 3rd, Monjazez S, Milton S, Glabe C. Monoclonal Antibodies against A β 42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in vitro and in Alzheimer Disease Brain. *J Biol Chem*. 2014; 289:32131–43. [PubMed: 25281743]
134. Bitan G, Lomakin A, Teplow D. Amyloid β -protein Oligomerization - Prenucleation Interactions Revealed by Photo-Induced Cross-Linking of Unmodified Proteins. *J Biol Chem*. 2001; 276:35176–35184. [PubMed: 11441003]
135. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid β -protein (A β) assembly: A β 40 and A β 42 oligomerize through distinct pathways. *Proc Natl Acad Sci USA*. 2003; 100:330–335. [PubMed: 12506200]
136. Roychaudhuri R, Yang M, Deshpande A, Cole GM, Frautschy S, Lomakin A, Benedek GB, Teplow DB. C-terminal Turn Stability Determines Assembly Differences Between A β 40 and A β 42. *J Mol Biol*. 2013; 425:292–308. [PubMed: 23154165]
137. (a) Kloniecki M, Jablonowska A, Poznanski J, Langridge J, Hughes C, Campuzano I, Giles K, Dadlez M. Ion Mobility Separation Coupled with MS Detects Two Structural States of Alzheimer's Disease A β 1–40 Peptide Oligomers. *J Mol Biol*. 2011; 407:110–124. [PubMed: 21237171] (b) Sitkiewicz E, Kloniecki M, Poznanski J, Bal W, Dadlez M. Factors Influencing Compact–Extended Structure Equilibrium in Oligomers of A β 1–40 Peptide—An Ion Mobility Mass Spectrometry Study. *J Mol Biol*. 2014; 426:2871–2885. [PubMed: 24857861] (c) Chen YR, Glabe CG. Distinct Early Folding and Aggregation Properties of Alzheimer amyloid- β Peptides A β 40 and A β 42: Stable Trimer or Tetramer Formation by A β 42. *J Biol Chem*. 2006; 281:24414–24422. [PubMed: 16809342]
138. Liu R, McAllister C, Lyubchenko Y, Sierks MR. Residues 17–20 and 30–35 of β -amyloid Play Critical Roles in Aggregation. *J Neurosci Res*. 2004; 75:162–171. [PubMed: 14705137]
139. (a) Williams AD, Portelius E, Kheterpal I, Guo JT, Cook KD, Xu Y, Wetzel R. Mapping A β Amyloid Fibril Secondary Structure Using Scanning Proline Mutagenesis. *J Mol Biol*. 2004; 335:833–842. [PubMed: 14687578] (b) Bernstein SL, Wytenbach T, Baumketner A, Shea JE, Bitan G, Teplow DB, Bowers MT. Amyloid β -protein: Monomer Structure and Early Aggregation States of A β 42 and its Pro19 Alloform. *J Am Chem Soc*. 2005; 127:2075–2084. [PubMed: 15713083] (c) Masuda Y, Uemura S, Ohashi R, Nakanishi A, Takegoshi K, Shimizu T, Shirasawa T, Irie K. Identification of Physiological and Toxic Conformations in A β 42 Aggregates. *Chembiochem*. 2009; 10:287–295. [PubMed: 19115328]
140. Gu L, Ngo S, Guo Z. Solid-support Electron Paramagnetic Resonance (EPR) Studies of A β 40 Monomers Reveal a Structured State with Three Ordered Segments. *J Biol Chem*. 2012; 287:9081–9089. [PubMed: 22277652]
141. Bramucci E, Paiardini A, Bossa F, Pascarella S. PyMod: Sequence Similarity Searches, Multiple Sequence-Structure Alignments, and Homology Modeling within PyMOL. *BMC Bioinformatics*. 2012; 13(4):S2.doi: 10.1186/1471-2105-13-S4-S2.S2-2105-13-S4-S2
142. Lazo ND, Grant MA, Condrón MC, Rigby AC, Teplow DB. On the Nucleation of Amyloid β -Protein Monomer Folding. *Protein Sci*. 2005; 14:1581–1596. [PubMed: 15930005]

143. Chen W, Mousseau N, Derreumaux P. The Conformations of the Amyloid- β (21-30) Fragment can be Described by Three Families in Solution. *J Chem Phys.* 2006; 125:084911. [PubMed: 16965061]
144. Chebaro Y, Mousseau N, Derreumaux P. Structures and Thermodynamics of Alzheimer's Amyloid- β A β (16-35) Monomer and Dimer by Replica Exchange Molecular Dynamics Simulations: Implication for Full-Length A β Fibrillation. *J Phys Chem B.* 2009; 113:7668–7675. [PubMed: 19415895]
145. (a) Cruz L, Rao JS, Teplow DB, Urbanc B. Dynamics of Metastable β -hairpin Structures in the Folding Nucleus of Amyloid β -protein. *J Phys Chem B.* 2012; 116:6311–6325. [PubMed: 22587454] (b) Smith MD, Cruz L. Effect of Ionic Aqueous Environments on the Structure and Dynamics of the A β (21-30) Fragment: A Molecular-Dynamics Study. *J Phys Chem B.* 2013; 117:6614–6624. [PubMed: 23675877]
146. Doran TM, Anderson EA, Latchney SE, Opanashuk LA, Nilsson BL. Turn Nucleation Perturbs Amyloid β Self-Assembly and Cytotoxicity. *J Mol Biol.* 2012; 421:315–328. [PubMed: 22326870]
147. (a) Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic Mutations of APP and Resistance of A β to Physiologically Relevant Proteolytic Degradation. *Lancet.* 2003; 361:1957–1958. [PubMed: 12801742] (b) Smith MD, Cruz L. Changes to the Structure and Dynamics in Mutations of A β (21-30) Caused by Ions in Solution. *J Phys Chem B.* 2013; 117:14907–14915. [PubMed: 24261958]
148. Maji SK, Ogorzalek Loo RR, Inayathullah M, Spring SM, Vollers SS, Condron MM, Bitan G, Loo JA, Teplow DB. Amino Acid Position-Specific Contributions to Amyloid β -Protein Oligomerization. *J Biol Chem.* 2009; 284:23580–23591. [PubMed: 19567875]
149. (a) Ono K, Condron MM, Teplow DB. Effects of the English (H6R) and Tottori (D7N) Familial Alzheimer Disease Mutations on Amyloid β -Protein Assembly and Toxicity. *J Biol Chem.* 2010; 285:23186–23197. [PubMed: 20452980] (b) Ono K, Condron MM, Teplow DB. Structure-Neurotoxicity Relationships of Amyloid β -Protein Oligomers. *Proc Natl Acad Sci USA.* 2009; 106:14745–14750. [PubMed: 19706468]
150. Bitan G, Vollers SS, Teplow DB. Elucidation of Primary Structure Elements Controlling Early Amyloid β -Protein Oligomerization. *J Biol Chem.* 2003; 278:34882–34889. [PubMed: 12840029]
151. (a) Sinha S, Lopes DH, Bitan GA. Key Role for Lysine Residues in Amyloid β -Protein Folding, Assembly and Toxicity. *ACS Chem Neurosci.* 2012; 3:473–481. [PubMed: 22860216] (b) Xu W, Zhang C, Derreumaux P, Gräslund A, Morozova-Roche L, Mu Y. Intrinsic Determinants of A β (12-24) pH-dependent Self-assembly Revealed by Combined Computational and Experimental Studies. *PLoS One.* 2011; 6:e24329. [PubMed: 21957446] (c) Chi EY, Frey SL, Winans A, Lam KL, Kjaer K, Majewski J, Lee KY. Amyloid-beta Fibrillogenesis Seeded by Interface-induced Peptide Misfolding and Self-assembly. *Biophys J.* 2010; 98:2299–308. [PubMed: 20483339] (d) Tycko R. Physical and Structural Basis for Polymorphism in Amyloid Fibrils. *Protein Sci.* 2014; 23:1528–39. [PubMed: 25179159] (e) Adler J, Scheidt HA, Krüger M, Thomas L, Huster D. Local Interactions Influence the Fibrillation Kinetics, Structure and Dynamics of A β (1-40) but Leave the General Fibril Structure Unchanged. *Phys Chem Chem Phys.* 2014; 16:7461–71. [PubMed: 24626742]
152. (a) Zhang S, Iwata K, Lachenmann MJ, Peng JW, Li S, Stimson ER, Lu Y, Felix AM, Maggio JE, Lee JP. The Alzheimer's Peptide A β Adopts a Collapsed Coil Structure in Water. *J Struct Biol.* 2000; 130:130–141. [PubMed: 10940221] (b) Lim KH, Collver HH, Le YT, Nagchowdhuri P, Kenney JM. Characterizations of Distinct Amyloidogenic Conformations of the A β (1-40) and (1-42) Peptides. *Biochem Biophys Res Commun.* 2007; 353:443–449. [PubMed: 17184733]
153. Yan Y, McCallum SA, Wang C. M35 Oxidation Induces A β 40-Like Structural and Dynamical Changes in A β 42. *J Am Chem Soc.* 2008; 130:5394–5395. [PubMed: 18376837]
154. Rosenman DJ, Connors CR, Chen W, Wang C, Garcia AE. A β Monomers Transiently Sample Oligomer and Fibril-Like Configurations: Ensemble Characterization Using a Combined MD/NMR Approach. *J Mol Biol.* 2013; 425, 3338–3359.
155. Yan Y, Wang C. A β 42 is More Rigid than A β 40 at the C Terminus: Implications for A β Aggregation and Toxicity. *J Mol Biol.* 2006; 364:853–862. [PubMed: 17046788]

156. Yan Y, Liu J, McCallum SA, Yang D, Wang C. Methyl Dynamics of the Amyloid- β peptides A β 40 and A β 42. *Biochem Biophys Res Commun*. 2007; 362:410–414. [PubMed: 17709094]
157. (a) Vivekanandan S, Brender JR, Lee SY, Ramamoorthy A. A partially Folded Structure of Amyloid-beta(1-40) in an Aqueous Environment. *Biochem Biophys Res Commun*. 2011; 411:312–316. [PubMed: 21726530] (b) Bhowmik D, MacLaughlin CM, Chandrakesan M, Ramesh P, Venkatramani R, Walker GC, Maiti S. pH Changes the Aggregation Propensity of Amyloid- β without Altering the Monomer Conformation. *Phys Chem Chem Phys*. 2014; 16:885–9. [PubMed: 24292856]
158. Hwang TL, van Zijl PC, Mori S. Accurate Quantitation of Water-amide Proton Exchange Rates using the Phase-modulated CLEAN Chemical Exchange (CLEANEX-PM) Approach with a fast-HSQC (FHSQC) Detection Scheme. *J Biomol NMR*. 1998; 11:221–226. [PubMed: 9679296]
159. Rezaei-Ghaleh N, Andreetto E, Yan LM, Kapurniotu A, Zweckstetter M. Interaction between Amyloid beta Peptide and an Aggregation Blocker Peptide Mimicking Islet Amyloid Polypeptide. *PLoS One*. 2011; 6:e20289. [PubMed: 21633500]
160. Bitan G, Teplow DB. Rapid Photochemical Cross-linking – A New Tool for Studies of Metastable, Amyloidogenic Protein Assemblies. *Acc Chem Res*. 2004; 37:357–364. [PubMed: 15196045]
161. (a) Hukushima K, Nemoto K. Exchange Monte Carlo Method and Application to Spin glass Simulations. *J Phys Soc Jpn*. 1996; 65:1604–1608. (b) Sugita Y, Okamoto Y. Replica-exchange Molecular Dynamics Method for Protein Folding. *Chem Phys Lett*. 1999; 314:141–151.
162. Nguyen PH, Okamoto Y, Derreumaux P. Communication: Simulated Tempering with Fast On-the-fly Weight Determination. *J Chem Phys*. 2013; 138:061102. [PubMed: 23425452]
163. (a) Laio A, Parrinello M. Escaping Free-energy Minima. *Proc Natl Acad Sci USA*. 2002; 99:12562–12566. [PubMed: 12271136] (b) Laio A, Gervasio FL. Metadynamics: A Method to Simulate Rare Events and Reconstruct the Free Energy in Biophysics, Chemistry and Material Science. *Rep Prog Phys*. 2008; 71:126601. doi: 10.1088/0034-4885/71/12/126601 (c) Barducci A, Bonomi M, Derreumaux P. Assessing the Quality of the OPEP Coarse-grained Force Field. *J Chem Theory Comput*. 2011; 7:1928–1934. [PubMed: 26596453]
164. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and Reparametrization of the OPLS-AA Force field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides. *J Phys Chem B*. 2001; 105:6474–6487.
165. (a) Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of Multiple Amber Force Fields and Development of Improved Protein Backbone Parameters. *Proteins Struct Funct Bioinf*. 2006; 65:712–725. (b) Best RB, Hummer G. Optimized Molecular Dynamics Force Fields applied to the Helix-Coil Transition of Polypeptides. *J Phys Chem B*. 2009; 113:9004–9015. [PubMed: 19514729] (c) Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, Shaw DE. Improved Side-chain Torsion Potentials for the Amber ff99SB Protein Force Field. *Proteins Struct Funct Bioinf*. 2010; 78:1950–1958.
166. Piana S, Lindorff-Larsen K, Shaw DE. How Robust are Protein Folding Simulations with respect to Force Field Parametrization? *Biophys J*. 2011; 100:L47–L49. [PubMed: 21539772]
167. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of Simple Potential Functions for Simulating Liquid Water. *J Chem Phys*. 1983; 79:926.
168. Berendsen HJC, Grigera JR, Straatsma TP. The Missing Term in Effective Pair Potentials. *J Phys Chem*. 1987; 91:6269–6271.
169. Horn HW, Swope WC, Pitara JW, Madura JD, Dick TJ, Hura GL, Head-Gordon T. Development of an Improved Four-Site Water Model for Biomolecular Simulations: TIP4P-Ew. *J Chem Phys*. 2004; 120:9665–9678. [PubMed: 15267980]
170. Shaw DE, Maragakis P, Lindorff-Larsen K, Piana S, Dror RO, Eastwood MP, Bank JA, Jumper JM, Salmon JK, Shan Y, Wriggers W. Atomic-level Characterization of the Structural Dynamics of Proteins. *Science*. 2010; 330:341–346. [PubMed: 20947758] (b) Lindorff-Larsen K, Piana S, Dror RO, Shaw DE. How Fast-folding Proteins Fold. *Science*. 2011; 334:517–520. [PubMed: 22034434] (c) Lindorff-Larsen K, Maragakis P, Piana S, Eastwood MP, Dror RO, Shaw DE. Systematic Validation of Protein Force Fields against Experimental Data. *PLoS One*. 2012; 7:e32131. [PubMed: 22384157] (d) Piana S, Lindorff-Larsen K, Shaw DE. Protein Folding Kinetics and Thermodynamics from Atomistic Simulation. *Proc Natl Acad Sci USA*. 2012;

109:17845–17850. [PubMed: 22822217] (e) Lindorff-Larsen K, Trbovic N, Maragakis P, Piana S, Shaw DE. Structure and Dynamics of an Unfolded Protein Examined by Molecular Dynamics Simulation. *J Am Chem Soc.* 2012; 134:3787–3791. [PubMed: 22339051] (f) Wang W, Ye W, Jiang C, Luo R, Chen HF. New Force Field on Modeling Intrinsically Disordered Proteins. *Chem Biol Drug Des.* 2014; 84:253–269. [PubMed: 24589355]

171. (a) Sgourakis NG, Yan Y, McCallum SA, Wang C, Garcia AE. The Alzheimer's Peptides Adopt Distinct Conformations in Water: a Combined MD/NMR study. *J Mol Biol.* 2007; 368:1448–1457. [PubMed: 17397862] (b) Sgourakis NG, Merced-Serrano M, Boutsidis C, Drineas P, Du Z, Wang C, Garcia AE. Atomic-level Characterization of the Ensemble of the A β (1-42) Monomer in Water using Unbiased Molecular Dynamics Simulations and Spectral Algorithms. *J Mol Biol.* 2011; 405:570–583. [PubMed: 21056574]
172. Ball KA, Phillips AH, Nerenberg PS, Fawzi NL, Wemmer DE, Head-Gordon T. Homogeneous and Heterogeneous Tertiary Structure Ensembles of amyloid-beta Peptides. *Biochemistry.* 2011; 50:7612–7628. [PubMed: 21797254]
173. (a) Choy WY, Forman-Kay JD. Calculation of Ensembles of Structures Representing the Unfolded State of an SH3 Domain. *J Mol Biol.* 2001; 308:1011–1032. [PubMed: 11352588] (b) Marsh JA, Forman-Kay JD. Structure and Disorder in an Unfolded State under Nondenaturing Conditions from Ensemble Models Consistent with a Large Number of Experimental Restraints. *J Mol Biol.* 2009; 391:359–374. [PubMed: 19501099] (c) Krzeminski M, Marsh JA, Neale C, Choy WY, Forman-Kay JD. Characterization of Disordered Proteins with ENSEMBLE. *Bioinformatics.* 2013; 29:398–399. [PubMed: 23233655]
174. Ball KA, Phillips AH, Wemmer DE, Head-Gordon T. Differences in β -Strand Populations of Monomeric A β 40 and A β 42. *Biophys J.* 2013; 104:2714–2724. [PubMed: 23790380]
175. Zhu M, De Simone A, Schenk D, Toth G, Dobson CM, Vendruscolo M. Identification of Small-molecule Binding Pockets in the Soluble Monomeric Form of the A β 42 Peptide. *J Chem Phys.* 2013; 139:035101. [PubMed: 23883055]
176. Lin YS, Bowman GR, Beauchamp KA, Pande VS. Investigating how Peptide Length and a Pathogenic Mutation Modify the Structural Ensemble of Amyloid beta Monomer. *Biophys J.* 2012; 102:315–324. [PubMed: 22339868]
177. Lin YS, Pande VS. Effect of Familial Mutations on the Monomer Structure of A β 42. *Biophys J.* 2012; 103:L47–L49. [PubMed: 23260058]
178. (a) Granata, D. Ph D Thesis. SISSA, Italy: Octobre. 2013 Characterizing Structure and Free Energy Landscape of Proteins by NMR-guided Metadynamics. (b) Granata D, Camilloni C, Vendruscolo M, Laio A. Characterization of the free-energy landscapes of proteins by NMR-guided metadynamics. *Proc Natl Acad Sci USA.* 2013; 110:6817–6822. [PubMed: 23572592]
179. Chebaro Y, Dong X, Laghaei R, Derreumaux P, Mousseau N. Replica Exchange Molecular Dynamics Simulations of Coarse-grained Proteins in Implicit Solvent. *J Phys Chem B.* 2009; 113:267–274. [PubMed: 19067549]
180. (a) Maupetit J, Tuffery P, Derreumaux P. A Coarse-grained Protein Force Field for Folding and Structure Prediction. *Proteins.* 2007; 69:394–408. [PubMed: 17600832] (b) Derreumaux P. Folding a 20 amino acid alpha beta Peptide with the Diffusion process-controlled Monte Carlo Method. *J Chem Phys.* 1997; 107:1941–1947. (c) Derreumaux P. A Diffusion Process-controlled Monte Carlo Method for Finding the Global Energy Minimum of a Polypeptide Chain. 1. Formulation and Test on a Hexadecapeptide. *J Chem Phys.* 1997; 106:5260–5270. (d) Derreumaux P. Generating Ensemble Averages for Small Proteins from Extended Conformations by Monte Carlo Simulations. *Phys Rev Lett.* 2000; 85:206–209. [PubMed: 10991195] (e) Derreumaux P, Mousseau N. Coarse-grained Protein Molecular Dynamics Simulations. *J Chem Phys.* 2007; 126:025101. [PubMed: 17228975] (f) Derreumaux P, Vergoten G, Lagant P. A Vibrational Molecular-force field of Model Compounds with Biological Interest. 1. Harmonic Dynamics of Crystalline Urea at 123-K. *J Comput Chem.* 1990; 11:560–568. (g) Derreumaux P, Dauchez M, Vergoten G. The Structures and Vibrational Frequencies of a series of Alkanes using the SPASIBA Force Field. *J Mol Struct.* 1993; 295:203–221. (h) Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tufféry P. PEP-FOLD: An Updated de novo Structure Prediction Server for both Linear and Disulfide bonded Cyclic Peptides. *Nucleic Acids Res.* 2012; 40(Web Server issue):W288–93. [PubMed: 22581768] (i) Shen Y, Maupetit J, Derreumaux P, Tufféry P.

Improved PEP-FOLD Approach for Peptide and Miniprotein Structure Prediction. *J Chem Theory Comput.* 2014; 10:4745–4758. [PubMed: 26588162]

181. (a) Irbäck A, Mitternacht S, Mohanty S. An Effective All-Atom Potential for Proteins. *PMC Biophys.* 2009; 2:2.doi: 10.1186/1757-5036-2-2 [PubMed: 19356242] (b) Mitternacht S, Staneva I, Härd T, Irbäck A. Comparing the Folding Free-Energy Landscapes of A β 42 Variants with Different Aggregation Properties. *Proteins Struct Funct Bioinf.* 2010; 78:2600–2608.
182. Côté S, Derreumaux P, Mousseau N. Distinct Morphologies for Amyloid beta Protein Monomer : A β 1-40, A β 1-42, A β 1-40(D23N). *J Chem Theory Comput.* 2011; 7:2584–2592. [PubMed: 26606631]
183. Sterpone F, Nguyen PH, Kalimeri M, Derreumaux P. Importance of the Ion-Pair Interactions in the OPEP Coarse-grained Force Field: Parametrization and Validation. *J Chem Theory Comput.* 2013; 9:4574–4584. [PubMed: 25419192]
184. (a) Yang M, Teplow DB. Amyloid β -Protein Monomer Folding: Free Energy Surfaces Reveal Alloform Specific Differences. *J Mol Biol.* 2008; 384:450–464. [PubMed: 18835397] (b) Lam AR, Teplow DB, Stanley HE, Urbanc B. Effects of the Artic (E22 $\rightarrow$ G) Mutation on Amyloid beta-protein Folding: Discrete Molecular Dynamics Study. *J Am Chem Soc.* 2008; 130:17413–17422. [PubMed: 19053400]
185. Rauscher S, Gapsys V, Volkhardt A, Blau C, de Groot BL, Grubmüller H. Structural Ensemble of Intrinsically Disordered Proteins Depend Strongly on Force Field. *Biophys J.* 2014; 106:271a.
186. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble Amyloid beta-protein Dimers Isolated from Alzheimer Cortex directly Induce Tau Hyperphosphorylation and Neuritic Degeneration. *Proc Natl Acad Sci USA.* 2011; 108:5819–5824. [PubMed: 21421841]
187. Autiero I, Saviano M, Langella E. In silico Investigation and Targeting of amyloid β Oligomers of Different Size. *Mol Biosyst.* 2013; 9:2118–2124. [PubMed: 23708585]
188. Berhanu WM, Hansmann UH. Structure and Dynamics of amyloid- β Segmental Polymorphisms. *PLoS One.* 2012; 7:e41479. [PubMed: 22911797]
189. Yu X, Zheng J. Polymorphic Structures of Alzheimer's β -amyloid Globulomers. *PloS One.* 2011; 6:e20575. [PubMed: 21687730]
190. Ma B, Nussinov R. Polymorphic Triple beta-sheet Structures Contribute to Amide Hydrogen/deuterium (H/D) Exchange Protection in the Alzheimer amyloid-beta 42 Peptide. *J Biol Chem.* 2011; 286:34244–34253. [PubMed: 21832091]
191. Derreumaux P. From Polypeptide Sequences to Structures using Monte Carlo Simulations and an Optimized Potential. *J Chem Phys.* 1999; 111:2301–2310.
192. Forcellino F, Derreumaux P. Computer Simulations Aimed at Structure Prediction of Supersecondary Motifs in Proteins. *Proteins.* 2001; 45:159–166. [PubMed: 11562945]
193. Chebaro Y, Pasquali S, Derreumaux P. The Coarse-grained OPEP Force Field for Non-amyloid and amyloid Proteins. *J Phys Chem B.* 2012; 116:8741–8752. [PubMed: 22742737]
194. Kalimari M, Derreumaux P, Sterpone F. Are Coarse-grained Models Apt to Detect Protein Thermal Stability? The Case of OPEP Force Field. *J Non-Cryst Solids.* 2015; 407:494–501. [PubMed: 28100926]
195. Côté S, Laghaei R, Derreumaux P, Mousseau N. Distinct Dimerization for Various Alloforms of the amyloid-beta Protein : Abeta(1-40), Abeta(1-42), and Abeta(1-40)(D23N). *J Phys Chem B.* 2012; 116:4043–4055. [PubMed: 22409719]
196. Laghaei R, Mousseau N, Wei G. Effect of the Disulfide Bond on the Monomeric Structure of Human Amylin Studied by Combined Hamiltonian and Temperature Replica Exchange Molecular Dynamics Simulations. *J Phys Chem B.* 2010; 114:7071–7077. [PubMed: 20429571]
197. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FT, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M. All-atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. *J Phys Chem B.* 1998; 102:3586–3616. [PubMed: 24889800]
198. Ferrara P, Apostolakis J, Caflisch A. Evaluation of a Fast Implicit Solvent Model for Molecular Dynamics Simulations. *Proteins.* 2002; 46:24–33. [PubMed: 11746700]

199. Takeda T, Klimov DK. Probing the Effect of Amino-terminal Truncation for Abeta1-40 Peptides. *J Phys Chem B*. 2009; 113:6692–6702. [PubMed: 19419218]
200. Kim S, Takeda T, Klimov DK. Mapping Conformational Ensembles of Abeta Oligomers in Molecular Dynamics Simulations. *Biophys J*. 2010; 99:1949–1958. [PubMed: 20858441]
201. Lockhart C, Kim S, Kumar R, Klimov DK. Does Aminoacid Sequence Determine the Properties of Abeta Dimer? *J Chem Phys*. 2011; 135:035103. [PubMed: 21787025]
202. Mitternacht S, Staneva I, Hard T, Irback A. Monte Carlo Study of the Formation and Conformational Properties of Dimers of Abeta42 Variants. *J Mol Biol*. 2011; 410:357–367. [PubMed: 21616081]
203. Urbanc B, Betnel M, Cruz L, Bitan G, Teplow DB. Elucidation of Amyloid β -protein Oligomerization Mechanisms: Discrete Molecular Dynamics Study. *J Am Chem Soc*. 2010; 132:4266–4280. [PubMed: 20218566]
204. Barz B, Urbanc B. Dimer Formation Enhances Structural Differences between Amyloid β -protein (1-40) and (1-42): an Explicit-solvent Molecular Dynamics Study. *PloS One*. 2012; 7:e34345. [PubMed: 22509291]
205. Chong SH, Ham S. Atomic-level Investigations on the Amyloid- β Dimerization Process and its Driving Forces in Water. *Phys Chem Chem Phys*. 2012; 14:1573–1575. [PubMed: 22186967]
206. (a) Yano A, Okamoto A, Nomura K, Higai S, Kurita N. Difference in Dimer Conformation between Amyloid- β (1-42) and (1-43) Proteins: Replica Exchange Molecular Dynamics Simulations in Water. *Chem Phys Lett*. 2014;595–596. 242–249.(b) Nguyen PH, Mai LS, Derreumaux P. Amyloid Oligomer Structure Characterization from Simulations : A General Method. *J Chem Phys*. 2014; 140:094105. [PubMed: 24606351]
207. Zhang T, Zhang J, Derreumaux P, Mu Y. Molecular Mechanism of the Inhibition of EGCG on the Alzheimer A β (1-42) Dimer. *J Phys Chem B*. 2013; 117:3993–4002. [PubMed: 23537203]
208. Chebaro Y, Jiang P, Zang T, Mu Y, Nguyen PH, Mousseau N, Derreumaux P. Structures of A β 17-42 Trimers in Isolation and with Five Small-molecule Drugs using a Hierarchical Computational Procedure. *J Phys Chem B*. 2012; 116:8412–8422. [PubMed: 22283547]
209. Qiu D, Shenkin PS, Hollinger FP, Still WC. The GB/SA Continuum Model for solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii. *J Phys Chem A*. 1997; 101:3005–3014.
210. Barz B, Olubiyi OO, Strodel B. Early Amyloid β -protein Aggregation Precedes Conformational Change. *Chem Commun*. 2014; 50:5373–5375.
211. Ferrone F. Analysis of Protein Aggregation Kinetics. *Methods in Enzymology*. 1999; 309:256–274. [PubMed: 10507029]
212. Oosawa, F., Asakura, S. *Thermodynamics of the Polymerization of Protein*. Academic; Waltham, MA: 1975.
213. Wegner A. Spontaneous Fragmentation of Actin Filaments in Physiological Conditions. *Nature*. 1982; 296:266–267. [PubMed: 7199623]
214. Ferrone FA, Hofrichter J, Eaton WA. Kinetics of Sick Hemoglobin Polymerization: II. A Double Nucleation Mechanism. *J Mol Biol*. 1985; 183:611–631. [PubMed: 4020873]
215. Nasica-Labouze J, Mousseau N. Kinetics of amyloid Aggregation: a Study of the GNNQQNY Prion Sequence. *PLoS Comput Biol*. 2012; 8:1002782.
216. Irback A, Jonsson SÆ, Linnemann N, Linse B, Wallin S. Aggregate Geometry in Amyloid Fibril Nucleation. *Phys Rev Lett*. 2013; 110:058101. [PubMed: 23414048]
217. Bhattacharyya AM, A K Thakur AK, Wetzel R. Polyglutamine Aggregation Nucleation: Thermodynamics of a Highly Unfavorable Protein Folding Reaction. *Proc Natl Acad Sci USA*. 2005; 102:15400–15405. [PubMed: 16230628]
218. Fay N, Inoue YJ, Bousset L, Taguchi H, Melki R. Assembly of the Yeast Prion Ure2p into Protein Fibrils. Thermodynamic and Kinetic Characterization. *J Biol Chem*. 2003; 278:30199–30205. [PubMed: 12777380]
219. Li MS, Co NT, Reddy G, Hu CK, Straub JE, Thirumalai D. Factors Governing Fibrillogenesis of Polypeptide Chains Revealed by Lattice Models. *Phys Rev Lett*. 2010; 105:218101. [PubMed: 21231356]

220. Abeln S, Vendruscolo M, Dobson CM, Frenkel D. A Simple Lattice Model that Captures Protein Folding, Aggregation and Amyloid Formation. *PLoS One*. 2014; 9:e85185.doi: 10.1371/journal.pone.0085185 [PubMed: 24454816]
221. Mompeán M, González C, Lomba E, Laurents DV. Combining Classical MD and QM Calculations to Elucidate Complex System Nucleation: A Twisted, Three-Stranded, Parallel β -Sheet Seeds Amyloid Fibril Conception. *J Phys Chem B*. 2014; 118:7312–7316. [PubMed: 24918329]
222. De Simone A, Kitchen C, Kwan AH, Sunde M, Dobson CM, Frenkel D. Intrinsic Disorder Modulates Protein Self-Assembly and Aggregation. *Proc Natl Acad Sci USA*. 2012; 109:6951–6956. [PubMed: 22509003]
223. Bieler NS, Knowles TPJ, Frenkel D, Vacha R. Connecting Macroscopic Observables and Microscopic Assembly Events in Amyloid Formation Using Coarse Grained Simulations. *PLoS Comput Biol*. 2012; 8:e1002692.doi: 10.1371/journal.pcbi.1002692 [PubMed: 23071427]
224. Lomakin A, Teplow DB, Kirschner DA, Benedek GB. Kinetic Theory of Fibrillogenesis of Amyloid β -Protein. *Proc Natl Acad Sci USA*. 1997; 94:7942–7947. [PubMed: 9223292]
225. Fawzi NL, Okabe Y, Yap EH, Head-Gordon T. Determining the Critical Nucleus and Mechanism of Fibril Elongation of the Alzheimer's $A\beta$ (1–40) Peptide. *J Mol Biol*. 2007; 365:535–550. [PubMed: 17070840]
226. Collins SR, Douglass A, Vale RD, Weissman JS. Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition. *PLoS Biol*. 2004; 2:1582–1590.
227. Nguyen PH, Li MS, Stock G, Straub JE, Thirumalai D. Monomer Adds to Preformed Structured Oligomers of $A\beta$ -Peptides by a Two-Stage Dock-Lock Mechanism. *Proc Natl Acad Sci USA*. 2007; 104:111–116. [PubMed: 17190811]
228. Takeda T, Klimov DK. Dissociation of $A\beta$ (16–22) Amyloid Fibrils Probed by Molecular Dynamics. *J Mol Biol*. 2007; 368:1202–1213. [PubMed: 17382346]
229. Li MS, Klimov DK, Straub JE, Thirumalai D. Probing the Mechanisms of Fibril Formation Using Lattice Models. *J Chem Phys*. 2008; 129:175101.doi: 10.1063/1.2989981 [PubMed: 19045373]
230. Co NT, Li MS. New Method for Determining Size of Critical Nucleus of Fibril Formation of Polypeptide Chains. *J Chem Phys*. 2012; 137:095101.doi: 10.1063/1.4749257 [PubMed: 22957596]
231. (a) Cabriolu R, Auer S. Amyloid Fibrillation Kinetics: Insight from Atomistic Nucleation Theory. *J Mol Biol*. 2011; 411:275–285. [PubMed: 21645521] (b) Garai K, Sahoo B, Sengupta P, Maiti S. Quasihomogeneous Nucleation of Amyloid beta Yields Numerical Bounds for the Critical Radius, the Surface Tension, and the Free Energy Barrier for Nucleus Formation. *J Chem Phys*. 2008; 128:045102. [PubMed: 18248009]
232. Kashchiev D, Cabriolu R, Auer S. Confounding the Paradigm: Peculiarities of Amyloid Fibril Nucleation. *J Am Chem Soc*. 2013; 135:1531–1539. [PubMed: 23305200]
233. Baftizadeh F, Biarnes X, Pietrucci F, Affinito F, Laio A. Multidimensional View of Amyloid Fibril Nucleation in Atomistic Detail. *J Am Chem Soc*. 2012; 134:3886–3894. [PubMed: 22276669]
234. Baftizadeh F, Pietrucci F, Biarnes X, Laio A. Nucleation Process of a Fibril Precursor in the C-Terminal Segment of Amyloid- β . *Phys Rev Lett*. 2013; 110:168103. [PubMed: 23679641]
235. Hilbich C, Kisters-Woike B, Reed J, Masters C, Beyreuther K. Substitutions of Hydrophobic Amino Acids Reduce the Amyloidogenicity of Alzheimer's Disease $\beta A4$ Peptides. *J Mol Biol*. 1992; 228:460–473. [PubMed: 1453457]
236. Tjernberg L, Naslund J, Lindqvist F, Johansson J, Karlstrom A, Thyberg J, Terenius L, Nordstedt C. Arrest of β -Amyloid Fibril Formation by a Pentapeptide Ligand. *J Biol Chem*. 1996; 271:8545–8548. [PubMed: 8621479]
237. Kheterpal I, Williams A, Murphy C, Bledsoe B, Wetzel R. Structural Features of the β Amyloid Fibril Elucidated by Limited Proteolysis. *Biochemistry*. 2001; 40:11757–11767. [PubMed: 11570876]
238. Piana S, Laio A. A Bias-Exchange Approach to Protein Folding. *J Phys Chem B*. 2007; 111:4553–4559. [PubMed: 17419610]

239. Nguyen PH, Derreumaux P. Conformational Ensemble and Polymorphism of the All-Atom Alzheimer's A β (37-42) Amyloid Peptide Oligomers. *J Phys Chem B*. 2013; 117:5831–5840. [PubMed: 23581814]
240. Yang YI, Gao YQ. Computer Simulation Studies of A β 37-42 Aggregation Thermodynamics and Kinetics in Water and Salt Solution. *J Phys Chem B*. 2015; 119:662–670. [PubMed: 24861904]
241. Lu Y, Wei G, Derreumaux P. Structural, Thermodynamical, and Dynamical Properties of Oligomers Formed by the Amyloid NNQQ Peptide: Insights from Coarse-Grained Simulations. *J Chem Phys*. 2012; 137:025101.doi: 10.1063/1.4732761 [PubMed: 22803563]
242. Wei G, Mousseau N, Derreumaux P. Computational Simulations of the Early Steps of Protein Aggregation. *Prion*. 2007; 1:3–8. [PubMed: 19164927]
243. Mousseau N, Derreumaux P. Exploring Energy Landscapes of Protein Folding and Aggregation. *Front Biosci*. 2008; 13:4495–516. [PubMed: 18508525]
244. Wei G, Song W, Derreumaux P, Mousseau N. Self-assembly of Amyloid-forming Peptides by Molecular Dynamics Simulations. *Front Biosci*. 2008; 13:5681–92. [PubMed: 18508615]
245. Nasica-Labouze J, Meli M, Derreumaux P, Colombo G, Mousseau N. A Multiscale Approach to Characterize the Early Aggregation Steps of the Amyloid-Forming Peptide GNNQQNY from the Yeast Prion Sup-35. *PLoS Comput Biol*. 2011; 5:e1002051.doi: 10.1371/journal.pcbi.1002051
246. Santini S, Wei G, Mousseau N, Derreumaux P. Pathway Complexity of Alzheimer's beta-amyloid Abeta16-22 Peptide Assembly. *Structure*. 2004; 12:1245–55. [PubMed: 15242601]
247. Santini S, Mousseau N, Derreumaux P. In Silico Assembly of Alzheimer's A β 16-22 Peptide into β -Sheets. *J Am Chem Soc*. 2004; 126:11509–11516. [PubMed: 15366896]
248. Petty SA, Decatur SM. Intersheet Rearrangement of Polypeptides During Nucleation of β -Sheet Aggregates. *Proc Natl Acad Sci USA*. 2005; 102:14272–14277. [PubMed: 16176990]
249. Kittner M, Knecht V. Disordered Versus Fibril-Like Amyloid β (25-35) Dimers in Water: Structure and Thermodynamics. *J Phys Chem B*. 2010; 114:15288–15295. [PubMed: 20964446]
250. Whittleston CS, Wales DJ. Thermodynamics and Kinetics of Aggregation for the GNNQQNY Peptide. *J Am Chem Soc*. 2007; 129:16005–16014. [PubMed: 18052168]
251. Sciarretta KL, Gordon DJ, Petkova AT, Tycko R, Meredith SC. A β 40-Lactam(D23/K28) Models a Conformation Highly Favorable for Nucleation of Amyloid. *Biochemistry*. 2005; 44:6003–6014. [PubMed: 15835889]
252. Reddy G, Straub JE, Thirumalai D. Influence of Preformed Asp23-Lys28 Salt Bridge on the Conformational Fluctuations of Monomers and Dimers of A β Peptides with Implications for Rates of Fibril Formation. *J Phys Chem B*. 2009; 113:1162–1172. [PubMed: 19125574]
253. Wood SJ, Wetzel R, Martin JD, Hurle MR. Prolines and Amyloidogenicity in Fragments of the Alzheimer's Peptide β /A4. *Biochemistry*. 1995;34, 724–730.
254. Larini L, Shea JE. Role of β -Hairpin Formation in Aggregation: The Self-Assembly of the Amyloid- β (25-35) Peptide. *Biophys J*. 2012; 103:576–586. [PubMed: 22947874]
255. Grabenauer M, Wu C, Soto P, Shea JE, Bowers MT. Oligomers of the Prion Protein Fragment 106-126 are Likely Assembled from β -Hairpins in Solution, and Methionine Oxidation Inhibits Assembly Without Altering the Peptide's Monomeric Conformation. *J Am Chem Soc*. 2010; 132:532–539. [PubMed: 20020713]
256. Liang C, Derreumaux P, Wei G. Structure and Aggregation Mechanism of β 2-Microglobulin (83-99) Peptides Studied by Molecular Dynamics Simulations. *Biophys J*. 2007; 93:3353–3362. [PubMed: 17693474]
257. Liang C, Derreumaux P, Mousseau N, Wei G. The β -Strand-Loop- β -Strand Conformation Is Marginally Populated in β 2-Microglobulin (20-41) Peptide in Solution as Revealed by Replica Exchange Molecular Dynamics Simulations. *Biophys J*. 2008; 95:510–517. [PubMed: 18408040]
258. Qiao Q, Bowman GR, Huang X. Dynamics of an Intrinsically Disordered Protein Reveal Metastable Conformations that Potentially Seed Aggregation. *J Am Chem Soc*. 2013; 135:16092–16101. [PubMed: 24021023]
259. Wu C, Shea JE. Structural Similarities and Differences Between Amyloidogenic and Non-Amyloidogenic Islet Amyloid Polypeptide (IAPP) Sequences and Implications for the Dual Physiological and Pathological Activities of These Peptides. *PLoS Comput Biol*. 2013; 9:e1003211.doi: 10.1371/journal.pcbi.1003211 [PubMed: 24009497]

260. Cheon M, Chang I, Mohanty S, Luheshi LM, Dobson CM, Vendruscolo M, Favrin G. Structural Reorganisation and Potential Toxicity of Oligomeric Species Formed During the Assembly of Amyloid Fibrils. *PLoS Comput Biol*. 2007; 3:1727–1738. [PubMed: 17941703]
261. (a) Colletier JP, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, Flot D, Cascio D, Sawaya MR, Eisenberg D. Molecular Basis for Amyloid- β Polymorphism. *Proc Natl Acad Sci USA*. 2011; 108:16938–16943. [PubMed: 21949245] (b) Armstrong AH, Chen J, McKoy AF, Hecht MH. Mutations That Replace Aromatic Side Chains Promote Aggregation of the Alzheimer's A β Peptide. *Biochemistry*. 2011; 50:4058–4067. [PubMed: 21513285]
262. Kaye R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of Lipid Bilayers is a Common Conformation-Dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases. *J Biol Chem*. 2004; 279:46363–46366. [PubMed: 15385542]
263. Quist A, Doudevski L, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R. Amyloid Ion Channels: A Common Structural Link for Protein-Misfolding Disease. *Proc Natl Acad Sci USA*. 2005; 102:10427–10432. [PubMed: 16020533]
264. Engel MFM, Khemtouri L, Kleijer CC, Meeldijk HJD, Jacobs J, Verkleij AJ, de Kruijff B, Killian JA, Hoppener JWM. Membrane Damage by Human Islet Amyloid Polypeptide Through Fibril Growth at the Membrane. *Proc Natl Acad Sci USA*. 2008; 105:6033–6038. [PubMed: 18408164]
265. Kastorna A, Trusova V, Gorbenko G, Kinnunen P. Membrane effects of Lysozyme Amyloid Fibrils. *Chem Phys Lipids*. 2012; 165:331–337. [PubMed: 22406142]
266. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD. Amyloid- β Peptide (A β) Neurotoxicity Is Modulated by the Rate of Peptide Aggregation: A β Dimers Trimers Correlate with Neurotoxicity. *J Neurosci*. 2008; 28:11950–11958. [PubMed: 19005060]
267. Butterfield SM, Lashuel HA. Amyloidogenic Protein-Membrane Interactions: Mechanistic Insight from Model Systems. *Angew Chem Int Ed Engl*. 2010; 49:5628–5654. [PubMed: 20623810]
268. Williams TL, Serpell LC. Membrane and Surface Interactions of Alzheimer's A β Peptide – Insights into the Mechanism of Cytotoxicity. *FEBS J*. 2011; 278:3905–3917. [PubMed: 21722314]
269. Connelly L, Jang H, Arce FT, Capone R, Kotler SA, Ramachandran S, Kagan BL, Nussinov R, Lal R. Atomic Force Microscopy and MD Simulations Reveal Pore-Like Structures of All-D-Enantiomer of Alzheimer's β -Amyloid Peptide: Relevance to the Ion Channel Mechanism of AD Pathology. *J Phys Chem B*. 2012; 116:1728–1735. [PubMed: 22217000]
270. Bokvist M, Lindstrom F, Watts A, Grobner G. Two Types of Alzheimer's β -Amyloid (1-40) Peptide Membrane Interactions: Aggregation Preventing Transmembrane Anchoring Versus Accelerated Surface Fibril Formation. *J Mol Biol*. 2004; 335:1039–1049. [PubMed: 14698298]
271. Zhao H, Tuominen EK, Kinnunen PK. Formation of Amyloid Fibers Triggered by Phosphatidylserine-Containing Membranes. *Biochemistry*. 2004; 43:10302–10307. [PubMed: 15301528]
272. Yates EA, Owens SL, Lynch MF, Cucco EM, Umbaugh CS, Legleiter J. Specific Domains of A β Facilitate Aggregation on and Association with Lipid Bilayers. *J Mol Biol*. 2013; 425:1915–1933. [PubMed: 23524134]
273. Tofoleanu F, Buchete NV. Molecular Interactions of Alzheimer's A β Protofilaments with Lipid Membranes. *J Mol Biol*. 2012; 421:572–586. [PubMed: 22281438]
274. Nagarathinam A, Höflinger P, Bühler A, Schäfer C, McGovern G, Jeffrey M, Staufenbiel M, Jucker M, Baumann F. Membrane-anchored A β Accelerates Amyloid Formation and Exacerbates Amyloid-associated Toxicity in Mice. *J Neurosci*. 2013; 33:19284–19294. [PubMed: 24305824]
275. Shao H, Jao S, Ma K, Zagorski MG. Solution Structures of Micelle-bound Amyloid beta-(1-40) and beta-(1-42) Peptides of Alzheimer's Disease. *J Mol Biol*. 1999; 285:755–773. [PubMed: 9878442]
276. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ. Solution Structure of Amyloid beta-peptide(1-40) in a Water-micelle Environment. Is the Membrane-spanning Domain Where We Think It Is? *Biochemistry*. 1998; 37:11064–11077. [PubMed: 9693002]

277. Gorbenko GP, Trusova V. Protein Aggregation in a Membrane Environment. *Advances in Protein Chemistry and Structural Biology*. 2011; 84:113–142. [PubMed: 21846564]
278. Gorbenko GP, Kinnunen PK. The Role of Lipid-protein Interactions in Amyloid-type Protein Fibril Formation. *Chem Phys Lipids*. 2006; 142:72–82.
279. Lin H, Bhatia R, Lal R. Amyloid beta Protein Forms Ion Channels: Implications for Alzheimer's Disease Pathophysiology. *FASEB J*. 2001; 15:2433–2444. [PubMed: 11689468]
280. Morita M, Hamada T, Tendo Y, Hata T, Vestergaard MC, Takagi M. Selective Localization of Alzheimer's Amyloid beta in Membrane Lateral Compartments. *Soft Matter*. 2012; 8:2816–2819.
281. Nag S, Sarkar B, Chandrakesan M, Abhyanakar R, Bhowmik D, Kombrabail M, Dandekar S, Lerner E, Haas E, Maiti A. Folding Transition Underlies the Emergence of Membrane Affinity in amyloid- β . *S. Phys Chem Chem Phys*. 2013; 15:19129–19133. [PubMed: 24121316]
282. Benilova I, Karran E, De Strooper B. The Toxic A β Oligomer and Alzheimer's Disease: An Emperor in Need of Clothes. *Nat Neurosci*. 2012; 15:349–357. [PubMed: 22286176]
283. Davis CH, Berkowitz ML. Structure of the amyloid-beta (1-42) Monomer Absorbed to Model Phospholipid Bilayers: a Molecular Dynamics Study. *J Phys Chem B*. 2009; 113:14480–14486. [PubMed: 19807060]
284. Davis CH, Berkowitz ML. Interaction between Amyloid-beta (1-42) Peptide and Phospholipid Bilayers: a Molecular Dynamics Study. *Biophys J*. 2009; 96:785–797. [PubMed: 19186121]
285. Davis CH, Berkowitz ML. A Molecular Dynamics Study of the Early Stages of Amyloid-beta(1-42) Oligomerization: The Role of Lipid Membranes. *Proteins*. 2010; 78:2533–2545. [PubMed: 20602359]
286. Lockhart C, Klimov DK. Alzheimer's A β 10-40 Peptide Binds and Penetrates DMPC Bilayer: An Isobaric-isothermal Replica Exchange Molecular Dynamics Study. *J Phys Chem B*. 2014; 118:2638–2648. [PubMed: 24547901]
287. Yu X, Zheng J. Cholesterol Promotes the Interaction of Alzheimer β -Amyloid Monomer with Lipid Bilayer. *J Mol Biol*. 2012; 421:561–571. [PubMed: 22108168]
288. Miyashita N, Straub JE, Thirumalai D. Structures of beta-amyloid Peptide 1-40, 1-42, and 1-55 - The 672-726 Fragment of APP- in a Membrane Environment with Implications for Interactions with gamma-secretase. *J Am Chem Soc*. 2009; 131:17843–17852. [PubMed: 19995075]
289. Buchete NV, Tycko R, Hummer G. Molecular Dynamics Simulations of Alzheimer's beta-amyloid Protofilaments. *J Mol Biol*. 2005; 353:804–821. [PubMed: 16213524]
290. Buchete NV, Hummer G. Structure and Dynamics of Parallel beta-sheets, Hydrophobic core, and Loops in Alzheimer's A β Fibrils. *Biophys J*. 2007; 92:3032–3039. [PubMed: 17293399]
291. Tofoleanu F, Brooks BR, Buchete NV. Modulation of Alzheimer's A β Protofilament-Membrane Interactions by Lipid Headgroups. *ACS Chem Neurosci*. 2015 in press.
292. Tofoleanu F, Buchete NV. Alzheimer A β Peptide Interactions with Lipid Membranes: Fibrils, Oligomers and Polymorphic Amyloid Channels. *Prion*. 2012; 6:339–345. [PubMed: 22874669]
293. Jang H, Ma B, Lal R, Nussinov R. Models of Toxic beta-sheet Channels of Protegrin-1 Suggest a Common Subunit Organization Motif Shared with Toxic Alzheimer beta-amyloid Ion Channels. *Biophys J*. 2008; 95:4631–4642. [PubMed: 18708452]
294. Jang H, Arce FT, Capone R, Ramachandran S, Lal R, Nussinov R. Misfolded Amyloid Ion Channels Present Mobile beta-sheet Subunits in contrast to Conventional Ion Channels. *Biophys J*. 2009; 97:3029–3037. [PubMed: 19948133]
295. Jang H, Arce FT, Ramachandran S, Kagan BL, Lal R, Nussinov R. Familial Alzheimer's Disease Osaka Mutant (E22) β -barrels Suggest an Explanation for the Different A β 1-40/42 Preferred Conformational States Observed by Experiment. *J Phys Chem B*. 2013; 117:11518–11529. [PubMed: 24000923]
296. Strodel B, Lee JW, Whittleston CS, Whales DJ. Transmembrane Structures for Alzheimer's A β (1-42) Oligomers. *J Am Chem Soc*. 2010; 132:13300–13312. [PubMed: 20822103]
297. Poojari C, Kukol A, Strodel B. How the Amyloid- β Peptide and Membranes Affect Each Other: An Extensive Simulation Study. *Biochim Biophys Acta*. 2013; 1828:327–339. [PubMed: 22975281]

298. Poojari C, Strodel B. Stability of Transmembrane Amyloid β -peptide and Membrane Integrity Tested by Molecular Modeling of Site-specific A β 42 Mutations. *PLoS One*. 2013; 8:e78399. [PubMed: 24244308]
299. Xu Y, Shen J, Luo X, Zhu W, Chen K, Ma J, Jiang H. Conformational Transition of Amyloid beta-peptide. *Proc Natl Acad Sci USA*. 2005; 102:5403–5407. [PubMed: 15800039]
300. Lemkul JA, Bevan DR. A Comparative Molecular Dynamics Analysis of the Amyloid beta-peptide in a Lipid Bilayer. *Arch Biochem Biophys*. 2008; 470:54–63. [PubMed: 18053791]
301. Lemkul JA, Bevan DR. Lipid Composition Influences the Release of Alzheimer's Amyloid β -peptide from Membranes. *Protein Sci*. 2011; 20:1530–1545. [PubMed: 21692120]
302. Zhao LN, Chiu SW, Benoit J, Chew LY, Mu Y. Amyloid β Peptides Aggregation in a Mixed Membrane Bilayer: a Molecular Dynamics Study. *J Phys Chem B*. 2011; 115:12247–12256. [PubMed: 21910473]
303. Hoshino T, Mahmood MI, Mori K, Matsuzaki K. Binding and Aggregation Mechanism of Amyloid β -peptides onto the GM1 Ganglioside-Containing Lipid Membrane. *J Phys Chem B*. 2013; 117:8085–8094. [PubMed: 23688073]
304. (a) Manna M, Mukhopadhyay C. Binding, Conformational Transition and Dimerization of Amyloid- β Peptide on GM1-containing Ternary Membrane: Insights from Molecular Dynamics Simulation. *PLoS One*. 2013; 8:e71308. [PubMed: 23951128] (b) Devarajan S, Sharmika JE. Molecular Dynamics Study of GM1 Ganglioside Complex with Amyloid β peptide (A β 42) in Lipid Membrane. *J Mol Liquids*. 2014; 195:59–64.
305. Rushworth JV, Hooper NM. Lipid Rafts: Linking Alzheimer's Amyloid- β Production, Aggregation, and Toxicity at Neuronal Membranes. *Int J Alzheimers Dis*. 2010; 2011:603052. [PubMed: 21234417]
306. Pobandt T, Knecht V. Free Energy of Lipid Bilayer Defects Affected by Alzheimer's Disease-associated Amyloid- β 42 Monomers. *J Phys Chem B*. 2014; 118:3507–3516. [PubMed: 24597727]
307. (a) Wu C, Shea JE. Coarse-grained Models for Protein Aggregation. *Curr Opin Struct Biol*. 2011; 21:209–220. [PubMed: 21371882] (b) Shea JE, Urbanc B. Insights into A β Aggregation: a Molecular Dynamics Perspective. *Curr Top Med Chem*. 2012; 12:2596–2610. [PubMed: 23339310]
308. (a) Derreumaux, Coarse-grained models for protein folding and aggregation. *Methods Mol Biol*. 2013; 924:585–600. [PubMed: 23034764] (b) Morriss-Andrews A, Brown FL, Shea JE. A Coarse-grained Model for Peptide Aggregation on a Membrane Surface. *J Phys Chem B*. 2014; 118:8420–32. [PubMed: 24791936]
309. Friedman R. Aggregation of Amyloids in a Cellular Context: Modelling and Experiment. *Biochem J*. 2011; 438:415–426. [PubMed: 21867485]
310. Pellarin R, Caflisch A. Interpreting the Aggregation Kinetics of Amyloid Peptides. *J Mol Biol*. 2006; 360:882–892. [PubMed: 16797587]
311. Friedman R, Pellarin R, Caflisch A. Amyloid Aggregation on Lipid Bilayers and its Impact on Membrane Permeability. *J Mol Biol*. 2009; 387:407–415. [PubMed: 19133272]
312. Ayton S, Lei P, Bush AI. Metallostasis in Alzheimer's Disease. *Free Radical Biol Med*. 2013; 62:76–89. [PubMed: 23142767]
313. Leskovjan AC, Lanzirotti A, Miller LM. Amyloid Plaques in PSAPP Mice Bind less Metal than Plaques in Human Alzheimer's Disease. *Neuroimage*. 2009; 47:1215–1220. [PubMed: 19481608]
314. Hureau C. Coordination of Redox Active Metal Ions to the APP and to the amyloid-b Peptides Involved in AD. Part 1: An Overview. *Coord Chem Rev*. 2012; 256:2164–2174.
315. Roberts BR, Ryan TM, Bush AI, Masters CL, Duce JA. The Role of Metallobiology and Amyloid- β Peptides in Alzheimer's Disease. *Neurochem*. 2012; 120:149–166.
316. Faller P, Hureau C. A Bioinorganic View of Alzheimer's Disease: When Misplaced Metal Ions (Re)direct the Electrons to the Wrong Target. *Chemistry*. 2012; 18:15910–20. [PubMed: 23180511]
317. Squitti RJ. Copper Dysfunction in Alzheimer's Disease: from Meta-analysis of Biochemical Studies to New Insight into Genetics. *Trace Elem Med Biol*. 2012; 26:93–6.

318. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by Synaptic Zinc to the Gender-disparate Plaque Formation in Human Swedish Mutant APP Transgenic Mice. *Proc Natl Acad Sci USA*. 2002; 99:7705–7710. [PubMed: 12032347]
319. Drew SC, Barnham KJ. The Heterogeneous Nature of Cu(2+) Interactions with Alzheimer's Amyloid- β Peptide. *Acc Chem Res*. 2011; 44:1146–1155. [PubMed: 21714485]
320. Faller P, Hureau C, Berthoumieu O. Role of Metal Ions in the Self-assembly of the Alzheimer's Amyloid-beta Peptide. *Inorg Chem*. 2013; 52:12193–206. [PubMed: 23607830]
321. Zawisza I, Rozga M, Bal W. Affinity of peptides (A β , APP, α -synuclein, PrP) for Metal ions (Cu, Zn). *Coord Chem Rev*. 2012; 256:2297–2307.
322. Hureau C, Dorlet P. Coordination of Redox Active Metal Ions to the APP Protein and to the Amyloid- β Peptides Involved in Alzheimer Disease. Part 2: How Cu(II) Binding Sites Depend on Changes in the A β Sequences. *Coord Chem Rev*. 2012; 256:2175–2187.
323. Xu L, Wang X, Shan S. Characterization of the Polymorphic States of Copper(II)-bound Abeta(1-16) Peptides by Computational Simulations. *J Comput Chem*. 2013; 34:2524–36. [PubMed: 24037720]
324. Azimi S, Rauk A. On the Involvement of Copper Binding to the N-terminus of the Amyloid Beta Peptide of Alzheimer's Disease: A Computational Study on Model Systems. *Int J Alzheimers Dis*. 2011; 2011:539762. [PubMed: 22191059]
325. Eury H, Bijani C, Faller P, Hureau C. Cu^{II} Coordination amyloid- β : Murine versus Human Peptide. *Angew Chem Int Ed*. 2011; 50:901–905.
326. Gunderson WA, Hernandez-Guzman J, Karr JW, Sun L, Szalai VA, Warncke KJ. Local Structure and Global Patterning of Cu²⁺ Binding in Fibrillar amyloid-beta [Abeta(1-40)] Protein. *J Am Chem Soc*. 2012; 134:18330–7. [PubMed: 23043377]
327. Parthasarathy S, Long F, Miller Y, Xiao Y, McElheny D, Thurber K, Ma B, Nussinov R, Ishii Y. Molecular-level Examination of Cu²⁺ Binding Structure for Amyloid Fibrils of 40-residue Alzheimer's beta by Solid-state NMR Spectroscopy. *J Am Chem Soc*. 2011; 133:3390–400. [PubMed: 21341665]
328. Hureau C, Coppel Y, Dorlet P, Solari PL, Sayen S, Guillon E, Sabater L, Faller P. Deprotonation of the Asp1-Ala2 Peptide Bond Induces Modification of the Dynamic Copper(II) Environment in the Amyloid-b Peptide near Physiological pH. *Angew Chem Int Ed*. 2009; 48:9522–9525.
329. Miller Y, Ma BY, Nussinov R. Metal Binding Sites in Amyloid Oligomers: Complexes and Mechanisms. *Coord Chem Rev*. 2012; 256:2245–2252.
330. Xu L, Wang XJ, Wang XC. Effects of Zn²⁺ Binding on the Structural and Dynamic Properties of Amyloid B Peptide Associated with Alzheimer's Disease: Asp(1) or Glu(11)? *ACS Chem Neuro*. 2013; 4:1458–1468.
331. Chassaing S, Collin F, Dorlet P, Gout J, Hureau C, Faller P. Copper and Heme-mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and anti-ROS Compounds. *Curr Top Med Chem*. 2012; 12:2573–2595. [PubMed: 23339309]
332. Alies B, Renaglia E, Rozga M, Bal W, Faller P, Hureau C. Cu(II) Affinity for the Alzheimer's Peptide: Tyrosine Fluorescence Studies Revisited. *Anal Chem*. 2013; 85:1501–1518. [PubMed: 23249207]
333. Jiang D, Zhang L, Grant GP, Dudzik CG, Chen S, Patel S, Hao Y, Millhauser GL, Zhou F. The Elevated Copper Binding Strength of Amyloid-beta Aggregates Allows the Sequestration of Copper from Albumin: A Pathway to Accumulation of Copper in Senile Plaques. *Biochemistry*. 2013; 52:547–56. [PubMed: 23237523]
334. Alies B, Badei B, Faller P, Hureau C. Reevaluation of Copper(I) Affinity for Amyloid-b Peptides by Competition with Ferrozine, an Unusual Copper(I) Indicator. *Chemistry*. 2012; 18:1161–1167. [PubMed: 22189983]
335. Xiao Z, Gottschlich L, van der Meulen R, Udagedara SR, Wedd AG. Evaluation of Quantitative Probes for Weaker Cu(i) Binding Sites Completes a set of Four Capable of Detecting Cu(i) Affinities from Nanomolar to Attomolar. *Metallomics*. 2013; 5:501–13. [PubMed: 23579336]
336. (a) Viles JH. Metal ions and Amyloid Formation in Neurodegenerative Diseases. *Coord Chem Rev*. 2012; 256:2271–2284. (b) Miller Y, Ma B, Nussinov R. Zinc Ions Promote Alzheimer A β Aggregation via Population Shift of Polymorphic States. *Proc Natl Acad Sci USA*. 2010;

- 107:9490–9495. [PubMed: 20448202] (c) Mithu VS, Sarkar B, Bhowmik D, Chandrakesan M, Maiti S, Madhu PK. Zn(++) Binding Disrupts the Asp(23)-Lys(28) Salt Bridge without Altering the hairpin-Shaped Cross- β Structure of A β (42) Amyloid Aggregates. *Biophys J*. 2011; 101:2825–32. [PubMed: 22261072] (d) Garai K, Sahoo B, Kaushalya SK, Desai R, Maiti S. Zinc Lowers Amyloid-beta Toxicity by Selectively Precipitating Aggregation Intermediates. *Biochemistry*. 2007; 46:10655–63. [PubMed: 17718543]
337. Zhu X, Su B, Wang X, Smith MA, Perry G. Causes of Oxidative Stress in Alzheimer Disease. *Cell Mol Life Sci*. 2007; 64:2202–10. [PubMed: 17605000]
338. Cassagnes LE, Herve V, Nepveu F, Hureau C, Faller P, Collin F. The Catalytically Active Copper-amyloid-Beta State: Coordination Site Responsible for Reactive Oxygen Species Production. *Angew Chem Int Ed*. 2013; 52:11110–3.
339. La Penna G, Hureau C, Andreussi O, Faller P. Identifying, by First-Principles Simulations, Cu[amyloid-beta] Species Making Fenton-type Reactions in Alzheimer's Disease. *J Phys Chem B*. 2013; 117:16455–67. [PubMed: 24313818]
340. James SA, Volitakis I, Adlard PA, Duce JA, Masters CL, Cherny RA, Bush AI. Elevated Labile Cu Is Associated with Oxidative Pathology in Alzheimer Disease. *Free Radical Biol Med*. 2012; 52:298–302. [PubMed: 22080049]
341. Ceccom J, Cosledan F, Halley H, Frances B, Lassalle JM, Meunier B. Copper Chelator Induced Efficient Episodic Memory Recovery in a non-Transgenic Alzheimer's Mouse Model. *PLoS One*. 2012; 7:e43105. [PubMed: 22927947]
342. Rodriguez-Rodriguez C, Telpoukhovskaia M, Orvig C. The art of Building Multifunctional Metal-binding Agents from Basic Molecular Scaffolds for the Potential Application in Neurodegenerative Diseases. *Coord Chem Rev*. 2012; 256:2308–2332.
343. Crouch PJ, Barnham KJ. Therapeutic Redistribution of Metal Ions to Treat Alzheimer's Disease. *Acc Chem Res*. 2012; 45:1604–11. [PubMed: 22747493]
344. Pithadia AS, Lim MH. Metal-associated Amyloid-beta Species in Alzheimer's Disease. *Curr Opin Chem Biol*. 2012; 16:67–73. [PubMed: 22366383]
345. You H, Tsutsui S, Hameed S, Kannanayakal TJ, Chen L, Xia P, Engbers JD, Lipton SA, Stys PK, Zamponi GW. A β Neurotoxicity Depends on Interactions between Copper Ions, Prion Protein, and N-methyl-D-aspartate Receptors. *Proc Natl Acad Sci USA*. 2012; 109:1737–1742. [PubMed: 22307640]
346. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA Receptor Trafficking by Amyloid-beta. *Nat Neurosci*. 2005; 8:1051–1058. [PubMed: 16025111]
347. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A. Deleterious Effects of Amyloid beta Oligomers Acting as an Extracellular Scaffold for mGluR5. *Neuron*. 2010; 66:739–754. [PubMed: 20547131]
348. Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu GQ, Mucke L. Reversing EphB2 Depletion Rescues Cognitive Functions in Alzheimer Model. *Nature*. 2011; 469:47–52. [PubMed: 21113149]
349. Yanagisawa K, Ihara Y. GM1 Ganglioside-bound Amyloid beta-protein in Alzheimer's Disease Brain. *Neurobiol Aging*. 1998; 19(1 Suppl):S65–67. [PubMed: 9562471]
350. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, Wilson MR. The Extracellular Chaperone Clusterin Influences Amyloid Formation and Toxicity by Interacting with Prefibrillar Structures. *FASEB J*. 2007; 21:2312–2322. [PubMed: 17412999]
351. Narayan P, Orte A, Clarke RW, Bolognesi B, Hook S, Ganzinger KA, Meehan S, Wilson MR, Dobson CM, Klenerman D. The Extracellular Chaperone Clusterin Sequesters Oligomeric Forms of the Amyloid- β (1–40) Peptide. *Nat Struct Mol Biol*. 2011; 19:79–83. [PubMed: 22179788]
352. Stanyon HF, Viles JH. Human Serum Albumin can Regulate Amyloid- β Peptide Fiber Growth in the Brain Interstitium: Implications for Alzheimer Disease. *J Biol Chem*. 2012; 287:28163–28168. [PubMed: 22718756]
353. Likó I, Mák M, Klement É, Hunyadi-Gulyás É, Pázmány T, Medzihradszky KF, Urbányi Z. Evidence for an Extended Interacting Surface between beta-amyloid Serum Amyloid P Component. *Neurosci Lett*. 2007; 412:51–55. [PubMed: 17141957]

354. Andreetto E, Yan LM, Tatarek-Nossol M, Velkova A, Frank R, Kapurniotu A. Identification of Hot Regions of the A β -IAPP Interaction Interface as High-affinity Binding Sites in both Cross- and Self-association. *Angew Chem Int Ed*. 2010; 49:3081–3085.
355. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T. Transthyretin Protects Alzheimer's Mice from the Behavioral and Biochemical Effects of A β Toxicity. *Proc Nat Acad Sci USA*. 2008; 105:2681–2686. [PubMed: 18272491]
356. Coria F, Castano E, Prelli F, Larrondo-Lillo M, Van Duinen S, Shelanski M, Frangione B. Isolation and Characterization of Amyloid PComponent from Alzheimer's Disease and Other Types of Cerebral Amyloidosis. *Lab Invest*. 1988; 58:454–458. [PubMed: 2965774]
357. Dohler F, Sepulveda-Falla D, Krasemann S, Altmeppen H, Schluter H, Hildebrand D, Zerr I, Matschke J, Glatzel M. High Molecular Mass Assemblies of Amyloid- β Oligomers Bind Prion Protein in Patients with Alzheimer's Disease. *Brain*. 2014; 137:873–876. [PubMed: 24519981]
358. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer's Disease A β Peptides is Induced by Small Changes in the A β 42 to A β 40 Ratio. *EMBO J*. 2010; 29:3408–3420. [PubMed: 20818335]
359. Jan A, Gokce O, Luthi-Carter R, Lashuel HA. The Ratio of Monomeric to Aggregated Forms of A β 40 and A β 42 is an Important Determinant of Amyloid-beta Aggregation, Fibrillogenesis, and Toxicity. *J Biol Chem*. 2008; 283:28176–89. [PubMed: 18694930]
360. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM. Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein. *J Neurosci*. 2010; 30:6367–6374. [PubMed: 20445063]
361. Gunther EC, Strittmatter SM. Beta-amyloid Oligomers and Cellular Prion Protein in Alzheimer's Disease. *J Mol Med*. 2010; 88:331–338. [PubMed: 19960174]
362. Chen S, Yadav SP, Surewicz WK. Interaction between Human Prion Protein and Amyloid-beta (A β) Oligomers: Role of N-terminal Residues. *J Biol Chem*. 2010; 285:26377–26383. [PubMed: 20576610]
363. Balducci C, Beeg M, Stravalaci M, Bastone A, Scip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G. Synthetic Amyloid-beta Oligomers Impair Long-term Memory Independently of Cellular Prion Protein. *Proc Natl Acad Sci USA*. 2010; 107:2295–2300. [PubMed: 20133875]
364. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A. Prion protein and A β -related Synaptic Toxicity Impairment. *EMBO Mol Med*. 2010; 2:306–310. [PubMed: 20665634]
365. Kessels HW, Nguyen LN, Nabavi S, Malinow R. The Prion Protein as a Receptor for Amyloid-beta. *Nature*. 2010; 466:E3–4. discussion E4-5. [PubMed: 20703260]
366. Cisse M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L. Ablation of Cellular Prion Protein Does not Ameliorate Abnormal Neural Network Activity or Cognitive Dysfunction in the J20 Line of Human Amyloid Precursor Protein Transgenic Mice. *J Neurosci*. 2011; 31:10427–10431. [PubMed: 21775587]
367. Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J. Interaction between Prion Protein and Toxic Amyloid β Assemblies can be Therapeutically Targeted at Multiple Sites. *Nat Commun*. 2011; 2:336. [PubMed: 21654636]
368. Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ. Alzheimer's Disease Brain-derived Amyloid- β -Mediated Inhibition of LTP in vivo is Prevented by Immunotargeting Cellular Prion Protein. *J Neurosci*. 2011; 31:7259–7263. [PubMed: 21593310]
369. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM. Alzheimer Amyloid- β Oligomer Bound to Postsynaptic Prion Protein Activates Fyn to Impair Neurons. *Nat Neurosci*. 2012; 15:1227–1235. [PubMed: 22820466]
370. Bate C, Williams A. Amyloid- β -induced Synapse Damage is Mediated via Cross-linkage of Cellular Prion Proteins. *J Biol Chem*. 2011; 286:37955–37963. [PubMed: 21900234]

371. Kudo W, Lee HP, Zou WQ, Wang X, Perry G, Zhu X, Smith MA, Petersen RB, Lee HG. Cellular Prion Protein is Essential for Oligomeric Amyloid- β -induced Neuronal Cell Death. *Hum Mol Genet.* 2012; 21:1138–44. [PubMed: 22100763]
372. Nicoll AJ, Panico S, Freir DB, Wright D, Terry C, Risse E, Herron CE, O'Malley T, Wadsworth JD, Farrow MA, Walsh DM, Saibil HR, Collinge J. Amyloid- β Nanotubes are Associated with Prion Protein-dependent Synaptotoxicity. *Nat Commun.* 2013; 4:2416. [PubMed: 24022506]
373. Zou WQ, Xiao X, Yuan J, Puoti G, Fujioka H, Wang X, Richardson S, Zhou X, Zou R, Li S. Amyloid-beta42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain. *J Biol Chem.* 2011; 286:15095–15105. [PubMed: 21393248]
374. Ferrer I, Blanco R, Carmona M, Puig B, Ribera R, Rey M, Ribalta T. Prion Protein Expression in Senile Plaques in Alzheimer's Disease. *Acta Neuropathol.* 2001; 101:49–56. [PubMed: 11194941]
375. Krieger J, Fusco G, Lewitzky M, Simister PC, Marchant J, Camilloni C, Feller SM, De Simone A. Conformational Recognition of an Intrinsically Disordered Protein. *Biophys J.* 2014; 106:1771–1779. [PubMed: 24739176]
376. (a) Derreumaux P. Evidence that the 127-164 Region of Prion Proteins has Two Equi-energetic Conformations with beta or alpha Features. *Biophys J.* 2001; 81:1657–65. [PubMed: 11509378]
(b) Santini S, Claude JB, Audic S, Derreumaux P. Impact of the Tail and Mutations G131V and M129V on Prion Protein Flexibility. *Proteins.* 2003; 51:258–65. [PubMed: 12660994] (c) Santini S, Derreumaux P. Helix H1 of the Prion Protein is Rather Stable against Environmental Perturbations: Molecular Dynamics of Mutation and Deletion Variants of PrP(90-231). *Cell Mol Life Sci.* 2004; 61:951–60. [PubMed: 15095015]
377. Gallion SL. Modeling Amyloid-beta As HomogeneousDodecamers and in Complex with Cellular Prion Protein. *Plos One.* 2012; 7:e49375. [PubMed: 23145167]
378. Chebaro Y, Derreumaux PJ. The Conversion of Helix H2 to Beta-sheet is Accelerated in the Monomer and Dimer of the Prion Protein upon T183A Mutation. *Phys Chem B.* 2009; 113:6942–6948.
379. Barducci A, Chelli R, Procacci P, Schettino V, Gervasio FL, Parrinello M. Metadynamics Simulation of Prion Protein: Beta-structure Stability and the Early Stages of Misfolding. *J Am Chem Soc.* 2006; 128:2705–2710. [PubMed: 16492057]
380. De Simone A, Dodson GG, Fraternali F, Zagari A. Water Molecules as Structural Determinants among Prions of Low Sequence Identity. *FEBS Lett.* 2006; 580:2488–2894. [PubMed: 16638576]
381. Cobb NJ, Apostol MI, Chen S, Smirnovas V, Surewicz WK. Conformational Stability of Mammalian Prion Protein Amyloid Fibrils is Dictated by a Packing Polymorphism within the Core Region. *J Biol Chem.* 2014; 289:2643–2650. [PubMed: 24338015]
382. Cordeiro Y, Kraineva J, Ravindra R, Lima LM, Gomes MP, Foguel D, Winter R, Silva JL. Hydration and Packing Effects on Prion Folding and Beta-sheet Conversion. High Pressure Spectroscopy and Pressure Perturbation Calorimetry Studies. *J Biol Chem.* 2004; 279:32354–32359. [PubMed: 15173173]
383. De Simone A, Zagari A, Derreumaux P. Structural and Hydration Properties of the Partially Unfolded States of the Prion Protein. *Biophys J.* 2007; 93:1284–1292. [PubMed: 17483173]
384. Eghiaian F, Daubenfeld T, Quenet Y, van Audenhaege M, Bouin AP, van der Rest G, Grosclaude J, Rezaei H. Diversity in Prion Protein Oligomerization Pathways Results from Domain Expansion as Revealed by hydrogen/deuterium Exchange and Disulfide linkage. *Proc Natl Acad Sci USA.* 2007; 104:7414–7419. [PubMed: 17442756]
385. Schwarzingner S, Horn AH, Ziegler J, Sticht H. Rare Large Scale Subdomain Motions in Prion Protein can Initiate Aggregation. *J Biomol Struct Dyn.* 2006; 23:581–590. [PubMed: 16615804]
386. Khosravani H, Zhang Y, Tsutsui S, Hameed S, Altier C, Hamid J, Chen L, Villemaire M, Ali Z, Jirik FR, Zamponi GW. Prion Protein Attenuates Excitotoxicity by Inhibiting NMDA Receptors. *J Cell Biol.* 2008; 181:551–565. [PubMed: 18443219]
387. Sarell CJ, Syme CD, Rigby SE, Viles JH. Copper(II) Binding to Amyloid-beta Fibrils of Alzheimer's Disease Reveals a Picomolar Affinity: Stoichiometry and Coordination Geometry

are Independent of Abeta Oligomeric forms. *Biochemistry*. 2009; 48:4388–4402. [PubMed: 19338344]

388. Hu NW, Nicoll AJ, Zhang D, Mably AJ, O'Malley T, Purro SA, Terry C, Collinge J, Walsh DM, Rowan MJ. MGLu5 Receptors and Cellular Prion Protein Mediate Amyloid- β -facilitated Synaptic Long-term Depression in Vivo. *Nat Commun*. 2014; 5:3374. [PubMed: 24594908]
389. Chen X, Lin R, Chang L, Xu S, Wei X, Zhang J, Wang C, Anwyl R, Wang Q. Enhancement of Long-term Depression by Soluble Amyloid β Protein in Rat Hippocampus is Mediated by Metabotropic Glutamate Receptor and Involves Activation of p38MAPK, STEP and Caspase-3. *Neuroscience*. 2013; 253:435–443. [PubMed: 24012839]
390. Kessels HW, Nabavi S, Malinow R. Metabotropic NMDA Receptor Function is Required for β -amyloid-induced Synaptic Depression. *Proc Natl Acad Sci USA*. 2013; 110:4033–4038. [PubMed: 23431156]
391. Mota SI, Ferreira IL, Pereira C, Oliveira CR, Rego AC. Amyloid-beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures. *Curr Alzheimer Res*. 2012; 9:844–856. [PubMed: 22631440]
392. Brito-Moreira J, Paula-Lima AC, Bomfim TR, Oliveira FB, Sepulveda FJ, De Mello FG, Aguayo LG, Panizzutti R, Ferreira ST. A β Oligomers Induce Glutamate Release from Hippocampal Neurons. *Curr Alzheimer Res*. 2011; 8:552–562. [PubMed: 21244351]
393. Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C. The Pursuit of Susceptibility Genes for Alzheimer's Disease: Progress and Prospects. *Trends Genet*. 2010; 26:84–93. [PubMed: 20080314]
394. Narayan P, Meehan S, Carver JA, Wilson MR, Dobson CM, Klenerman D. Amyloid- β Oligomers are Sequestered by both Intracellular and Extracellular Chaperones. *Biochemistry*. 2012; 51:9270–9276. [PubMed: 23106396]
395. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has Chaperone-like Activity Similar to that of Small Heat Shock Proteins. *J Biol Chem*. 1999; 274:6875–81. [PubMed: 10066740]
396. Wyatt AR, Yerbury JJ, Poon S, Wilson MR. Therapeutic Targets in Extracellular Protein Deposition Diseases. *Curr Med Chem*. 2009; 16:2855–2866. [PubMed: 19689268]
397. Wyatt AR, Yerbury JJ, Wilson MR. Structural Characterization of Clusterin-chaperone Client Protein Complexes. *J Biol Chem*. 2009; 284:21920–21927. [PubMed: 19535339]
398. Wyatt AR, Yerbury JJ, Berghofer P, Greguric I, Katsifis A, Dobson CM, Wilson MR. Clusterin Facilitates in Vivo Clearance of Extracellular Misfolded Proteins. *Cell Mol Life Sci*. 2011; 68:3919–3931. [PubMed: 21505792]
399. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is Transported on Lipoproteins and Albumin in Human Plasma. *J Biol Chem*. 1996; 271:32916–32922. [PubMed: 8955133]
400. Kuo YM, Kokjohn TA, Kalback WM, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE. Amyloid-beta Peptides Interact with Plasma Proteins and Erythrocytes: Implications for their Quantitation in Plasma. *Biochem Biophys Res Commun*. 2000; 268:750–756. [PubMed: 10679277]
401. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schioesmacher M, Whaley J, Swindlehurst C. Isolation and Quantification of Soluble Alzheimer's beta-peptide From Biological Fluids. *Nature*. 1992; 359:325–327. [PubMed: 1406936]
402. Lame ME, Chambers EE, Blatnik M. Quantification of Amyloid beta Peptides A β (1-38), A β (1-40), and A β (1-42) in Human Cerebrospinal Fluid by Ultra-performance Liquid Chromatography-tandem Mass Spectrometry. *Anal Biochem*. 2011; 419:133–139. [PubMed: 21888888]
403. Stevens R, Elmendorf D, Gourlay M, Stroebel E, Gaafar H. Application of Fluoroimmunoassay to Cerebrospinal Fluid Immunoglobulin G and Albumin. *J Clin Microbiol*. 1979; 10:346–50. [PubMed: 114535]
404. Rózga M, Kloniecki M, Jablonowska A, Dadlez M, Bal W. The binding Constant for Amyloid Abeta40 Peptide Interaction with Human Serum Albumin. *Biochem Biophys Res Commun*. 2007; 364:714–718. [PubMed: 18028874]

405. Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Näslund J, Richards G, Huber W, Döbeli H, Nordstedt C. Endogenous Proteins Controlling Amyloid beta-peptide Polymerization. Possible Implications for beta-amyloid Formation in the Central Nervous System and in Peripheral Tissues. *J Biol Chem.* 1999; 274:15990–15995. [PubMed: 10347147]
406. Milojevic J, Esposito V, Das R, Melacini G. Understanding the Molecular Basis for the Inhibition of the Alzheimer's A β -peptide Oligomerization by Human Serum Albumin using Saturation Transfer Difference and Off-resonance Relaxation NMR Spectroscopy. *J Am Chem Soc.* 2007; 129:4282–4290. [PubMed: 17367135]
407. Milojevic J, Melacini G. Stoichiometry and Affinity of the Human Serum Albumin-Alzheimer's A β Peptide Interactions. *Biophys J.* 2011; 100:183–192. [PubMed: 21190670]
408. Garg A, Manidhar DM, Gokara M, Mileda C, Reddy CS, Subramanyam R. Elucidation of the Binding Mechanism of Coumarin Derivatives with Human Serum Albumin. *Plos One.* 2013; 8(5):e63805. [PubMed: 23724004] (b) Raz Y, Miller Y. Interactions between A β and Mutated Tau Lead to Polymorphism and Induce Aggregation of A β -mutated tau Oligomeric Complexes. *Plos One.* 2013; 8:e73303. [PubMed: 23951348]
409. Mullard A. Sting of Alzheimer's Failures Offset by Upcoming Prevention Trials. *Nat Rev Drug Discov.* 2012; 11:657–660. [PubMed: 22935790]
410. Pujadas L, Rossi D, Andrés R, Teixeira CM, Serra-Vidal B, Parcerisas A, Maldonado R, Giralte E, Crulla N, Soriano E. Reelin Delays Amyloid-beta Fibril Formation and Rescues Cognitive Deficits in a Model of Alzheimer's Disease. *Nat Commun.* 2014; 5:3443.doi: 10.1038/ncomms4443 [PubMed: 24599114]
411. Pratim Bose P, Chatterjee U, Nerelius C, Govender T, Norström T, Gogoll A, Sandegren A, Göthelid E, Johansson J, Arvidsson PI. Poly-N-Methylated Amyloid beta-peptide (A β) C-terminal Fragments Reduce A β Toxicity in Vitro and in *Drosophila Melanogaster*. *J Med Chem.* 2009; 52:8002–8009. [PubMed: 19908889]
412. Amijee H, Bate C, Williams A, Virdee J, Jeggo R, Spanswick D, Scopes DIC, Mazzitelli J, Doig A. The N-methylated peptide SEN304 Powerfully Inhibits A β (1-42) Toxicity by Perturbing Oligomer Formation. *Biochemistry.* 2012; 51:8338–8352. [PubMed: 23025847]
413. Hopping G, Kellock J, Barnwal RP, Law P, Bryers J, Varani G, Caughey B, Daggett V. Designed α -sheet Peptides Inhibit Amyloid Formation by Targeting Toxic Oligomers. *Elife.* 2014; 3:e01681. [PubMed: 25027691]
414. Bieschke J, Herbst M, Wiglenda T, Friedrich RP, Boeddrich A, Schiele F, Kleckers D, Lopez del Amo JM, Grüning BA, Wang Q, Schmidt MR, Lurz R, Anwyl R, Schnoegl S, Fändrich M, Frank RF, Reif B, Günter S, Walsh DM, Wanker EE. Small-molecule Conversion of Toxic Oligomers to Nontoxic β -sheet-rich Amyloid Fibrils. *Nat Chem Biol.* 2012; 8:93–101.
415. Richard T, Poupard P, Nassra M, Papastamoulis Y, Iglésias ML, Krisa S, Waffo-Teguo P, Mérellon JM, Monti JP. Protective Effect of e-viniferin on β -amyloid Peptide Aggregation Investigated by Electrospray Ionization Mass Spectrometry. *Bioorg Med Chem.* 2011; 19:3152–3155. [PubMed: 21524590]
416. Richard T, Papastamoulis Y, Waffo-Teguo P, Monti JP. 3D NMR Structure of a Complex between the Amyloid beta peptide(1-40) and the Polyphenol epsilon-viniferin Glucoside: Implications in Alzheimer's Disease. *Biochim Biophys Acta.* 2013; 1830(11):5068–5074. 2013. [PubMed: 23830862]
417. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE. EGCG Redirects Amyloidogenic Polypeptides into Unstructured, off-pathway Oligomers. *Nat Struct Mol Biol.* 2008; 15, 558–566.
418. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE. EGCG Remodels Mature alpha-synuclein and amyloid-beta Fibrils and Reduces Cellular Toxicity. *Proc Nat Acad Sci USA.* 2010; 107:7710–7715. [PubMed: 20385841]
419. Wang SH, Liu FF, Dong XY, Sun Y. Thermodynamic Analysis of the Molecular Interactions between Amyloid β -Peptide 42 and (–)-Epigallocatechin-3-gallate. *J Phys Chem B.* 2010; 114:11576–11583. [PubMed: 20718413]
420. Liu FF, Dong XY, He L, Middelberg AP, Sun Y. Molecular Insight into Conformational Transition of Amyloid β -Peptide 42 Inhibited by (–)-Epigallocatechin-3-gallate Probed by Molecular Simulations. *J Phys Chem B.* 2011; 115:11879–11887. [PubMed: 21899367]

421. Lopez del Amo JM, Fink U, Dasari M, Grelle G, Wanker EE, Bieschke J, Reif B. Structural Properties of EGCG-induced, nontoxic Alzheimer's disease A β Oligomers. *J Mol Biol.* 2012; 421(4-5):517–524. [PubMed: 22300765]
422. Attanasio F, Convertino M, Magno A, Caflisch A, Corazza A, Harridas H, Esposito G, Cataldo S, Pignataro B, Milardi D, Rizzarelli E. Carnosine Inhibits A β ₄₂ Aggregation by Perturbing the H-Bond Network in and around the Central Hydrophobic Cluster. *ChemBioChem.* 2013; 14:583–592. [PubMed: 23440928]
423. Arai T, Araya T, Sasaki D, Taniguchi A, Sato T, Sohma Y, Kanai M. Rational Design Identification of a Non-peptidic Aggregation Inhibitor of Amyloid β based on a Pharmacophore Motif obtained from cyclo[-Lys-Leu-Val-Phe-Phe]. *Angew Chem Int Ed Engl.* 2014; 53:8236–8239. [PubMed: 24931598]
424. Sato M, Murakami K, Uno M, Nakagawa Y, Katayama S, Akagi K, Masuda Y, Takegoshi K, Irie K. Site-specific Inhibitory Mechanism for Amyloid β ₄₂ Aggregation by Catechol-type Flavonoids Targeting the Lys Residues. *J Biol Chem.* 2013; 288:23212–23214. [PubMed: 23792961]
425. Palhano FL, Lee J, Grimster NP, Kelly JW. Toward the Molecular Mechanism(s) by which EGCG Treatment Remodels Mature Amyloid Fibrils. *J Am Chem Soc.* 2013; 135:7503–7510. [PubMed: 23611538]
426. Tomiyama T, Kaneko H, Kataoka K, Asano S, Endo N. Rifampicin Inhibits the Toxicity of Pre-aggregated Amyloid Peptides by Binding to Peptide Fibrils and Preventing Amyloid-cell Interactio. *Biochem J.* 1997; 322:859–865. [PubMed: 9148761]
427. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. Anthraquinones Inhibit Tau Aggregation and Dissolve Alzheimer's Paired Helical Filaments in vitro and in Cells. *J Biol Chem.* 2005; 280:3628–3635. [PubMed: 15525637]
428. Necula M, Kaye R, Milton S, Glabe CG. Small Molecule Inhibitors of Aggregation Indicate that Amyloid beta Oligomerization and Fibrillization Pathways are Independent and Distinct. *J Biol Chem.* 2007; 282:10311–10324. [PubMed: 17284452]
429. Scherzer-Attali R, Pellarin R, Convertino M, Frydman-Marom A, Egoz-Matia N, Peled S, Levy-Sakin M, Shalev DE, Caflisch A, Gazit E, Segal D. Complete Phenotypic Recovery of an Alzheimer's disease Model by a Quinonetryptophan Hybrid Aggregation Inhibitor. *PLoS One.* 2010; 5:e11101. [PubMed: 20559435]
430. Convertino M, Vitalis A, Caflisch A. Disordered binding of smallmolecules to A β (12-28). *J Biol Chem.* 2011; 286:41578–41588. [PubMed: 21969380]
431. Scherzer-Attali R, Convertino M, Pellarin R, Gazit E, Segal D, Caflisch A. Methylations of Tryptophan-modified Naphthoquinone Affect its Inhibitory Potential toward A β Aggregation. *J Phys Chem B.* 2013; 117:1780–1789. [PubMed: 23259849]
432. Zhang T, Xu W, Mu Y, Derreumaux P. Atomic and Dynamic Insights into the Beneficial Effect of the 1,4-naphthoquinon-2-yl-L-tryptophan Inhibitor on Alzheimer's A β ₁₋₄₂ Dimer in terms of Aggregation and Toxicity. *ACS Chem Neurosci.* 2013; 5:148–159. [PubMed: 24246047]
433. Brenke R, Kozakov D, Chuang GY, Beglov D, Hall D, Landon MR, Mattos C, Vajda S. Fragment-based Identification of Druggable 'hot spots' of Proteins using Fourier Domain Correlation Techniques. *Bioinformatics.* 2009; 25:621–627. [PubMed: 19176554]
434. McGann M. FRED Pose Prediction and Virtual Screening Accuracy. *J Chem Inf Model.* 2011; 51:578–596. [PubMed: 21323318]
435. Kroth H, Ansaloni A, Varisco Y, Jan A, Sreenivasachary N, Rezaei-Ghaleh N, Giriens V, Lohmann S, Lopez-Deber MP, Adolfsson O, Pihlgren M, Paganetti P, Froestl W, Nagel-Steger L, Willbold D, Schrader T, Zweckstetter M, Pfeifer A, Lashuel HA, Muhs A. Discovery and Structure Activity Relationship of Small Molecule Inhibitors of Toxic β -amyloid-42 Fibril Formation. *J Biol Chem.* 2012; 287:34786–34800. [PubMed: 22891248]
436. Connors CR, Rosenman DJ, Lopes DH, Mittal S, Bitan G, Sorci M, Belfort G, Garcia A, Wang C. Tranilast Binds to A β Monomers and Promotes A β Fibrillation. *Biochemistry.* 2013; 52:3995–4002. [PubMed: 23679559]

437. Tarus B, Nguyen PH, Berthoumieu O, Faller P, Doig AJ, Derreumaux P. Molecular Structure of the NQTrp Inhibitor with the AlzheimerA β 1-28 Monomer. *Eur J Med Chem.* 2015; 91:43–50. DOI: 10.1016/j.ejmech.2014.07.002 [PubMed: 25011560]
438. Novick PA, Lopes DH, Branson KM, Esteras-Chopo A, Graef IA, Bitan G, Pande VS. Design of β -amyloid Aggregation Inhibitors from a Predicted Structural Motif. *J Med Chem.* 2012; 55:3002–3010. [PubMed: 22420626]
439. Stefanova NA, Muraleva NA, Korbolina EE, Kiseleva E, Maksimova KY, Kolosova NG. Amyloid Accumulation is a Late Event in Sporadic Alzheimer's Disease-like Pathology in Nontransgenic Rats. *Oncotarget.* 2015; 6:1396–413. [PubMed: 25595891]
440. Alzheimer Disease & Frontotemporal Dementia Mutation Database. <http://www.molgen.ua.ac.be/admutations/>
441. Rovelet-Lecrux A, Tuominen H, Majamaa K, Campion D, Remes AM. APP Locus Duplication in a Finnish Family with Dementia and Intracerebral Haemorrhage. *J Neurol Neurosurg Psychiatry.* 2007; 78:1158–1159. [PubMed: 17442758]
442. St George-Hyslop PH. Molecular Genetics of Alzheimer's Disease. *Biol Psychiatry.* 2000; 47:183–199. [PubMed: 10682216]
443. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B. Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Yype. *Science.* 1990; 248:1124–1126. [PubMed: 2111584]
444. Kaden D, Harmeier A, Weise C, Munter LM, Althoff V, Rost BR, Hildebrand PW, Schmitz D, Schaefer M, Lurz R, Skodda S, Yamamoto R, Arlt S, Finckh U, Multhaup G. Novel APP/A β Mutation K16N Produces Highly Toxic Heteromeric A β Oligomers. *EMBO Mol Med.* 2012; 4:647–659. [PubMed: 22514144]
445. Nomura S, Umeda T, Tomiyama T, Mori H. The E693 (Osaka) Mutation in Amyloid Precursor Protein Potentiates Cholesterol-mediated Intracellular Amyloid β Toxicity via its Impaired Cholesterol Efflux. *J Neuro Res.* 2013; 91:1541–1550.
446. Shimizu T, Fukuda H, Murayama S, Izumiyama N, Shirasawa T. Isoaspartate Formation at Position 23 of Amyloid beta Peptide Enhanced Fibril Formation and Deposited onto Senile Plaques and Vascular Amyloids in Alzheimer's Disease. *J Neurosci Res.* 2002; 70:451–461. [PubMed: 12391606]
447. Hashimoto Y, Matsuoka M. A mutation Protective Against Alzheimer's Disease Renders Amyloid β Precursor Protein Incapable of Mediating Neurotoxicity. *J Neurochem.* 2014; 130(2):291–300. [PubMed: 24646423]
448. Qahwash I, Weiland KL, Lu Y, Sarver RW, Kletzien RF, Yan R. Identification of a Mutant Amyloid Peptide that Predominantly Forms Neurotoxic Protofibrillar Aggregates. *J Biol Chem.* 2003; 278:23187–23195. [PubMed: 12684519]
449. Moskovitz J, Maiti P, Lopes DH, Oien DB, Attar A, Liu T, Mittal S, Hayes J, Bitan G. Induction of Methionine-sulfoxide Reductases Protects Neurons from Amyloid β -protein Insults in vitro and in vivo. *Biochemistry.* 2011; 50:10687–10697. [PubMed: 22059533]
450. Harmeier A, Wozny C, Rost BR, Munter LM, Hua H, Georgiev O, Beyermann M, Hildebrand PW, Weise C, Schaffner W, Schmitz D, Multhaup G. Role of Amyloid-Beta Glycine 33 in Oligomerization, Toxicity, and Neuronal Plasticity. *J Neurosci.* 2009; 29:7582–7590. [PubMed: 19515926]
451. Kim W, Hecht MH. Mutations Enhance the Aggregation Propensity of the Alzheimer's A Beta Peptide. *J Mol Biol.* 2008; 377:565–574. [PubMed: 18258258]
452. Kim W, Hecht MH. Generic Hydrophobic Residues Are Sufficient to Promote Aggregation of the Alzheimer's A β 42 Peptide. *Proc Natl Acad Sci USA.* 2006; 103:15824–15829. [PubMed: 17038501]
453. Sandebring A, Welander H, Winblad B, Graff C, Tjernberg LO. The Pathogenic A β 43 Is Enriched in Familial and Sporadic Alzheimer Disease. *PLoS One.* 2013; 8:e55847. [PubMed: 23409063]
454. Conicella AE, Fawzi NL. The C-terminal Threonine of A β 43 Nucleates Toxic Aggregation via Structural and Dynamical Changes in Monomers and Protofibrils. *Biochemistry.* 2014; 53:3095–105. [PubMed: 24773532]

455. Messa M, Colombo L, del Favero E, Cantù L, Stoilova T, Cagnotto A, Rossi A, Morbin M, Di Fede G, Tagliavini F, Salmona M. The Peculiar Role of the A2V Mutation in Amyloid-beta 1-42 Molecular Assembly. *J Biol Chem*. 2014; 289:24143–24152. [PubMed: 25037228]
456. Liu YW, He YH, Zhang YX, Cai WW, Yang LQ, Xu LY, Kong QP. Absence of A673T Variant in APP Gene Indicates an Alternative Protective Mechanism Contributing to Longevity in Chinese Individuals. *Neurobiol Aging*. 2014; 35:935.e11–e12.
457. Bamne MN, Demirci FY, Berman S, Snitz BE, Rosenthal SL, Wang X, Lopez OL, Kamboh LI. Investigation of an Amyloid Precursor Protein Protective Mutation (A673T) in a North American Case-control Sample of Late-onset Alzheimer's Disease. *Neurobiol Aging*. 2014; 35:1779e15–e16.
458. Benilova I, Gallardo R, Ungureanu AA, Castillo Cano V, Snellinx A, Ramakers M, Bartic C, Rousseau F, Schymkowitz J, De Strooper B. The Alzheimer Disease Protective Mutation A2T Modulates Kinetic and Thermodynamic Properties of Amyloid-beta (Abeta) Aggregation. *J Biol Chem*. 2014; 289:30977–30989. [PubMed: 25253695]
459. Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, van der Brug M, Liu Y, Ernst JA, Watts RJ, Atwal JK. Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein. *J Biol Chem*. 2014; 289:30990–31000. [PubMed: 25253696]
460. Coskuner O, Wise-Scira O, Perry G, Kitahara T. The Structures of the E22delta Mutant-type Amyloid-beta Alloforms and the Impact of E22delta Mutation on the Structures of the Wild-type Amyloid-beta Alloforms. *ACS Chem Neurosci*. 2013; 4:310–320. [PubMed: 23421682]
461. Baumketner A, Krone MG, Shea JE. Role of the Familial Dutch Mutation E22Q in the Folding and Aggregation of the 15-28 Fragment of the Alzheimer Amyloid-beta Protein. *Proc Natl Acad Sci USA*. 2008; 105:6027–6032. [PubMed: 18408165]
462. Huet A, Derreumaux P. Impact of the Mutation A21G (Flemish Variant) on Alzheimer's Beta-amyloid Dimers by Molecular Dynamics Simulations. *Biophys J*. 2006; 91:3829–3840. [PubMed: 16891372]
463. Okamoto A, Yano A, Nomura K, Higai S, Kurita N. Effect of D23N Mutation on the Dimer Conformation of Amyloid-beta Proteins: Ab Initio Molecular Simulations in Water. *J Mol Graph Model*. 2014; 50:113–124. [PubMed: 24793052]
464. Viet MH, Nguyen PH, Ngo ST, Li MS, Derreumaux P. Effect of the Tottori Familial Disease Mutation (D7N) on the Monomers and Dimers of Abeta40 and Abeta42. *ACS Chem Neurosci*. 2013; 4:1446–1457. [PubMed: 24041307]
465. Viet MH, Nguyen PH, Derreumaux P, Li MS. Effect of the English Familial Disease Mutation (H6R) on the Monomers and Dimers of Abeta40 and Abeta42. *ACS Chem Neurosci*. 2014; 5:646–657. [PubMed: 24949887]
466. Truong PM, Viet MH, Nguyen PH, Hu CK, Li MS. Effect of Taiwan Mutation (D7H) on Structures of Amyloid-beta Peptides: Replica Exchange Molecular Dynamics Study. *J Phys Chem B*. 2014; 118:8972–8981. [PubMed: 25010208]
467. Takeda T, Klimov DK. Side Chain Interactions Can Impede Amyloid Fibril Growth: Replica Exchange Simulations of Abeta Peptide Mutant. *J Phys Chem B*. 2009; 113:11848–11857. [PubMed: 19708712]
468. Lu Y, Wei G, Derreumaux P. Effects of G33A and G33I Mutations on the Structures of Monomer and Dimer of the Amyloid-beta Fragment 29-42 by Replica Exchange Molecular Dynamics Simulations. *J Phys Chem B*. 2011; 115:1282–1288. [PubMed: 21186801]
469. Brown AM, Lemkul JA, Schaum N, Bevan DR. Simulations of Monomeric Amyloid-beta Peptide (1-40) with Varying Solution Conditions and Oxidation State of Met35: Implications for Aggregation. *Archives of Biochemistry and Biophysics*. 2014; 545:44–52. [PubMed: 24418316]
470. Yano A, Okamoto A, Nomura K, Higai S, Kurita N. Difference in Dimer Conformation Between Amyloid-beta(1-42) and (1-43) Proteins: Replica Exchange Molecular Dynamics Simulations in Water. *Chemical Physics Letters*. 2014; 595:242–249.
471. Anand P, Nandel FS, Hansmann UH. The Alzheimer's Beta Amyloid (Abeta1-39) Monomer in an Implicit Solvent. *J Chem Phys*. 2008; 128:165102. [PubMed: 18447506]

472. Anand P, Nandel FS, Hansmann UH. The Alzheimer Beta-amyloid (Abeta(1-39) Dimer in an Implicit Solvent. *J Chem Phys.* 2008; 129:195102. [PubMed: 19026087]
473. Nguyen PH, Tarus B, Derreumaux P. Familial Alzheimer A2V Mutation Reduces the Intrinsic Disorder and Completely Changes the Free Energy Landscape of the Abeta1-28 Monomer. *J Phys Chem B.* 2014; 118:501–510. [PubMed: 24372615]
474. Meral D, Urbanc B. Discrete Molecular Dynamics Study of Oligomer Formation by N-terminally Truncated Amyloid Beta-protein. *J Mol Biol.* 2013; 425:2260–2275. [PubMed: 23500806]
475. Gillman AL, Jang H, Lee J, Ramachandran S, Kagan BL, Nussinov R, TeranArce F. Activity and Architecture of Pyroglutamate-modified Amyloid-beta (A β 25-35) pores. *J Phys Chem B.* 2014; 118:7335–7344. [PubMed: 24922585]
476. Lee J, Gillman AL, Jang H, Ramachandran S, Kagan BL, Nussinov R, Teran Arce F. Role of the Fast Kinetics of Pyroglutamate-modified Amyloid-beta Oligomers in Membrane Binding and Membrane Permeability. *Biochemistry.* 2014; 53:4704–4714. [PubMed: 24950761]
477. Zhuravlev PI, Reddy G, Straub JE, Thirumalai D. Propensity to Form Amyloid Fibrils Is Encoded as Excitations in the Free Energy Landscape of Monomeric Proteins. *J Mol Biol.* 2014; 426:2653–2666. [PubMed: 24846645]
478. Liang C, Ni R, Smith JE, Childers WS, Mehta AK, Lynn DG. Kinetic Intermediates in Amyloid Assembly. *J Am Chem Soc.* 2014; 136:15146–14149. [PubMed: 25313920]
479. Baell J, Walters MA. Chemistry: Chemical con Artists First Drug Discovery. *Nature.* 2014; 513:481–483. [PubMed: 25254460]
480. Ingólfsson HI, Thakur P, Herold KF, Hobart EA, Ramsey NB, Periole X, de Jong DH, Zwama M, Yilmaz D, Hall K, Maretzky T, Hemmings HC Jr, Blobel C, Marrink SJ, Koçer A, Sack JT, Andersen OS. Phytochemical Perturb Membranes and Promiscuously Alter Protein Function. *ACS Chem Biol.* 2014; 9:1788–1798. [PubMed: 24901212]
481. Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH. Brain Amyloid-beta Oligomers in Ageing and Alzheimer's Disease. *Brain.* 2013; 136:1383–1398. [PubMed: 23576130]
482. Hamilton-Brown P, Bekard I, Ducker WA, Dunstan D, Dave E. How Does Shear Affect Abeta Fibrillogenesis? *J Phys Chem B.* 2008; 112:16249–16251. [PubMed: 19367889]
483. Dunstan D, Hamilton-Brown P, Asimakis P, Duckerand W, Bertolini J. Shear Flow Promotes Amyloid-beta Fibrillization. *Protein Eng Des Sel.* 2009; 22:741–746. [PubMed: 19850675]
484. Lee C, Bird S, Shaw M, Jean L, Vaux DJ. Combined Effects of Agitation, Macromolecular Crowding, and Interfaces on Amyloidogenesis. *J Biol Chem.* 2012; 287:38006–38019. [PubMed: 22988239]
485. Gruebele M, Thirumalai D. Perspective: Reaches of Chemical Physics in Biology. *J Chem Phys.* 2013; 139:121701. [PubMed: 24089712]
486. Esbjörner EK, Chan F, Rees E, Erdelyi M, Luheshi LM, Bertocini CW, Kaminski CF, Dobson CM, Kaminski Schierle GS. Direct Observations of Amyloid Beta Self-assembly in Live Cells Provide Insights into Differences in the Kinetics of Abeta(1-40) and Abeta(1-42) Aggregation. *Chem Biol.* 2014; 21:732742.
487. Li C, Charlton LM, Lakkavaram A, Seale C, Wang G, Young GB, MacDonald JM, Pielak GJ. Differential Dynamical Effects of Macromolecular Crowding on an Intrinsically Disordered Protein and a Globular Protein: Implications for In-cell NMR spectroscopy. *J Am Chem Soc.* 2008; 130:6310–6311. [PubMed: 18419123]
488. Li C, Liu M. Protein Dynamics in Living Cells Studied by In-cell NMR Spectroscopy. *FEBS Lett.* 2013; 587:1008–1011. [PubMed: 23318712]
489. Lu P, Bai XC, Ma D, Xie T, Yan C, Sun L, Yang G, Zhao Y, Zhou R, Scheres SH, Shi Y. Three-dimensional Structure of Human Gamma-secretase. *Nature.* 2014; 512:166. [PubMed: 25043039]
490. Dominguez L, Foster L, Meredith SC, Straub JE, Thirumalai D. Structural Heterogeneity in Transmembrane Amyloid Precursor Protein Homodimer Is a Consequence of Environmental Selection. *J Am Chem Soc.* 2014; 136:9619–9626. [PubMed: 24926593]

Biographies

Jessica Nasica-Labouze: Institut de Biologie Physico-Chimique - CNRS UPR 9080 - 13, rue Pierre et Marie Curie - F-75005 Paris, France, and Statistical and biological physics, SISSA, Via Bonomea, 265 - 34136 Trieste, Italy.

Jessica Nasica-Labouze is a Postdoctoral Fellow on the Talents FVG outgoing mobility Fellowship (Conorzio per l'AREA di ricerca di Trieste) and is involved in a collaborative project between UPR9080 CNRS, Paris and SISSA, Italy. She got her Ph.D. in biophysics at the Université de Montréal (Canada) where she worked on characterizing the self-assembly mechanism of amyloid peptides and then did a postdoc at SISSA, investigating the dynamics of chromatin via coarsegrained simulations. Her current research interests focus mainly on the effects of protective and pathogenic mutations on the folding and interactions of the amyloid-beta protein, involved in Alzheimer's disease, via a wide spectrum of computational methods.

Olivia Berthoumieu: CNRS, Laboratoire de Chimie de Coordination, 205 Route de Narbonne, 31077 Toulouse, France.

Olivia Berthoumieu is a post-doctoral researcher at the Coordination Chemistry Department in Toulouse, France. She graduated from Oxford University, where she received a PhD in Biochemistry. Her research interests include (a) membrane proteins as tools for bionanotechnological applications; (b) ligand-receptor interactions study and high resolution imaging using atomic force microscopy (AFM); (c) metal ions interactions with the amyloid-beta peptide and inhibition of A β aggregation.

Sébastien Côté: Department of Physics, Université de Montréal, C.P. 6128, succ. Centre-ville, Montréal (Quebec), Canada H3C 3J7.

Sébastien Côté is currently a Ph.D. student under the supervision of Professor Normand Mousseau in the Department of Physics at Université de Montréal in Montréal, Canada. He received his Honours B.Sc. in Physics at McGill University, Montréal, Canada in 2009. His

research interests are non-amyloid/amyloid proteins folding/oligomerization, peptide–membrane interactions, and the development of new coarse-grained methodologies.

Normand Mousseau: Normand Mousseau is Professor of Physics and Canada Research Chair in Computational Physics of Complex Materials at Université de Montréal. He obtained his Ph.D. from Michigan State University and pursued post-doctoral studies at Oxford University, UK, and Université de Montréal. His research interests focus on the kinetics of complex systems at the atomic scale studied with the help of various computational methods often developed in his group. Over the last few years, in biophysics, he has been working on the first steps of amyloid aggregation as well as protein flexibility. He is currently working on the development of new coarse-grained potentials in addition to pursuing a number of avenues for accelerated sampling techniques.

Tong Zhang: School of Biological Sciences, Nanyang Technological University (NTU), 60 Nanyang Drive, Singapore, 637551, and UPR9080 CNRS, Paris.

Tong Zhang is a Ph.D. student under supervision of Prof. Derreumaux and Associate Professor Yuguang Mu in the School of Biological Sciences at NTU Singapore. He received his B.Sc. in Biology in the Nanyang Technological University, Singapore in 2010. His research interests are to use computer aided approaches to understand the folding and aggregation of Alzheimer's A β , A β /small molecule interactions. tzhang2@e.ntu.edu.sg

Yuguang Mu: School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore, 637551.

Yuguang Mu is an Associate Professor in the School of Biological Sciences of Nanyang Technological University in Singapore. He got his Ph.D. in Shandong University, China and postdoc training under the Alexander von Humboldt foundation in Germany. His research interests are (a) MD simulation method and data analysis method development; (b) Peptide, protein folding, unfolding study, specially aimed at folding, misfolding mechanism which could lead to amyloid fibril; (c) DNA dynamics, DNA –protein, DNA-counterions interaction study.

Andrew Doig: Manchester Institute of Biotechnology, 131 Princess Street, University of Manchester, Manchester M1 7DN, UK.

Andrew Doig is a Professor of Biochemistry at the University of Manchester. He got his Ph.D. at the University of Cambridge, UK and postdoc training in the Department of Biochemistry at Stanford University, USA. His research interests are (a) drug discovery for Alzheimer's Disease; (b) bioinformatics studies on drug target proteins, genes in mouse development, amyloidoses and protein vibrational spectroscopy; (c) effects of β -amyloid on the proteome, metabolome and cytoskeleton.

Birgit Strodel: Forschungszentrum Jülich GmbH, Institute of Complex Systems: Structural Biochemistry (ICS-6), 52425 Jülich, Germany.

Birgit Strodel is the Head of the Multiscale Modeling Group at the Jülich Research Centre and is an Assistant Professor at the Institute of Theoretical and Computational Chemistry at the Heinrich Heine University Düsseldorf. Her main research interests are in the thermodynamics and kinetics of protein aggregation, and protein-protein interactions. A large part of the simulations performed in her lab focus on the aggregation of amyloidogenic peptides, aiming to understand the molecular basis of Alzheimer's disease.

Nicolae-Viorel Buchete: School of Physics, University College Dublin, Belfield, Dublin 4, Ireland.

Nicolae-Viorel (Vio) Buchete is a Lecturer of Theoretical & Computational Nano-Bio Physics in the School of Physics, and a PI in the Complex & Adaptive Systems Laboratory, a research institute in the University College Dublin (UCD), Ireland. He got his PhD from Boston University, and he held a postdoctoral research fellowship at the National Institutes of Health in Bethesda, MD, USA. Ongoing research projects in his group at UCD are concerned with statistical mechanics and conformational dynamics of biomolecular systems, protein folding, amyloid aggregation, structural aspects of systems biology and bioinformatics, and with multiscale modeling of biomolecules and complex fluids.

Alfonso De Simone: Department of Life Sciences, Imperial College London, South Kensington, London SW7 2AZ.

Alfonso De Simone is Lecturer and Group Leader at the Department of Life Sciences of the Imperial College London. He obtained the Ph.D. in 2007 in structural biology at the University of Padova. He was then postdoctoral research associate at the University of Cambridge in the laboratory of Chris Dobson, working at new combinations of biomolecular NMR and molecular simulations to characterize structure and dynamics of transient protein states along biochemical processes, including protein aggregation into amyloids, enzymatic reactions and biomaterial assembly. In 2011 he established his group at Imperial College London where he is working at the definition of advanced methods at the interface of solution/solid-state NMR and molecular simulations. Current research topics span intrinsically disordered proteins, membrane proteins, biotechnologically relevant enzymes and biomaterials.

Peter Faller: CNRS, Laboratoire de Chimie de Coordination, and University Paul Sabatier of Toulouse205, Route de Narbonne, 31077 Toulouse, France.

Professor in Chemistry at the University of Toulouse Paul Sabatier (F) and group leader at the Laboratoire de Chimie de Coordination du CNRS. Born in St. Gallen (CH); trained teacher for elementary school (Kreuzlingen, CH); Study of (Bio)Chemistry (Univ.Zürich, CH); PhD in (Bio)Chemistry on metallothioneins (Univ. Zürich); post-doc on photosystem II. Ongoing research projects of the group are on the interaction of amyloidogenic peptides with metal ions, inhibitors and markers.

Angel E. Garcia: Department of Physics, Applied Physics and Astronomy, and Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York. USA

Angel E. Garcia is a Professor of Physics at Rensselaer Polytechnic Institute. He obtained a PhD in Theoretical Physics from Cornell University. His main research interest is the understanding of the physico-chemical principles that determine protein folding, stability and dynamics, and the application of these principles to built computer models that describe these processes. A main effort in his laboratory has been the characterization of the ensemble of conformations adopted by the A β -peptides in the monomeric state. He uses state of the art enhanced sampling methods and parallel computers to perform atomistic simulations of various forms of the A β peptides in explicit solvent, and over multiple microseconds timescales. These simulations are carefully validated against J-couplings, RDC and other data.

Alessandro Laio: Statistical and biological physics, SISSA, Via Bonomea 265, 34136, Trieste, Italy. Alessandro Laio is Associate Professor at the Physics department of SISSA. He got a Ph.D. in solid-state physics in SISSA. Then he moved for a postdoc to ETH, Switzerland, where he worked first on a QM/MM approach to molecular biochemistry, then on the development of techniques for computer simulations on rare events. His current research interests are: (a) the development of techniques aimed at computing the free energy by atomistic simulations. (b) Protein folding, protein aggregation and protein-protein interaction. (c) structural bioinformatics and algorithm development for data mining.

Mai Suan Li: Institute of Physics Polish Academy of Sciences, Al. Lotnikow 32/46, 02-668 Warsaw, Poland.

Mai Suan Li is a Professor of Physics at the Institute of Physics Polish Academy of Sciences. He got his Ph.D. at the Kishinev State University, Moldova and habilitation degree at the Institute of Physics Polish Academy of Sciences. His research interests are (a) development of coarse-grained models for studying protein folding and misfolding; (b) protein unfolding under external mechanical force; (c) mechanisms of protein and peptide aggregation; (d) computer-aided drug design for Alzheimer's disease, influenza A virus and breast cancer.

Simone Melchionna: IPCF, Consiglio Nazionale delle Ricerche, P.le A. Moro 2, 00185, Rome, Italy.

Simone Melchionna is a researcher at the Institute for the Chemico-Physical Processes, of the Consiglio Nazionale delle Ricerche. He has a Ph.D. in chemistry from the University of

Rome – La Sapienza, during which we developed techniques for Molecular Dynamics of biological systems, such as constrained mechanics, enhanced sampling and isothermal-isobaric dynamical approaches. Then he moved for three years to Cambridge where he worked on confined fluids and water via density functional and other theoretical approaches. Subsequently, he worked on Lattice Boltzmann and multiscale simulation numerical methods, with applications to DNA translocation. His research focuses on high-performance computing applied to proteins and other biological systems.

Phuong Nguyen: Laboratoire de Biochimie Theorique, IBPC, 13 rue Pierre et Marie Curie, 75005, Paris, France.

Phuong Nguyen is CR1 permanent researcher at CNRS. He got a Ph.D in Condensed Matter Theory at the Physics Department of Bielefeld University, Germany. His postdoc at the Chemistry Department of Frankfurt University, Germany focused on nonequilibrium molecular dynamics simulations aimed at understanding energy flows, photoinduced conformational dynamics in biomolecules. His current research focuses on the development and application of efficient, physically rigorous theoretical methods for studying equilibrium and nonequilibrium structure, dynamics and thermodynamics of single and amyloid proteins at all-atom and coarse-grained levels.

Anant Paravastu: Department of Chemical and Biomedical Engineering, Florida State University and Florida A&M University and the National High Magnetic Field Laboratory, 2525 Pottsdamer St., Tallahassee, Florida, 32310 USA

Anant Paravastu is an Associate Professor of Chemical and Biomedical Engineering at Florida State University. He received his Ph.D. in chemical engineering at the University of California, Berkeley, USA and his postdoctoral training at the National Institutes of Health. His primary research interests are in solid state NMR structural analysis of peptide assemblies, including A β oligomers and designer peptide nanofibers with applications in regenerative medicine.

Samuela Pasquali: Laboratoire de Biochimie Théorique, CNRS UPR 9080 – Université Paris Diderot. Samuela Pasquali is Associate professor in the Biology/Biochemistry department of the university of Paris Diderot, where she teaches math and bioinformatics to biology students. She got a Ph.D. in statistical physics in 2005 at New York University, having worked on theoretical modeling of RNA folding and polymer folding under confinement. She then moved to Paris at ESPCI for a 3-years postdoc on numerical approaches to compute Casimir forces, both classical (Van der Waals) and quantum. In 2008 she was hired as an associate professor at Paris Diderot and since then she devoted her research to the problem of RNA folding for which she developed efficient coarse-grained model and the improvement of the coarse-grained protein model for amyloid and non-amyloid proteins.

David J. Rosenman: Department of Biology, Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY 12180, USA

David J. Rosenman got his B.S. with Honors in Biology from the California Institute of Technology in 2009. He became a PhD student in the Biology Department at Rensselaer Polytechnic Institute in 2010, under the mentorship of Dr. Angel E. García and Dr. Chunyu Wang. His research focuses on the combined use of molecular dynamics and nuclear magnetic resonance techniques to characterize the conformational ensembles of the amyloid beta (A β) peptides implicated in Alzheimer's disease.

Fabio Sterpone: Laboratoire de Biochimie Théorique, IBPC, 13 Rue Pierre et Marie Curie, Paris, France.

Fabio Sterpone is currently researcher at the CNRS, France. He graduated from the University of Paris UPMC (Biophysics) and occupied several post-doc positions later on; he

dealt with quantum classical simulations of materials and the effect of solvent on biomolecular structure and dynamics. Presently, he is mainly interested in the study of protein stability and aggregation in extreme-environments by applying and developing multi-scale simulation methodologies.

Bogdan Tarus: Laboratory of Theoretical Biochemistry - UPR 9080, IBPC, 13 rue Pierre et Marie Curie, 75005 Paris, France.

Bogdan Tarus is postdoc at the Laboratory of Theoretical Biochemistry, Institut de Biologie Physico-Chimique. He got a PhD in physical chemistry at Boston University, Massachusetts. Then he moved for a postdoc to Heidelberg University, Germany, where he continued to work on amyloid protein aggregation. Moving to INRA, France, he worked on designing of small chemical compounds that interact with proteins of biological interest. His work at IBPC involves studying of amyloid protein aggregation and developing of chemical compounds to inhibit the aggregation. His current research interests are: protein dynamics and aggregation using computational methods at atomistic and coarsegrained resolution, drug design, protein-drug interaction, and inhibition of protein aggregation.

John H Viles: School of Biological and Chemical Sc., Queen Mary, University of London, London E1 4AS Dr John Viles has an active research program studying protein misfolding associated with amyloid formation in neurodegenerative diseases. Biophysical approaches include: NMR; CD; IR; EPR and transmission electron microscopy. His main research areas include: Copper and zinc in Alzheimer's disease; the structure and misfolding of the prion protein in TSE's 'mad-cow' disease; Amyloid-beta and its protein binding partners. He received his Ph.D. from the University of London in 1994 and continued his research with Prof P J Sadler (FRS) studying metallo-proteins using NMR. In 1997 he took up a post-doctoral position with Prof P Wright at the Scripps Research Institute, California. In collaboration, with the Nobel Laureate, Prof S Prusiner, he has published a number of significant papers on the structure of the prion protein. He returned to the UK in 2000 to take up a lectureship position at Queen Mary and is currently an Associate Professor (Reader) in Biochemistry at Queen Mary, University of London.

Chunyu Wang: Department of Biological Sciences, and Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York, USA Chunyu Wang is an Associate Professor of Biology at Rensselaer Polytechnic Institute. He obtained his PhD in Biochemistry from Cornell University and MD from Peking Union Medical College. He mainly uses solution NMR technique to study the structure, dynamics and interactions of Amyloid- β peptide ($A\beta$), in combination with molecular dynamics simulation. His other interests include intein-mediated protein splicing and related phenomena, such as Hedgehog autoprocessing.

Philippe Derreumaux: Laboratoire de Biochimie Théorique, UPR9090 CNRS, IBPC, 13 Rue Pierre et Marie Curie, Paris, France

Philippe has been director of UPR9080 since 2007 and is senior member of IUF. He got his HDR in Physics at Pierre and Marie Curie University. He has worked with Gerard Vergoten, Warner Peticolas, Martin Karplus and Tamar Schlick during 1993-2004. Presently, he is interested in the development of enhanced conformational techniques, and coarse-grained protein (OPEP) and ARN (Hire-RNA) models. The theoretical advances are used to understand the aggregation process of amyloid proteins, and notably the $A\beta$ protein, in aqueous solution, and comprehend the equilibrium conformation ensemble and dynamics of $A\beta$ in a crowding environment with the prion protein and serum albumin or in a real cell environment.

Figure 1.

Schematics describing known structural motifs for Aβ1-40 WT and Aβ1-40 D23N fibrils. Arrows, thin lines, and colored symbols represent β-strand regions, non-β-strand regions, and selected residues, respectively. (A) Molecular conformation of Aβ molecules within fibrils, with arrows representing β-strand regions. (B) Organization of Aβ monomers into a protofilament. Each Aβ peptide contributes two β-strands to two stacked in-register parallel β-sheets, with hydrogen bonding interactions between equivalent β-strands along the fibril axis. (C) Cross-section of the Aβ1-40 fibril model of Petkova *et al.* composed of two protofilaments.^(27,29) (D) Two distinct side chain arrangements experimentally observed for different Aβ1-40 fibrils. (E) Fibril cross-section predicted of the Aβ1-40 model determined by Paravastu *et al.* and composed of three protofilaments.⁽⁶⁷⁾ (F) The antiparallel β-sheet arrangement reported by Qiang *et al.* for fibrils of the Iowa Aβ1-40 D23N peptide.^(29,101)

Figure 2.

All-atom pictures of cross-sections of brain-derived Aβ1-40 fibrils modeled by Lu *et al.*⁽²⁹⁾ (A), compared to cross-sections of models for *in vitro* generated fibrils reported by Paravastu *et al.*⁽⁶⁷⁾ (B) and Petkova *et al.*⁽²⁷⁾ (C). The fibrils in (B) and (C) correspond to the diagrams shown in Figure 1C and 1E, respectively.

Figure 3.

Proposed models for non-fibrillar A β aggregates. As in Figure 1, arrows, thin lines, and colored symbols represent β -strand and non- β -strand regions, and selected residues, respectively. (A) The antiparallel β -hairpin conformation predicted by Hoyer *et al.* for the monomer⁽¹¹⁴⁾ and suggested by Scheidt *et al.* for protofibrils.^(120,121) (B) The dimer structure proposed for preglobulomers by Yu *et al.*⁽¹²³⁾. (C) The disc-shaped pentamer model proposed by Ahmed *et al.*⁽¹²⁴⁾. (D) Two different views of the antiparallel β -sheet model for 150 kDa oligomers, reported by Tay *et al.*⁽¹¹¹⁾. (E) X-ray crystallographic structure of the trimer of the designed cyclic A β 17-36 peptide.^(127b) (F) Representative structures of highest populations in the MD ensembles of the A β 21-30 WT peptide with the D23-K28 salt bridge (left) and the A β 21-30 peptide with pS26 substitution (right).⁽⁴⁷⁾

Figure 4. Transient REMD-sampled conformations of A β monomers bearing similarity to experimental intrapeptide models of higher order aggregates. **(A)** β -hairpin models for A β 1-42 and A β 1-40 monomers derived from the simulations of Rosenman *et al.*,^(154b) based on the most populated cross-region backbone hydrogen bonds and secondary structure proclivities in the ensemble. Residues that have a high population for both donor to acceptor and acceptor to donor backbone hydrogen bonds are illustrated with a bold line. Sampled conformations matching these models exist as high-ranking centroid structures. **(B)** Ribbon overlay of residues 16-35 for centroid 3 derived from clustering analysis of the A β 1-40 simulation^(154b) and the solution NMR structure of monomeric A β 1-40 in complex with a phage selected affibody (PDB entry 2OTK) published by Hoyer *et al.*⁽¹¹⁴⁾. **(C)** Intrapeptide model for A β 1-40 fibrils based on ss-NMR, as published by Bertini *et al.*⁽⁹⁸⁾. **(D)** Intrapeptide model for A β 1-42 “on pathway” pentamers based on ss-NMR, as published by Ahmed *et al.*⁽¹²⁴⁾.

Figure 5.

Per residue probabilities of β -strand, turn and others (coil and α -helix) for the A β 1-40 and A β 1-42 dimers as computed by different simulation protocols. As seen in Table 2, the total α -helix content amounts to less than 1.3% in Ref. 195, 202, 203 and 204 so others represent coil. In ref. 195, there is a total of 4.4% of α -helix in the dimers of A β 1-42 and there is a probability of 27% for residues 23-28 to form α -helix. In Ref. 204, there is a total of 8.4% of α -helix in the dimers of A β 1-42 and there is a probability of 45% for residues 13-17 to form a α -helix. (A) HT-REMD with the CG OPEP model and implicit solvent.⁽¹⁹⁵⁾ (B) united-atom CHARMM19 REMD with the SASA implicit solvent.⁽¹⁹⁹⁾ (C1) CG DMD with implicit solvent.⁽²⁰³⁾ (C2) all-atom MD with OPLS-AA/SPCE.⁽²⁰⁴⁾ (C3) all-atom MD with OPLS-AA/TIP3P.⁽²⁰⁴⁾ (D) All-atom MC with implicit solvent.^(181a) (E) all-atom REMD with OPLS-AA/TIP3P.⁽²⁰⁷⁾ All secondary structure probabilities were computed using STRIDE; except for (b) for which the secondary structures are determined using information on the ϕ and Ψ dihedral angles only, without consideration of the H-bond network. As such, the β -sheet probabilities for (b) must be considered as extended conformations and no turn probability can be determined. The vertical dotted white lines delimit the four regions: N-terminal (residues 1-16), CHC (residues 17-21), loop region in the fibril (residues 22-28), and C-terminal (residues 29-40/42).

Figure 6.

(A) Schematic plot of free energy of the aggregate, relative to the monomer, as a function of the aggregate size. The critical nucleus size corresponds to the peak of G , while G_{nucl} is the barrier to nucleation. (B) Time dependence of the fibril mass $M(t)$. Within homogeneous nucleation theory $M(t) \sim t^2$ at short time scales. The plateau corresponds to the lag phase, whose duration is proportional to $\exp(-G_{\text{nucl}}/k_B T)$. (C) A typical initial conformation for the (5+1) system in the lattice models with 8-bead sequence +HHPPHH-, where + and - refer to charged residues, while H and P denote hydrophobic and polar residues.⁽²²⁹⁾ (D) The final fibril conformation with the lowest energy. (E) Dependence of the adding time τ_{add} on the number of monomers that belong to the preformed template. Results are averaged over 50 Monte Carlo trajectories. At a concentration of 290 μM , τ_{add} becomes independent of N for N_{template} larger than 11. Arrow refers to $N_c=11$.⁽²³⁰⁾

Figure 7.

Free energy landscape of 18 A β 35-40 peptides estimated by atomistic metadynamics simulations with explicit solvent as a function of the number of antiparallel β -sheets and the number of number of antiparallel frontal packing (different β -sheets facing each other).^(178a) Basin 1 includes structures that are mainly disordered, with secondary structure elements formed only transiently. Basin 2 contains a much larger fraction of antiparallel β -sheets (up to 10–12 β -strands). The main characteristic of this basin is that the β -strands, although common, are not organized in a stable nucleus. These structures are only metastable, and can convert to the disordered melt in a few tenths of ns. Basin 3 includes instead structures with a specific inter-digitation of the side chains, which are stable at least on the ms time scale.

Figure 8. High-resolution AFM images of individual Aβ1-42 channels. They are most often observed as (A) tetrameric, or (B) pentameric subunits assemblies. Other types (e.g., hexameric) of pore-like Aβ structures were also reported.⁽²⁶⁹⁾

Figure 9.

Various models of membrane-bound A β studied by MD simulations. (A) Monomeric A β 1-40 is localized as a helical structure at the interface between membrane and solvent with the C-terminal helix inserting into the membrane.⁽²⁸⁸⁾ (B) A fibrillar A β 1-40 oligomer interacting with the membrane on the surface causes both a loss of β structure and a thinning of the membrane.⁽²⁷³⁾ (C) The membrane-inserted β -sheet tetramer composed of A β 1-42 allows water to permeate through the membrane⁽²⁹⁷⁾ and can further assemble into a pore structure.⁽²⁹⁶⁾ (D) A β 1-42 barrel structure leading to pore formation in the membrane, which allows water and ion transport across the membrane.^(293,294) Note that structures shown here are simulation-based models, as experimental high-resolution structures of membrane-bound A β peptides have yet to be resolved. The structural and mechanistic relationships between the simulation models are unknown. A β peptides are represented according to their local secondary structure: helices (red), β -sheets (yellow), and turns (silver). The bilayer phosphorus atoms (blue) are shown as van der Waals spheres and the lipid tails as licorice (cyan). For clarity, only water molecules inside the membrane are shown (van der Waals spheres).

Figure 10.

Models of the coordination sphere of different monomeric metal-A β complexes. K_d^{app} stands for apparent dissociation constant (i.e. dissociation constant at pH 7.4 in 0.1M salt and in the absence of buffer)

Figure 11.

Catalytic role of Cu-A β in the production of reactive oxygen species. Top: Cu-A β is able to catalyze the production of H₂O₂ and HO $^\bullet$ in the presence of a reducing agent and dioxygen. Bottom: The catalytic active state capable to catalyze the Fenton type reaction. Active are only the conformations with a diagonal ligation by the peptide remote from a angle of 180 $^\circ$ and in which the H₂O₂ binds to Cu(I) side on.

Figure 12.

A selection of ligands studied in the context of metal-mis-metabolism in AD. **A** and **B** have ionophoric properties, a dimeric form (compound 15) is derived from clioquinol where the covalent attachment of two hydroxyquinoline increases Cu(II) affinity and selectivity, **C** are water-soluble Cu(II) chelators, **C** and **D** are brain-penetrating Cu(II) ligands and **E** and **F** are bi-functional Cu(II) chelators with A β -targeting unit (for more details see Refs. 342 and 344).

Figure 13.

Physiological micro-molar concentrations of albumin inhibit fibre formation. (a) Kinetics of A β fibre formation in the presence of: no albumin (red); 1 μ M (dark green); 3 μ M (green); 5 μ M (light blue); and 10 μ M (dark blue) of albumin. (b) Competitive effects of albumin on total A β fibrils generated with a strong direct correlation between fraction of fibres generated and the calculated fraction of A β free to form fibres (not bound to increasing concentrations of albumin), based upon a K_d of 5 mM. Adapted from Stanyon *et al.*⁽³⁵²⁾.

Figure 14.
Chemical structures of small compound inhibitors of Aβ aggregation and toxicity.

Figure 15.

Contact probabilities of each Aβ1-42 each amino acid with compounds. (A) Between EGCG and Aβ1-42 dimer from atomistic REMD simulation.⁽²⁰⁷⁾ (B) Between NQTrp and Aβ1-42 dimer from atomistic REMD simulation.⁽⁴³²⁾ (C) Between 10 small organic molecular fragments (e.g., dimethyl ketone, furan and pyrazole) and Aβ1-42 monomer from REMD and FTMap.⁽¹⁷⁵⁾ Non-bonded (black bars) and hydrogen bonding (red bars) interactions are shown separately.

Figure 16.

Representative structures of Aβ1-42 dimer/NQTrp from atomistic REMD simulations. (A) Cluster 1, (B) Cluster 2, and (C) Cluster 8. Chains A and B are colored red and blue, respectively. The red and blue spheres represent the Cα atoms of Asp1. The center of mass of NQTrp is shown as green spheres, and we show NQTrp if it forms a contact < 4 Å with any heavy atom of Aβ1-42. Residues colored yellow assist in the reading.

Figure 17.

Aβ16-22 aggregation simulations under several conditions. Top panels. Pictorial representation of monomer aggregation for several simulation schemes: i) Langevin dynamics, ii) Langevin dynamics with Hydrodynamics Interactions (HI), and iii) Langevin dynamics with HI and longitudinal shear, shear rate $\dot{\gamma}/z=10^8 \text{ s}^{-1}$. The time-evolutions show the effect of HI on the aggregation kinetics. When shear-flow is activated also the details of the aggregation change: i.e. first two separate aggregates form and their relative motion in the shear flow (translation and rotation) guides their further encounter and fusion. Bottom panels. Time evolution of key parameters describing the aggregation process in shear-flow for different values of the shear rate $\dot{\gamma}/z$ ($0, 10^8, 10^9, 10^{10} \text{ s}^{-1}$): the gyration radius R_g (left panel), the number of inter-peptide hydrogen bonds formed between backbone NH and O groups (mid panel) and number of inter-peptide side-chain contacts (right panel). The system is composed of 18 peptides placed in a cubic box of $L=65 \text{ Å}$ and the shear gradient is generated along the Z direction.

Table 1

Summary of A β aggregation simulations from random states. In the timescale column, *sim* stands for the number of independent simulations, *rep* for the number of replicas for REMD or HT-REMD, and the time is that of one MD trajectory or one replica.

Ref.	Force field	Solvent model	Method	Timescale	A β alloforms	Oligomer size
195	OPEP 3.2	Implicit	HT-REMD	1.25 μ s $\times$ 26 rep	1-40, 1-42	2
199	CHARMM19	SASA	T-REMD	0.8 μ s $\times$ 24 rep $\times$ 8 sim	1-40	2
202	PROFASI	Implicit	MC	2 $\times$ 10 ¹⁰ steps $\times$ 40 sim	1-42	2
204 [‡]	OPLS-AA	SPC/E	MD	0.05 μ s $\times$ 1000 sim	1-40, 1-42	2
	OPLS-AA	TIP3P	MD	0.05 μ s $\times$ 1000 sim	1-40, 1-42	2
207	OPLS-AA	TIP3P	T-REMD	0.2 μ s $\times$ 64 rep	1-42	2
206	AMBER99sb	TIP4P-Ew	T-REMD	0.05 μ s $\times$ 52 rep	1-42, 1-43	2
205	AMBER99	TIP3P	MD	0.1 μ s	1-42	2
208	OPEP 3.2	Implicit	T-REMD	1.2 μ s $\times$ 22 rep	17-42	3
203 [‡]	CG	Implicit	DMD	6 $\times$ 10 ⁷ steps $\times$ 8 sim	1-40, 1-42	1-32
200	CHARMM19	SASA	T-REMD	0.8 μ s $\times$ 24 rep $\times$ 8 sim	10-40	4
210 [‡]	OPLS-AA	GB/SA	T-REMD	0.2 μ s $\times$ 5 sim	1-42	1-20

[‡] Large scale aggregation simulations resulting in an ensemble of oligomer sizes sampled and analysed.

[‡] The all-atom, explicit solvent simulations in Ref. 204 start from an ensemble of conformations obtained by the CG DMD simulations of Ref. 203.

Table 2

Secondary structure contents of A β 1-40 and A β 1-42 dimers using enhanced sampling techniques starting from randomly chosen states. Values from simulations are computed using STRIDE.

Ref.	A β 1-40				A β 1-42			
	Helix %	β -Strand %	Turn %	Random Coil %	α -Helix %	β -Strand %	Turn %	Coil %
149b [‡]	10.5	38.6	–	50.9	–	–	–	–
20 [‡]	0	12	28	60	11	3	26	60
195	1.3 $\pm$ 0.1	12.6 $\pm$ 0.1	50.7 $\pm$ 0.1	35.4 $\pm$ 0.1	4.4 $\pm$ 0.1	30.8 $\pm$ 0.1	32.4 $\pm$ 0.1	32.4 $\pm$ 0.1
202	–	–	–	–	0.9 $\pm$ 0.1	42.9 $\pm$ 0.7	33.0 $\pm$ 0.4	23.2 $\pm$ 0.8
203	0.1 $\pm$ 0.1	13.6 $\pm$ 1.6	40.6 $\pm$ 4.1	37.5 $\pm$ 5.0	0.0 $\pm$ 0.0	15.7 $\pm$ 1.9	39.2 $\pm$ 3.7	39.0 $\pm$ 4.9
204 [‡]	0.5 $\pm$ 0.1	5.5 $\pm$ 0.8	43.5 $\pm$ 3.6	46.8 $\pm$ 4.1	0.9 $\pm$ 0.2	6.6 $\pm$ 0.8	40.1 $\pm$ 3.2	48.0 $\pm$ 3.8
207	–	–	–	–	8.4 $\pm$ 0.7	11.9 $\pm$ 0.6	51.2 $\pm$ 1.0	28.5 $\pm$ 0.8

[‡] Circular dichroism-derived values using different sample preparations.

[‡] MD values starting from the CG DMD structures of Ref. 203 and using OPLS-AA and SPC/E. Similar values are obtained using OPLS-AA and TIP3P.

Table 3

Summary of molecular simulation studies focused on interactions of A β peptides with lipid membranes. DMPC stands for dimyristoylphosphatidyl-choline, POPC for palmitoyl-oleoylphosphatidylcholine, POPS for 1- palmitoyl, 2-oleoyl-sn-glycero-3-phosphoserine, and POPG for palmitoyl-oleoyl-phosphatidylglycerol.

References	A β system	Type of membrane	Simulation	Key notes
288	A β 40 monomer	Implicit IMM1	All-atom REMD	Helical A β structure at membrane-water interface.
299	A β 40 monomer	DPPC	All-atom MD	Helical A β structure in bilayer with tendency to exit the membrane and localize at membrane-water interface.
286	A β (10-40) monomer	DMPC	All-atom REMD	Helical A β structure at membrane-water interface.
283-285	A β 42 monomer and dimer	DPPC and DOPS	All-atom REMD and umbrella sampling MD	Binding of A β to membranes. Dimerization of membrane-bound A β .
273,291,292	A β 40 protofilament	POPE and POPC	All-atom MD	Interactions between A β fibrillar oligomers and membranes influence of lipid composition, structural effects.
300,301	A β 40 monomer	DPPC, POPC, POPS, POPC/POPS, rafts	All-atom MD	Stability of membrane-inserted A β . Effect of insertion depth and membrane composition
302-304	A β 42 dimer	Mixed bilayers with cholesterol and/or GM1 mimicking rafts	All-atom MD	Effect of rafts on membrane-binding and dimerization of A β .
296-298	A β 42 monomer and oligomers	Implicit IMM1 POPC, POPG, DPPC	All-atom Monte Carlo and MD	Structure prediction for transmembrane A β . Testing the stability and membrane effects of the resulting β -sheet structures. Effect of mutations.
293-295	A β barrels	DOPC, POPC, POPG	All-atom MD	Models for A β channel structures. Water and ion flux across membranes through A β pores. Effect of A β mutations.
311	A β 40 & A β 42 monomers	3 bead model for Lipids	Coarse-grained MD	A β adsorption and aggregation on small vesicles

Table 4

Computational studies on the variants, n.a. stands for not applicable.

Ref.	Mutations	A β alloforms	Oligomer size	Force field & solvent model	Method	Timescale	Theoretical findings upon mutation
473	A2V	1-28	1	CHARMM22* TIP3P	T-REMD	9.8 μ s	<ul style="list-style-type: none"> - population of β-hairpins increased 4-fold - intrinsic disorder decreased 2-fold - Free-energy landscape very different from WT
465	H6R	1-40, 1-42	1, 2	OPLS-AA TIP4P	MD	3.7 μ s	<ul style="list-style-type: none"> - rate of fibril formation increased - in Aβ1-42: increase in β-structure at C-terminal (monomer and dimer) + increased stability of 23-28 salt-bridge in monomer - in Aβ1-40: increase due to enhanced turn in region 25-29 and decrease in α-helix propensity in regions 10-13, 26-29 and 30-34 (monomer)
466	D7H	1-40, 1-42	1	OPLS-AA GB/SA	T-REMD	24 μ s	<ul style="list-style-type: none"> - 2-fold decrease in overall β-propensity + decrease in salt-bridge 23-28 formation in both monomers.
464	D7N	1-40, 1-42	1, 2	OPLS-AA TIP3P	MD	7.4 μ s	<ul style="list-style-type: none"> - monomer changes its fold and its salt-bridges network - dimer changes its secondary structure, salt-bridges and topology - increase in the aggregation rate
462	A21G	1-40, 1-42	2	GROMOS96 GB/SA	MD	60 ns	<ul style="list-style-type: none"> - mutation destabilizes β-sheets and slows down aggregation for Aβ1-40 but not Aβ1-42 - mutation increases the flexibility of the CHC in Aβ1-40 & Aβ1-42 - mutation affects intra- and inter-molecular salt-bridges involving Glu22, Asp23 and Lys25
177	E22K, E22Q, E22G, D23N	1-42	1	AMBERFF99SB TIP3P	MD	> 1000 μ s	<ul style="list-style-type: none"> - all monomers are rather disordered

Ref.	Mutations	A β alloforms	Oligomer size	Force field & solvent model	Method	Timescale	Theoretical findings upon mutation
460	E22	1-40, 1-42	1	AMBERFF99SBImplicit GB/SA	T-REMD	2.4 μ s	<ul style="list-style-type: none"> - elimination of electrostatic interactions of E22K and E22Q increases α-helices in region 20-23 - all mutants decrease α-helix propensity in the C-terminal region 33-36 but same β-propensity. - higher α-helix propensity (both Aβ1-40 & Aβ1-42) - turn structure in region 21-30 less abundant in both Aβ1-40 & Aβ1-42 - disappearance of key intramolecular interactions between N-terminal, CHC and C-terminal - Aβ1-40-mut is more prone to aggregation than Aβ1-42-mut - 30% decrease in Lys16 salt-bridges but strengthening of Lys28 salt-bridges
178	E22K	1-42	1	AMBERFF99SB TIP3P	MD	>700 μ s	<ul style="list-style-type: none"> - E22K increases α-helix propensity in region 20-24
184b	E22G	1-40, 1-42	1	CGImplicit	DMD	60*10 ⁷ steps	<ul style="list-style-type: none"> - E22G destabilizes contacts within the region 21-30 for Aβ1-40 & Aβ1-42 - major N-terminal structural change that prevents formation of β-hairpin at A2-F4 (Aβ1-40) - higher β-propensity in N-terminal: induces a toxic β-hairpin at R5-H13 (Aβ1-40)
463	D23N	15-40	2	AMBERFF99SB TIP4P-Ew	Minimization ab-initio FMO	n. a.	<ul style="list-style-type: none"> - disappearance of salt-bridge between Asp23 and Lys28 in parallel β-sheet conformation = loss of stability for parallel β-sheet conformer
202	F20E E22G E22G 131E	1-42	2	PHOFAS1 Implicit	MC	80*10 ¹⁰ steps	<ul style="list-style-type: none"> - all mutations affect the aggregation propensity - main structural variations in region 20-30

Ref.	Mutations	A β alloforms	Oligomer size	Force field & solvent model	Method	Timescale	Theoretical findings upon mutation
474	Pyroglutamate variants	3-40, 3-42, 11-40, 11-42	32	CG Implicit	DMD	3.2*10 ⁹ steps	<ul style="list-style-type: none"> - truncated variants form larger oligomers - Aβ3-40/42 has a more flexible & solvent exposed N-terminal region - Aβ11-40/42 sees its N-terminal be less accessible to the solvent which might explain why it is less toxic than full-length Aβ